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Anecdotal evidence indicated vaccine coverage disparities among foster-care (FCA) and 
natural-home adolescents (NHA). Arkansas laws require 5 vaccines for school entry 
(FVSE) to prevent 9 common childhood diseases. The study problem was that Pulaski 
County, Arkansas adolescent birth cohort (PCABC) immunization rates were low 
compared to U.S. adolescents for these FVSE. This study examined the extent to which 
(1) PCABC immunization rates were significantly different from those estimated for U.S. 
adolescents in 2006–2008, (2) NHA and FCA immunization rates were different in 2003–
2008; (3) sociodemographic variables mediate associations between home of residence 
(HOR), NHA or FCA, and up to date (UTD) status for FVSE; and (4) vaccination game 
theory (VGT) estimated deaths differ between individual-equilibrium and group-optimum 
behaviors. The methodologies applied were direct standardization, χ2, multiple logistic 
regressions, and VGT to analyze PCABC retrospective secondary data from the Arkansas 
immunization registry. The results revealed that U.S. adjusted UTD coverage rates for 
Hepatitis B, measles-mumps-rubella, and varicella were greater than those for PCABC. 
Race-adjusted FCA immunization rates were 120% higher than for NHA. Race mediated 
the association between HOR and UTD FVSE status, and African Americans had 80% 
greater odds of being UTD with FVSE compared to Caucasians. Group-optimum 
behavior was associated with fewer estimated deaths than individual equilibrium; thus, it 
is protective against disease outbreaks. Positive social change may occur among the 
PCABC when healthcare providers include these results in communications with parents 
at FCA and NHA community health clinics. Parental vaccine acceptance for their 
children may increase vaccinations and improve PCABC health and wellness. 
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Chapter 1: Introduction to the Study 
Introduction 
This dissertation examined the association between adolescent home of residence 
(HOR) and vaccination coverage uptake among the 1990 birth cohort in Pulaski County, 
Arkansas (PCA). In this study, adolescent vaccination behavior and disparity in vaccine 
coverage uptake were important and significant links in the resurgence and outbreaks of 
previously controlled or eradicated childhood vaccine-preventable diseases (VPDs; 
Centers for Disease Control and Prevention [CDC], 1999b; Immunization Action 
Coalition [IAC], 2012). Immunization rates for adolescents aged 13 to 19 years were low 
compared to childhood and adult immunization rates (CDC, 2008a; Mahon, Shea, 
Dougherty, & Loughlin, 2008). Adolescent vaccine coverage uptakes were also below 
coverage levels for those vaccines administered routinely in childhood (CDC, 2010a; 
IAC, 2011). I used vaccination game theory (VGT) to further explore and identify risk 
factors that influenced the five school-entry vaccine coverage uptakes among the 1990 
birth cohort in PCA. 
The five vaccines for school entry (FVSE) examined in this dissertation are 
tetanus-diphtheria/tetanus-diphtheria-acellular pertussis (Td/Tdap), hepatitis B (Hep B), 
measles-mumps-rubella (MMR), poliomyelitis (OPV/IPV), and varicella (VAR, 
chickenpox). FVSE in Arkansas are required and mandated by Arkansas law (Arkansas 
Department of Health [ADH], 2008; Jackson, 1969). The Arkansas immunization registry 
(AIR) is the legal repository for reporting every administered vaccine from birth to age 
22 years in Arkansas (ADH, 1995). Several counties in Arkansas reported that adolescent 
vaccine-coverage levels, especially for the FVSE, tended to be lower than the national 
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average (Safi et al., 2012). For example, PCA evidence showed that adolescent vaccine-
coverage levels for FVSE were lower than the national average. It was unclear whether 
coverage levels were lower among certain groups of adolescents or whether they were 
lower among all age groups. 
Differences emerged in vaccine coverage among adolescents in previous studies. 
For example, evidence suggested that children raised in nonparental-home settings were 
less likely to be up-to-date (UTD) on their preventive healthcare services compared to 
children in their natural home (Chu, Barker, & Smith, 2004; Darden, Gustafson, Nietert, 
& Jacobson, 2011). Immunization coverage is one preventive-health service that differed 
between foster-care and natural-home children (Chu et al., 2004; Darden et al., 2011). 
This dissertation further examined the vaccine UTD status of adolescents in the 1990 
PCA birth cohort from 1990 to 2008. 
Increased numbers of cases of vaccine-preventable disease among adolescents in 
Arkansas were a public health burden and concern. VPD outbreaks and resurgences in 
Arkansas aligned with underimmunization and low-immunization coverage (Haselow, 
2014). These VPD outbreaks among adolescents continued to increase in several counties 
in Arkansas between 2012 and 2014 including Pulaski, Faulkner, Lonoke, Saline, and 
White Counties (Haselow, 2014). In 2012, 248 pertussis cases emerged compared to 467 
pertussis cases in 2013. Similarly, 237 VAR cases emerged in 2012 compared to 249 
VAR cases in 2013 (Haselow, 2014). Thus, given the resurgence of previously controlled 
(Chiappini, Stival, Galli, & Martino, 2013) or eradicated childhood diseases, it is 
important to examine whether vaccination coverage levels for the FVSE are at or below 
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coverage levels in PCA between two groups of adolescents: natural-home adolescents 
(NHAs) and foster-care adolescents (FCAs). 
This dissertation has five major sections. The first section includes the 
background, purpose, significance, assumptions, delimitations, and social change 
implications of this dissertation. The second section is the literature review, which 
describes evidence from recent research studies on adolescent immunization coverage 
and factors that influenced vaccine-coverage levels. The focus in Chapter 3 is the 
dissertation methodology, whereas Chapter 4 presents data analysis and results. Finally, 
Chapter 5 of this dissertation presents the implications of the findings as well as 
recommendations. 
Background 
Measles-, mumps-, pertussis-, and VAR-outbreak resurgences continue to occur 
every year in the United States (CDC, 1998a; 2011a, 2011d, 2012g, 2015; Cherry, 2013; 
Gould et al., 2009; L. E. Lee et al., 2008; Lopez et al., 2006; Vitek, Aduddell, Brinton, 
Hoffman, & Redd, 1999; Wheeler, 2012). Counties in the southern portion of the United 
States have disproportionally high rates of VPD resurgence. Outbreaks of VPD 
negatively impacted public health departments’ resources and contributed to societal 
burdens (California Department of Public Health Immunization Branch, 2012; Wheeler et 
al., 2004). Examples of societal burdens include economic stress from lost work 
productivity, school absenteeism, hospitalization, and outbreak-investigation resources 
and costs (Gould et al., 2009; Parker et al., 2006; Safi et al., 2012; Thompson et al., 2007; 
Wheeler et al., 2004). 
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Adolescent immunization rates are appropriate measures of societal burdens 
(Byrd, Santibanez, & Chaves, 2011; Safi et al., 2012; Thompson et al., 2007). These 
metrics emerge through declining shifts in public trust, parental attitudes toward 
immunizations, and resurgence of VPD (Atwell et al., 2013; Darden et al., 2013; Dorell, 
Jain, & Yankey, 2011). Although vaccines have contributed to an overall decline in 
morbidity and mortality in society (CDC, 1998b, 1999b, 2007a), immunization rates 
among adolescents in PCA are consistently below nationally established immunization 
indicators (IAC, 2010; U.S. Department of Health and Human Services [USDHHS], 
2010c). 
The 1990 birth cohort PCA study determined differences among NHA and FCA 
immunization rates for FVSE. Arkansas immunization laws (AILs) require adolescents to 
complete all dose series of FVSE prior to age 18 years or before completing high school 
(ADH, 1993, 2004a; Bugenske, Stokley, Kennedy, & Dorell, 2012). Evidence from peer-
reviewed research indicated that adolescents in their natural-home environments are more 
likely to be UTD on their vaccination status compared to adolescents in foster care (Chu 
et al., 2004; Darden et al., 2011). Thus, in Arkansas, where universal vaccination 
coverage averaged lower than national coverage (CDC, 2011d), it was important to 
determine whether disparities in vaccination coverage existed between NHA and FCA 
children. 
The importance of calculated differences in immunization rates between the two 
groups established evidence for school-entry immunization-focused compliance 
interventions. Access to health care, insurance status (Smith, Stevenson, & Chu, 2006), 
immunization fragmentation of services, multiple providers, and sociodemographic 
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factors contributed to differences that affected immunization coverage in both groups 
(Smith, Singleton, & National Center for Immunization and Respiratory Diseases, 2011). 
I calculated immunization rates for each group and compared results to identify any 
differences in FVSE immunization rates and UTD status between NHA and FCA among 
adolescents in PCA. 
Arkansas Department of Health (ADH) and Advisory Committee on 
Immunization Practices (ACIP) criteria established cohort immunization-coverage rates 
for NHA and FCA. The Arkansas Department of Human Services (ADHS) required 
immunization for all children in foster care as part of FCA-mandated medical care under 
Medicaid regulations (ADHS, 2007, 2013). The criteria used to determine the percentage 
of adolescents with complete vaccination UTD status for FVSE were based on Arkansas 
Adolescent Immunization Rules and Regulations (see Appendix A, Table A1). Finally, I 
compared the calculated immunization rates for the 1990 birth cohort for the FVSE to 
U.S. national adjusted adolescent immunization rates for the same FVSE. 
Purpose 
This quantitative study had three main purposes. First was to examine differences 
in vaccine coverage for FVSE between PCA and their corresponding birth cohort in the 
United States. The second purpose was to examine differences in adolescent vaccine 
coverage for FVSE between NHA and FCA. Third, I calculated the costs and risks 
associated with vaccine payoff for the FVSE for individual and group behavior choices 
for the 1990 birth cohort, modeled on VGT (Bauch & Earn, 2004). This study was one of 




Parental attitudes, environmental factors, social distancing, and clinical reasons 
emerged as risk factors that adversely impacted immunization rates in this study. Parental 
attitudes (Omer, Richards, Ward, & Bednarczyk, 2012; Opel et al., 2013) and clinical 
reasons arose for adolescent disease prevention (CDC, 2009a). Adolescent immunization 
behaviors related to social distancing (Reluga, 2010; Sawyer, Carbone, Searle, & 
Robinson, 2007). Social-congregating impacted resurgence of VPDs including pertussis 
(Wheeler et al., 2004) and VAR (Gould et al., 2009) in Arkansas. Understanding 
immunization rates in a cohort supported compliance strategies to achieve 90% protective 
coverage in herd immunity (CDC, 2009b; McElligott et al., 2012). It was important to 
establish evidence to increase or maintain immunization rates required by Arkansas law 
in compliance with public health and safety. 
Arkansas vaccination-compliance expectation was that school administrators and 
school nurses would gain an understanding of the magnitude of adolescent immunization-
rate disparity in PCA. I analyzed 1990 birth cohort records in the Arkansas immunization 
registry database (AIRD) quantitatively and established differences among the 1990 
cohort immunization-rates uptake coverage and UTD status. The study design focused on 
FVSE disparities among adolescents based on HOR—NHA and FCA—gender, race, and 
ethnicity in the 1990 birth cohort for PCA. The positive social impact of improved 
immunization coverage and UTD status were increased life expectancy (CDC, 1999c) 
and reduced burden of hospitalization, disability, and deaths from VPD outbreak and 




The significance of this study was the ability to examine and establish differences 
in adolescent vaccination-coverage level between two groups of adolescents—NHA and 
FCA—living in PCA. Second, the study predicted estimated risks in payoff deaths 
associated with vaccine behavior among NHAs and FCAs in the 1990 birth cohort in 
PCA. Given evidence that vaccine coverage levels tend to be higher among NHAs 
compared to FCAs (Smith, Santoli, Chu, Ochoa, & Rodewald, 2005), it was important to 
examine whether this disparity also existed in PCA. Further analysis also explained 
whether HOR was a driving force behind disparities in adolescent vaccine-coverage 
levels for FVSE in PCA. 
The importance of examining disparities in vaccination coverage between NHAs 
and FCAs relates to primary prevention and the benefits of improved childhood and 
adolescent wellness (CDC, 1999d, 1999g; Shefer et al., 1999; USDHHS, 2009). 
Improvements in immunization coverage between NHAs and FCAs helps maintain good 
health, extend life expectancy, and reduce risk and exposure to VPDs. School 
absenteeism and poor student performance align with disease outbreaks (Davis, King, 
Moag, Cummings, & Magder, 2008). Immunization rate, vaccine coverage, and UTD 
status are national health indicators and surveillance tools for community health (CDC, 
2006a; USDHHS, 2010d). Immunization UTD status is a preventive health behavior 
(Bauch, Galvani, & Earn, 2003). Being current on vaccines aligns with the conduct of 
other clinical preventive services in a community (USDHHS, 2009), and helps measure 
the robustness of a preventive clinical healthcare system (Rodewald et al., 1999). 
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Immunization UTD status was the main outcome variable in this analysis to establish 
immunization rates among the 1990 birth cohort in PCA. 
Problem Statement 
The research problem was that reported immunization rates and uptake coverage 
for the routinely required FVSE among adolescents in PCA were persistently low 
compared to the U.S. average (CDC, 2012e). For example, PCA immunization rates were 
20–40% lower compared to the U.S. national average for adolescents (CDC, 2010a). 
Why this difference existed was uncertain, especially because FVSE were mandatory in 
PCA. However, one reason this difference existed was adolescents’ home setting. 
Differences in home setting partially explained this disparity (Zhao & Luman, 2010) in 
that preventive health services differed between adolescents who lived in the natural-care 
setting and those in foster care. 
This study examined vaccine-coverage disparities between NHAs and FCAs. 
Vaccine-coverage disparities among adolescents aligned with fragmentation of 
immunization services (Darden et al., 2011). Adolescents who lived in stable parental-
care environments and had a single medical home (Smith, Santoli, et al., 2005) had less 
fragmentation in immunization services (Darden et al., 2011). High-risk adolescents, such 
as FCAs, often resided in group-home environments. These high-risk adolescents had 
multiple providers and multiple facility types for their immunization services (Darden et 
al., 2011; Smith et al., 2011). Adolescent group homes included behavior-treatment 
facilities, juvenile correctional facilities, incarcerated housed adolescents, homes for 
persons experiencing homelessness, and institutionalized juveniles (Smith et al., 2011). In 
this study, FCAs were preidentified among the 1990 birth cohort for PCA. 
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I calculated and reported the 1990 birth cohort immunization rates for PCA in this 
study. Since 2006, Arkansas adolescents’ reported immunization rates have been 15–20% 
lower than U.S. national averages for FVSE (CDC, 2012e). Adolescent immunization 
rates of 90% or greater were essential to reduce risk of diseases (Glanz et al., 2010; 
Healthy People 2010, 2011; USDHHS, 2010c). Community immunity was maintained 
through immunization rates greater than 90% uptake coverage, as established in Healthy 
People 2020 (McCauley, Stokley, Stevenson, & Fishbein, 2008; USDHHS, 2010a). I 
compared calculated immunization rates for the 1990 PCA birth cohort to Healthy People 
2020 immunization standards to determine compliance or disparity. 
Research Questions and Hypotheses 
RQ1: Are the calculated 2006–2008 adolescent percent vaccination uptake (VCU) 
rates for FVSE among the 1990 birth cohort in PCA (PCABC) significantly 
different from the reported FVSE 2006–2008 U.S. national adolescent estimated 
immunization rates? 
Ho1: There is no difference between the 2006–2008 PCABC calculated 
percent VCU for the FVSE and the reported 2006–2008 U.S. adolescent 
national immunization teen (NIS-Teen) estimated percent VCU for the FVSE. 
Ha1: There is a difference between the 2006–2008 PCABC calculated percent 
VCU for the FVSE and the reported 2006–2008 U.S. adolescent NIS-Teen 
estimated percent VCU for the FVSE. 
RQ2: Are there differences in percentage of FVSE vaccine coverage uptake 
between NHA and FCA among adolescents in the 2003–2008 PCABC? 
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Ho2: There is no significant difference in FVSE coverage uptake between the 
HOR defined as NHA and FCA in the 2003–2008 PCABC. 
Ha2: There is a significant difference in FVSE coverage uptake between the 
HOR defined as NHA and FCA in the 2003–2008 PCABC. 
RQ3: Is the association between HOR, defined as NHA and FCA, and UTD 
FVSE coverage mediated through sociodemographic characteristics, which 
include age, race, ethnicity, and gender in PCABC? 
Ho3: The associations between HOR, defined as NHA or FCA, and UTD 
FVSE in PCABC is not mediated through sociodemographic characteristics, 
including age, race, ethnicity and gender. 
Ha3: The associations between HOR, defined as NHA or FCA, and UTD 
FVSE in PCABC is mediated through sociodemographic characteristics, 
including age, race, ethnicity and gender. 
RQ4: Will differences in individual vaccine payoff, measured by avoidance of 
disease development as a result of vaccine receipt, affect group interest, measured 
by deaths as a result of nonvaccination for the FVSE among the 1990 PCABC? 
Ho4: Differences in individual vaccine payoff, measured by avoidance of 
disease development as a result of vaccine receipt, will not affect group 
interest, measured by deaths as a result of nonvaccination, for the FVSE 
among the 1990 PCABC. 
Ha4: Differences in individual vaccine payoff, measured by avoidance of 
disease development as a result of vaccine receipt, will affect group interest, 
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measured by deaths as a result of nonvaccination, for the FVSE among the 
1990 PCABC. 
Theoretical Construct 
Theory of games (TOG; von Neumann & Morgenstern, 1944), as used in this 
study, enhanced understanding of how individual vaccine behavior affected the group 
interest. I used the TOG to model individual decisions to receive vaccination and its 
impact on the group interest. One feature of this vaccine-modeling construct was to 
examine how the impact of vaccine uptake related to vaccine payoff deaths (Bauch et al., 
2003). The TOG (von Neumann & Morgenstern, 1944) and VGT application (Bauch et 
al., 2003) offered important modeling for adolescent immunization actions, choices, or 
behaviors to maximize or minimize payoffs (Jackson, Leyton-Brown, & Shoham, 2015). 
The hallmark of the TOG (von Neumann & Morgenstern, 1944) and VGT application 
(Bauch et al., 2003) was to use mathematical models to predict how an individual’s 
decision to receive vaccine affected and compared to the outcome of group interests. 
Appendix B contains tables with VGT equations and calculations. Immunization 
acronyms are defined in Appendix C. In this study, 1990 PCABC immunization rates 
predicted outcomes. In the 1990 birth cohort, mathematical models determined how 
individuals’ self-interest decisions to vaccinate, called individual equilibrium in the 
model, affected the group’s altruistic interest, and called group optimum. I calculated the 
group interest as the cost of individuals who preemptively received vaccination and 
measured the cost by the number of adolescents in the cohort who were expected to die 
due to the failure of individuals to receive vaccination. 
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Another important feature of the game-theory construct was its relationship to 
community or herd immunity and the payoff from not receiving vaccination. If a 
community had immunity as a population, then theoretically, the ability of that disease-
causing agent to cause disease diminished because the agent was no longer active or 
present in the population (Baguelin et al., 2013). Community or herd immunity in a 
community increased through population decisions to vaccinate (Barclay et al., 2014; 
Domenech de Cellès, Riolo, Magpantay, Rohani, & King, 2014; Shim, Kochin, & 
Galvani, 2010; Shim, Meyers, & Galvani, 2011), thereby improving disease prevention 
and minimizing deaths associated with VPDs (Arinaminpathy et al., 2012; Blackwood, 
Cummings, Broutin, Iamsirithaworn, & Rohani, 2013). Likewise, herd immunity could 
impact an individual’s decision to receive vaccination. I examined this notion when I 
applied the mathematical constructs in the data analysis derived from VGT. 
Nature of the Study 
This cross-sectional study used quantitative methods to examine differences in 
adolescent vaccine coverage rates between NHAs and FCAs using the 1990 birth cohort 
immunization records in PCA. Additionally, I modeled individual vaccine uptake 
behaviors for the FVSE among NHAs and FCAs, and its impact on the group interest. 
Definitions 
The 1990 birth cohort defined all children born between January 1, 1990 and 
December 31, 1990 in PCA. I subdivided this 1990 birth cohort into a control group, 
NHA, and a research group, FCA. The NHAs were never under Arkansas child protective 
services as wards of the State of Arkansas mandated by judicial court orders. FCAs were 
wards of the State of Arkansas, mandated by judicial court orders until age 18. The age of 
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18 years was a significant factor because this was the cut-off age for enrollment in foster-
care services, graduation from high school, and adolescent status for immunization. 
Age-appropriate vaccine status: The correct age in months or years at which a 
specific vaccine must be administered (Dombkowski, Harrington, Hanauer, Kennedy, & 
Clark, 2012; Schempf, Minkovitz, Strobino, & Guyer, 2007). 
Arkansas immunization laws: Mandated age, grade, and specific types of vaccines 
are defined in Table II of the Arkansas Immunization Rules and Regulations (AIRR) 
established by Arkansas Board of Health (ADH, 2008). 
Arkansas immunization registry (AIR): Mandated by AIL in 1995; AIR is the 
legal repository for all reported and administered vaccines for all children in Arkansas 
(Arkansas Legislative Branch [ALB], 1995a). 
Five vaccines for school entry (FVSE): The FVSE were Td/Tdap, Hep B, MMR, 
OPV/IPV, and VAR (ADH, 2008). 
Foster-care adolescent (FCA): An adolescent up to age 18 years who does not 
live in their natural or adoptive parents’ residence and is under court-ordered judicial 
protective care, supported through ADHS control (ADHS, 2010). 
Group optimum: The group optimum is the level of maximum vaccine coverage 
that is best to protect the entire population against a VPD (Bauch et al., 2003). 
Immunization disparity: Deficiency in a specific type and specific number of 
doses for vaccines that fail to achieve 90% uptake of a routinely recommended vaccine 
dose, established in Healthy People 2020 (USDHHS, 2010a). 
Immunization rate: The proportion of vaccines in a dose series received by 
children, as prescribed in ACIP immunization schedules (CDC, 2007b, 2012k). 
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Individual equilibrium: Individual equilibrium focuses on maximizing self-
interest benefits from an outcome and minimizing the probability of the associated cost of 
the outcome (Bauch & Earn, 2004; Bauch et al., 2003; von Neumann & Morgenstern, 
1944). 
Natural-home adolescent (NHA): Adolescents who live with their natural or 
adoptive parents, have never been in child protective services, and attended public 
schools from 1996 to 2008 in PCA (ADHS, 2010). 
Payoffs: The benefit of receiving a vaccine, quantified by the number of deaths 
prevented by vaccine receipt. 
Routinely recommended vaccines: U.S. Food and Drug Administration licensed 
vaccines recommended by ACIP (CDC, 1999c; CDC, 2007c). 
Strategy: Strategies, which include vaccination, delayed vaccination, or no 
vaccination, are deliberate choices, actions, behaviors, or decisions employed by 
individuals or groups to achieve a desired outcome or payoff (Bauch et al., 2003; Chaves 
et al., 2008; Meyer, Seward, Jumaan, & Wharton, 2000; Reluga & Galvani, 2011; Shim, 
Chapman, & Galvani, 2010). 
Up-to-date status (UTD): The current vaccination-series completion of actual 
specific vaccine types and total number of doses in the series received at a given age and 
calendar date. The UTD is important for vaccine-series next-dose administration, disease 
exposure, and risk at time of an outbreak (Dombkowski, Lantz, & Freed, 2004b). 
Vaccination status: The recommended specific vaccine type and total number of 





This study retained four assumptions based on Arkansas vaccine requirements: 
• Assumption 1: Each child received all age-appropriate vaccines, from birth to 
age 18 years, and required vaccines during each school-grade milestone. 
Children who received childhood doses could not have completed the vaccine-
dose series or received the booster dose. Adolescents refused vaccine and 
immunization exemptions based on philosophical, religious, or personal 
reasons (ADH, 2003; Arkansas State Board of Health, 2003). 
• Assumption 2: Students were 6 years old in the first grade in 1996 and 
progressed regularly each year to the 12th grade. Further, Assumption 2 
included that a fourth-grade student was 10 years old in 2000 and progressed 
to seventh grade at the age of 13 in 2003. 
• Assumption 3: NHAs and FCAs progressed equally through similar public 
school systems in PCA and graduated from high school in 2008. 
• Assumption 4: NHAs’ and FCAs’ school attendance data were collected by 
October 15th each year from all school districts and systems in PCA. The 
1990 cohort school-attendance data were reported annually to the Arkansas 
Department of Education (ADE). For example, in 2002, PCA had 4,134 
adolescents aged 12 in the sixth grade in all public schools. This study 
examined the cohort as they progressed to the next grade until age 18 years as 
a unit block (FCA enrollment appears in Appendix A, Table A5). 
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Scope and Delimitations 
The scope of this study was adolescent immunization status in a 1990 birth cohort 
of all children born between January 1, 1990, and December 31, 1990, in PCA. The 
study’s delimitation also includes all children who attended public schools from 
kindergarten through 12th grade between 1996 and 2008 (ADE, 2009). Delimitations in 
this study included those aged 13 to 18 years, defined as adolescence, the population size 
of the study population, school attendance, parental control, and geography in PCA. I 
subdivided the age of adolescents in the 1990 birth cohort into the control group, NHA, 
and the study group, FCA. The delimitation focus was adolescents who were 13 years old 
in 2003 and born in PCA. The focus followed each year for vaccines received and 
reported to the AIR until age 18 years, in 2008 or upon graduation. 
The study population size and study population denominator consisted of five 
inclusion criteria in the 1990 birth cohort. These criteria were (a) FCAs enrolled under 
ADHS control under judicial court orders; (b) NHAs who lived with their parents; (c) 
types of vaccines, all five vaccines with number of doses with documented records in the 
AIR; (d) attended public schools in PCA; and (e) in the geographic contiguous borders 
and zip codes in PCA. 
Limitations 
AIR data contained several internal validity issues associated with many types of 
errors and reporting of immunization information. I excluded incomplete or mismatched 
records from the data analysis to minimize internal-validity limitations and unreliable 
results. Duplicate doses of the same vaccine were not included in immunization-rate 
calculations, based on the criteria delineated in Appendix A, Table A1. Incomplete 
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transmission of immunization records during reporting to the registry are common 
limitations in immunization-registry data (Stevenson et al., 2000). Electronic records and 
hard-paper reporting systems have limitations in transmission, formatting, standardization 
of documentation, and legibility of documents (CDC, 2000b; Stevenson et al., 2000). 
The registry data was built from health-provider documented and reported 
immunization histories of individually administered vaccines (CDC, 2001; Khare et al., 
2000). Consequently, the accuracy and completeness of the immunization histories and 
eliminating significant errors in child’s name, date of birth, vaccine types, no data 
reported, and overall duplicate records are important in calculating coverage estimates 
(Khare et al., 2000). Early enrollment of children into the registry from birth, when Hep 
B globulin was administered, enhances accuracy of the registry data. The CDC (2000c) 
recommended early enrollment, within 2 months of birth for each newborn child. 
PCA adolescent immunization-result generalizability is significant to the external 
validity of this immunization study. Adolescent immunization results from this study are 
generalized and limited to PCA, and did not include the entire Arkansas population or 
other populations. Researchers and future users may draw inferences to influence policy, 
awareness, knowledge, and social-marketing campaigns. However, my interpretations of 
the results are applicable and specific to adolescents in PCA. 
Social-Change Implication 
The social-change implication relates to primary prevention of VPD among 
adolescents (CDC, 1999c; Shefer et al., 1999). The social-change impact of 
understanding adolescent immunization uptake is valuable in public health functions. 
Improving immunization coverage among NHAs, FCAs, or other adolescents will 
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enhance their quality of life and life expectancy (CDC, 1999c) and reduce frequency of 
VPD outbreaks (Schaffer, Gillette, Hedberg, & Cieslak, 2006). The outcome of this study 
may influence five societal levels of social change: individual, institutional, 
organizational, community, and policy. 
Parents and adolescents of PCA constitute the individual level and are the primary 
target for social change. Because of results from this study, evidence of change in this 
group includes increased immunization knowledge, awareness, and positive attitudes 
toward immunization uptake. The second societal level likely to be impacted by findings 
from this study is the institutional level, comprised of school nurses in public schools in 
PCA whose focus is immunization compliance of FVSE. I include physicians and public 
health agencies in the organizational level, as their health practices influence adolescent 
behavior and access to immunization services. Community-level supports are cultural 
norms, attitudes, and availability of professionals and organizations that provide 
immunization services. 
The final level that findings from this study impact is the policymaker level. 
Policy-level change influences financing and eligibility criteria, as well as rules and 
regulations associated with adolescent immunization coverage. Arkansas’ major policy 
stakeholders include the Arkansas Departments of Education, Health, and Human 
services. The specific role of these departments influences policy change. 
Findings from this study potentially will benefit parents through increased 
immunization awareness and will support compliance with school-entry laws. This 
positive immunization chain effect could also benefit future populations through 
increased herd or community immunity. Results from this study identified disparities 
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among vaccines with low coverage among adolescents in the 1990 PCABC. The 
identified immunization disparity data stimulated innovative communication methods in 
the community to address parental vaccine safety and efficacy concerns in PCA. 
Summary 
Four research questions were cogent to examine whether disparities in FVSE 
vaccination coverage existed among a birth cohort in the archival AIRD. The first 
research question was pertinent to determine if a difference ensued between the 2006–
2008 PCABC calculated percent VCU for the FVSE and the reported 2006–2008 U.S. 
adolescent NIS-Teen estimated percent VCU for the FVSE. In the second research 
question, I examined if differences emerged in percentage of FVSE vaccine coverage 
uptake between NHAs and FCAs in the 2003–2008 PCABC. Third, I examined if the 
association between HOR, defined as NHA and FCA, and UTD FVSE coverage mediated 
through the sociodemographic characteristics of age, race, ethnicity, and gender in 
PCABC. With the fourth research question, I examined game-theory mathematical 
models to determine if individuals’ decisions to receive vaccine for the FVSE affected 
the group interest. 
The social-change implications maintain or improve awareness and understanding 
of FVSE vaccination coverage among NHAs and FCAs in PCA. Vaccines align with 
benefits of improved childhood, adolescent wellness, and public health (CDC, 1999c; 
Shefer et al., 1999). For this quantitative study, I used a cross-sectional study design, 
analyzed archival AIRD, and examined disparities in vaccine coverage for FVSE among 
NHAs and FCAs in PCA. 
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The next section is the literature review in Chapter 2. The literature review 
contributes detailed focus on published research on vaccination coverage, providing 
information on how vaccinations influenced disease elimination, resurgence, outbreaks, 
prevention, and control. The literature review further probes the theoretical basis for 
relationships between immunization behavior and negative consequences of low-
immunization rates. The key sections in this literature review included the search 
methods as well as the identification of gaps in the literature. Specific issues discussed in 
the literature review that relate to gaps in the literature include the economic burden 
associated with disease outbreaks, loss of workdays, school closings, and disability and 
mortality related to VPD. 
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Chapter 2: Literature Review 
Introduction 
Immunization rates among adolescents in Arkansas were disproportionately lower 
than the U.S. national average for routinely recommended vaccines and FVSE required 
for adolescents (ADH, 2014a; CDC, 2010d). The adolescent-vaccination-coverage uptake 
was a significant component in this study. The purpose of this cross-sectional study was 
to establish quantitative vaccine UTD status for the FVSE among the 1990 PCABC of 
NHAs and FCAs. The literature review focused on peer-reviewed articles, textbooks, and 
publications on the TOG, immunization rates, adolescent-vaccinations uptakes, laws, 
disparities, disease outbreaks, and resurgence. 
Literature-Search Strategy 
I accessed and retrieved published research articles from physical library and 
online databases. Peer-reviewed journals, reports, and bulletins from online databases 
accounted for more than 90% of the information used in this study. Examples of these 
databases included PubMed, Clinic Trials.gov, Cochran Library, Healthy People, The 
Community Guide, World Health Organization (WHO), and Global Health. The search 
strategy consisted of key words, databases, search engines, and retrieved articles from 
more than 5,000 published articles dated during the 5 years between 2008 and 2013. 
These key words included names of nine communicable and childhood diseases; 
Diphtheria, hepatitis B, measles, mumps, pertussis, poliomyelitis, rubella, tetanus, and 
varicella, vaccines, adolescents, immunization, vaccine rates, schedules, vaccine 
preventable diseases, disease outbreaks, resurgence and prevention, foster care 
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adolescents and health, natural home adolescents and health, school entry laws, vaccine 
rules, regulations, adverse events, Pulaski County, Arkansas, and immunization registry. 
The second search strategy of databases and search engines included the ALB, 
ADH, CDC, WHO, and Pub-Med indexed publications. Searches included public and 
private universities, the legislature, professional associations, and industry websites using 
immunization categories such as articles, reports, policies, press releases, and bulletins. 
Other databases were accessible through their websites with registered authorization, user 
identification, and a password. The ALB (2012) website yielded legislative reports and 
34 immunization laws enacted between 1987 and 2009. The third search strategy required 
physical access to documents at the ALB library and Arkansas State Board of Health 
archives. Immunization laws enacted before 1987 were not initially available on the ALB 
website. I physically accessed and retrieved pre-1987 immunization laws from bounded 
legislative historic archives at the Arkansas State Capitol in Little Rock, Arkansas. These 
pre-1987 immunization laws were significant foundations for AILs that affected 1990 
birth-cohort-immunization rates. Arkansas immunization laws relevant to this study were 
enacted between 1987 and 2009 and are listed in Appendix A., Table A2. I also 
physically accessed and retrieved other Arkansas historic immunizations reports and 
State Board of Health documents archived at ADH headquarters in Little Rock, Arkansas. 
Archived records from Arkansas Board of Health meetings provided important 
information on childhood- and adolescent immunization rates. 
Background 
School-entry vaccine mandates were one of the six key areas of concern identified 
in 2008 National Vaccine Advisory Committee (NVAC) recommendations. NVAC 
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(2008) recommendations addressed challenges in adolescent immunization. 
Immunization rates among adolescents in the 1990 PCABC were lower compared to 
adolescents nationally (ADH, 2012c; CDC, 2010c). The major focus areas within the 
scope of this study included coverage uptake rate and UTD status among adolescents in 
the 1990 PCABC and FVSE. Immunization barriers, behavior risk factors, parental 
knowledge, and access to vaccines were challenges that contributed to low adolescent-
vaccine-coverage uptake (CDC, 2005b; Washington State Department of Health, 2012). 
Similar immunization challenges persisted among adolescents in the 1990 PCABC, in 
spite of 2008 NVAC (2009) recommendations and the 1977 National Childhood 
Immunization Initiative. These challenges were in five key areas: venues for vaccine-
administration consent for immunization, communication, financing, surveillance, and 
the potential for school mandates (CDC, 2011f; NVAC, 2008, 2014; Stokley et al., 2009). 
The U.S. national goal for minimum vaccination achievement has been 90% for all 
children since 1977 (CDC, 1982, 2009d). School-entry vaccine mandates contributed and 
aligned with increased high childhood-vaccination-coverage rates and low rates of VPDs 
(Hinman, Orenstein, Williamson, & Darrington, 2002; Orenstein & Hinman, 1999). 
Vaccine contributions and achievements of public health, concepts of routine vaccination 
for children (Hamborsky, Kroger, & Wolfe, 2015), and continued outbreaks of VPD in 
recent years accounted for three significant and relevant challenge areas related to 
adolescent immunization coverage uptake. 
Vaccination and Public Achievements 
Vaccinations were one of the 10 greatest public health achievements during the 
20th century and the first decade of the 21st century (CDC, 1999h, 2011k). Vaccines 
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were fundamental cornerstones in preventing mortality from disease outbreaks (Schaffer 
et al., 2006), and increasing life expectancy (CDC, 1999c). During the 1950s, infant-
mortality rates improved in the United States, decreasing from 29.2 deaths per 1,000 live 
births to 7.1 deaths per 1,000 live births (CDC, 1999c). For example, in 1950, 33,300 
polio cases and 1,904 deaths ensued, compared to six cases and no deaths in 1990 (CDC, 
2011e). Vaccine-uptake coverage increased during the 20th century, eradicating smallpox 
in 1971 in the United States, and globally in 1980 (IAC, 2012). The trend in increased 
immunization rates among children and adolescents during the 20th century contributed 
to elimination of four major childhood diseases: measles (CDC, 2009e, 2009f; WHO, 
2013), neonatal tetanus, OPV/IPV (CDC, 200g), and rubella congenital syndrome (CDC, 
1999e; USDHHS, 2010e). 
Routine Vaccination for Children 
Childhood vaccines were cost effective in disease prevention, reducing the burden 
of morbidity (ADH, 2014b), infant mortalities, and disabilities associated with diseases 
such as poliomyelitis (CDC, 2009c; Salk, 1955a). Public support for vaccination 
increased during the 1950s when VPD outbreaks (Santoli et al., 2004; Washington State 
Department of Health, 2012) and epidemics caused high rates of infant mortality (CDC, 
1999e). Since 1967, AILs required vaccination against these highly communicable 
diseases including diphtheria, measles, pertussis, poliomyelitis, varicella, and more than 
nine childhood diseases from birth to age 22 years (ALB, 1967; CDC, 2010e, 2011g; 
Marin, Guris, Chaves, Schmid, S., & Seward, 2007; Vitek et al., 1999). School-entry 
regulations and immunization laws in Arkansas intended to increase immunization rates 
based on UTD requirements, shown in AIRR Table II (ADH, 2008). 
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Vaccine compliance for school-entry requirements prevented diseases and 
protected all children in daycare facilities, kindergarten to 12th grade, and college 
students (ADH, 1997, 2008). Similarly, immunization was a national health objective 
established by Healthy People 2000, 2010, and 2020 to increase childhood and adolescent 
immunization rates to reach the 90% threshold indicator (USDHHS, 2012). Furthermore, 
the ACIP annually updated immunization recommendations (Broder et al., 2006; CDC, 
1991a, 2005a, 2006c, 2007c, 2008b) and schedules, ensured adequate UTD, increased 
immunization rates, standardized national immunization policies, and encouraged 
practices to prevent disease resurgence and outbreaks (CDC, 1991b, 1998c, 1999f, 
2011h, 2013). 
Access to Immunization 
Given the potential disparity in vaccine coverage between NHAs and FCAs, it 
was important to examine access to immunization as a potential contributor to this 
disparity. The individual decision to vaccinate relates to self-interest (Galvani, Reluga, & 
Chapman, 2007; Ibuka, Li, Vietri, Chapman, & Galvani, 2014), actions of others (Hilbe, 
Nowak, & Sigmund, 2013; Meszaros et al., 1996), risk of infections, the perceived costs 
and benefits (Basu, Chapman, & Galvani, 2008), ethnicity and language preference 
(Haviland, Elliott,, & Hambarsoomian, 2011), and primary immunization access. Parents 
of adolescents who decided to vaccinate experienced lack of access to vaccines as 
another contributing immunization-barrier factor. 
The Vaccine for Children’s (VFC) program was a federal program intended to 
improve access to immunization for all eligible children (CDC, 1998d, 2011o, 2012c, 
2012m; Lee et al., 2007). The VFC improved child and adolescent UTD status based on 
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ACIP recommendations, access to vaccines, and medical home (Smith, Santoli, et al., 
2005) for vaccine. ACIP recommended children’s UTD coverage (2012a) include more 
than four doses of Td/Tdap (Broder et al., 2006), more than three doses of OPV/IPV, 
more than one dose of MMR, more than three doses of haemophilus influenza type b 
(Hib), and more than three doses of Hep B (CDC, 2005a; Salk, 1955b; Salmon et al., 
2009). Adolescents required two doses of VAR vaccine for school enrollment to improve 
waned immunity and reduce disease outbreaks (CDC, 2005b; Lopez et al., 2006). 
Barriers to Immunization 
Immunization barriers offered opportunities and challenges to vaccinated 
adolescents. Barriers included risk factors that contributed to potential challenges of low-
immunization rates (Kaplan, 2010), and low coverage for the FVSE among children and 
adolescents. I based adolescent immunization barriers described in this study on the TOG 
construct (von Neumann & Morgenstern, 1944), and how decisions to vaccinate 
influenced coverage uptake of individuals and groups (Bauch & Earn, 2004). TOG 
constructs compared immunization costs and benefits related to self-interest, minimized 
costs, and group-interest maximized-payoffs deaths. These constructs were central to the 
comprehension of other important barriers to immunization. The seven important barriers 
to immunization from the literature review comprised adolescent risky behaviors; 
parental factors; physicians; healthcare providers; clinicians; cultural and societal 
practices; and finance, policy, regulations, and laws. 
The great proportion of immunization barriers aligned with parental concerns. 
Parental immunization concerns (Daley et al., 2010; Dorell et al., 2011) and 
immunization barriers contributed to low immunization rates. Some studies listed these 
27 
 
four categories among other parental vaccine concerns: safety, effectiveness, adverse 
events, and efficacy (CDC, 2012f; Baxter et al., 2013; Freed, Clark, Butchart, Singer, & 
Davis, 2011; Hall & Jolley, 2011; Offit et al., 2002; Slade et al., 2009). Two studies listed 
knowledge and awareness as parental concerns (Caskey, Lindau, & Alexander, 2009; 
Shapiro et al., 2011) and two studies defined attitudes and beliefs as parental concerns 
(Gust, Darling, Kennedy, & Schwartz, 2008; Kennedy, Basket, & Sheedy, 2011a). Some 
studies about parental concerns and vaccinations provided information based on medical, 
philosophical, and religious beliefs (Klein et al., 2012; Safi et al., 2012; Thompson et al., 
2007). Vaccine exemptions for FVSE contributed to suboptimal and low immunization 
coverage (Diekema et al., 2005; Imdad et al., 2013). For example, high religious-
exemption counties had 33.1 per 100,000 pertussis incidence compared to 20.1 per 
100,000 pertussis incidences, p < .001, in low religious-exemption counties (Imdad et al., 
2013). Vaccines are safe, effective, and efficacious (CDC, 2012i, Civen et al., 2008; 
Lopez et al., 2006; Seward, Marin, & Vázquez, 2008; Shapiro et al., 2011). However, 
parental perceptions and attitudes were risk factors associated with immunization barriers 
such as vaccine hesitancy (Salmon, Dudley, Glanz, & Omer, 2015), vaccine refusal to 
immunize children against VPD such as pertussis (Civen et al., 2008; Dorell, Yankey, & 
Strasser, 2011; Dredze, Broniatowski, Smith, & Hilyard, 2015; Lopez et al., 2006; 
Seward et al., 2008; Shapiro et al., 2011). Children of parents who refused to immunize 
their children had a 23-fold risk of contracting pertussis compared to children of parents 
who had them vaccinated (Glanz et al., 2010). 
Five clinician-immunization-barrier risk factors were clinician decision support 
(Fiks et al., 2013; Hughes, Jones, Feemster, & Fiks, 2011; Szilagyi et al., 2006), clinical 
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practice (Fiks et al., 2013; Rand et al., 2011a; Rosenthal et al., 2008; Vadaparampil et al., 
2011), missed opportunities (Ladak, Gjelsvik, Feller, Rosenthal, & Montague, 2012; Lee 
et al., 2008), attitudes (M. M. Davis et al., 2006; Humiston et al., 2009), and electronic 
health records (EHR; Fiks et al., 2012; Shojania et al., 2009; Suh et al., 2012). Clinician-
decision support systems contributed to increased vaccination coverage through audit of 
health records in physicians’ practices, education materials (vaccine information 
statements), and physician education. The clinician-decision support system enhanced 
clinicians’ justifications to recommend adolescent vaccines during wellness visits (Fiks et 
al., 2013). EHRs effectively improved immunization rates in clinical practice, alerting 
physicians, families, and adolescents about their next visit and vaccine UTD status. For 
example, EHR immunization recall/reminder systems encouraged parents and 
adolescents to receive recommended vaccines during their next wellness visit (Smith, 
Lindley, Shefer, & Rodewald, 2009; Suh et al., 2012). Physician EHR systems alerted 
providers when the next adolescent vaccine dose was due (CDC, 2012j; Fiks et al., 2013). 
EHR systems also provided current clinical history evidence and minimized any lost 
opportunity to vaccinate adolescents in their medical homes or nonpediatric clinics, 
school athletic health physicals, and gynecological visits (Shojania et al., 2009; Smith, 
Jain, Stevenson, Männikkö, & Molina, 2009). 
Vaccinated adolescents reduced morbidity and mortality from VPD to protective 
levels. For example, morbidity from VAR reported cases in PCA declined to 11 cases in 
2010, compared to 46 VAR cases in 2006 (Lopez et al., 2006) before the 2007 ACIP 
second-dose policy. The initial varicella vaccine one dose was licensed and introduced in 
1995 (CDC, 1999a). In PCA in 2007, of 808 VAR cases among all ages, the county saw 
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172 cases (21.3%) among children and adolescents 10–18 years (ADH, 2012a). In 2001, 
PCA had 194 pertussis cases compared to 21 pertussis cases in 2011 in PCA (ADH, 
2012a). 
Barriers to immunization were significant risk factors that threatened public 
health and safety. These significant risk factors aligned with low immunization rates 
among adolescents (Dorell, Yankey, Kennedy, & Stokley, 2013). Since 2006, public 
school-entry vaccines required for adolescents in seventh grade included a Hep B series 
of three doses; an MMR two-dose series; a one-dose booster Tdap, and a two-dose series 
of VAR. Disease resurgences and outbreaks aligned with low immunization rates, 
unvaccinated adolescents, and imports of VPD (Glanz et al., 2010). Vaccination policies 
exempted adolescents from private or parochial schools (ADH, 2011b). 
Vaccine Preventable Disease Outbreaks in Recent Years 
In Arkansas, VPD resurgence and outbreaks had increased from 2005 to 2012 
(CDC, 2012h). For example, U.S. reported resurgence and outbreaks included measles 
(ADH, 2012b; Lopez et al., 2006; Vitek et al., 1999; J. G. Wheeler, 2012), mumps (ADH, 
2006; CDC, 2006c, 2010f), pertussis (ADH, 2012a; Wheeler et al., 2004), and VAR 
(Gould et al., 2009). These resurgences and outbreaks were attributable to unvaccinated 
adolescents, vaccine hesitancy (Salmon et al., 2015), low immunizations, and disease 
imports from endemic countries (CDC, 2011c). 
During the last 2 decades of the 20th century, VPD reported cases declined to 
historically low numbers for diphtheria, measles, mumps (CDC,1998c;WHO, 2013), 
pertussis( CDC, 2010g, 2011b), poliomyelitis (paralytic), rubella, VAR, and tetanus 
(CDC, 2006d, 2011j; Seward et al., 2008; WHO, 2011a, 2011b). However, significant 
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barriers to immunization contributed to low adolescent immunization rates (Klein et al., 
2012; Stokley et al., 2011). These new immunization barriers included religious 
exemptions (Imdad et al., 2013), immunization laws and policies (Safi et al., 2012; 
Thompson et al., 2007), parental attitudes and knowledge (Gust et al., 2008), and vaccine 
adverse events (Institute of Medicine, 2011a, 2011b). 
Significance of Immunization Barriers and Solutions 
VPD outbreaks resulted from immunization barriers. Disease outbreaks associated 
with unvaccinated persons increased in 2012 for all reported cases of Hep B (10 cases), 
measles (four cases Arkansas wide), pertussis (63 cases), and VAR (14 cases) in PCA 
(ADH, 2014a). Measles was an example of a disease eliminated in the United States in 
2000 (CDC, 2006b, 2011g). Other VPDs, including mumps, rubella, and VAR, were 
controlled to less than 200 cases per year (CDC, 2012b). Examples of the significance of 
immunization barriers were VPD outbreaks and resurgences that occurred annually 
during the past 5 years (CDC, 2012d). The largest VPD outbreaks and immunization 
barrier to date (2016) was the pertussis epidemic outbreak in Washington State in 2012 
(CDC, 2012g). This pertussis outbreak aligned with unvaccinated children and high 
immunization-exemption rates, providing another example of an immunization barrier. 
The potential immunization solutions defined in this study explained published 
research that illustrated increases in immunization rates and each level of individual or 
group optimum described in VGT (Bauch et al., 2003). Low-immunization rates 
increased the risk of disease outbreaks. The impacts of barriers to immunization to 
society consisted of negative outcomes, social and financial burdens to society, missed 
school and work days, and costs to public health resources (Wheeler et al., 2004). These 
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research-based attributable risk factors of immunization barriers included awareness and 
knowledge (Gust et al., 2008), parental attitudes, cultural and social beliefs, religious, 
philosophical, and medical beliefs (Thompson et al., 2007), parental refusal (Glanz et al., 
2009), vaccine safety (Institute of Medicine, 2012, 2013; NVAC, 2005), socioeconomic 
factors (Wooten, Luman, & Barker, 2007), insurance, and access. 
These immunization barriers were expressed as choices or behaviors to either 
preemptively vaccinate, delay, or refuse vaccination. The importance of vaccinated 
adolescents relates to costs such as disability, death, disease, infection, and recovery 
(Bauch et al., 2003). Bauch and Earn (2004) measured individual equilibrium and group-
optimum coverage-uptake levels based on archival immunization data collected in the 
AIRD. Differences in levels of vaccination associated with immunization barriers were 
influenced by differences in interest between individuals and groups (Bauch & Earn, 
2004). 
Public-health-agency and institution-implemented innovative strategies to 
increase immunization rates have also reduced VPD population risk and controlled 
disease exposure. Federal public health insurance programs, VFC, State Medicaid 
eligibility plans, school-entry laws, and healthcare-provider influence were effective 
vaccine-uptake strategies. In addition, adolescent and childhood immunization rates 
increased from 85% to 92% for certain vaccines (CDC, 2009b, 2012m). Although U.S. 
adolescent immunization rates improved, challenges persisted for achieved and desired 
90% immunization-rate indicators in Healthy People 2020 objectives (CDC, 2010b). 
Parental awareness and knowledge are essential for parental consent to immunize 
children and adolescents. Federal immunization laws encourage parents to receive 
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informed knowledge about the risks and benefits of vaccination. In addition, the National 
Childhood Vaccine Injury Act, section 2126 of the Public Health Service Act (USDHHS, 
1996) required healthcare-provider immunization information to educate parents and 
children during preventive and wellness visits. Federal law also mandates that parents 
receive vaccine-information statements (VIS) and other vaccine information before 
healthcare providers administer any vaccines to children or adolescents. All VIS and 
educational materials provide specific and relevant vaccine information that enhances 
parental awareness and knowledge. Parental knowledge and awareness influences 
positive vaccine perceptions and attitudes associated with parental vaccine acceptance for 
children and adolescents (Dorell, Yankey, Byrd, & Murphy, 2012; Glanz et al., 2010; 
Klein et al., 2012). Healthcare-provider information is important and influenced 89.7% of 
positive parental vaccination decisions (Kennedy et al., 2011). Physicians routinely 
recommend and administer MMR, OPV/IPV, and Td/Tdap childhood and adolescent 
vaccines. 
Underimmunizations 
Underimmunization was a significant finding in this dissertation, confirming 
previous research. Significant associations arose for underimmunizations (Smith, Chu, & 
Barker, 2004), with race, income, parental marital status, education, and number of 
children in the household (Kesselsa et al., 2012; Salmon et al., 2009). Similarly, children 
of parents who participated in the Special Supplemental Nutrition Program for Women, 
Infants and Children (WIC) were more likely to not have completed a vaccine-dose series 
compared to parents who did not participate in the program (CDC, 2014c; Salmon et al., 




Immunization registries functioned as official repositories of quantifiable 
evidence of adolescent-vaccine access. Immunization coverage for adolescents aged 10 to 
18 years in the United States lagged behind childhood rates for 19- to 35-month-old 
children and adults 65 years and older (CDC, 2010b). Adolescent catch-up vaccine doses 
improved in the NIS-Teen 2008 (CDC, 2009b). Vaccination data collection was through 
national immunization surveys (Smith, Hoaglin, Battaglia, Khare, & Barker, 2005), 
immunization-patient records from providers (Broder, Cohn, Schwartz, & Working 
Group on Adolescent Prevention Priorities, 2008), state and local immunization 
registries, immunization information systems, the Arkansas Children’s Network, and 
NIS-Teen (CDC, 2010b; Children’s Reporting and Information System [CHRIS], 2013). 
Immunization registries are confidential, population-based, computerized information 
systems that attempt to collect vaccination data about all children in a geographic area 
(CDC, 2010c, p. 5). Local immunization registries focus on their geographic catchment 
area, thereby providing tools for monitored immunization assessment and surveillance. 
Healthy People 2020 objectives for adolescent immunization are difficult to achieve. The 
challenges and associated risk factors include vaccine safety (Baggs et al., 2011), access 
to immunization, and provider-practice guidelines. In studies, health providers’ influence 
accounted for 21.5% of risk factors; parental attitudes included mistrust of safety of 
vaccines at 5.7%. Parental reluctance or refusal also contributed as challenges (Cooper et 
al., 2008; Glanz et al., 2009; Smith, Kennedy, Wooten, Gust, & Pickering, 2006). 
Arkansas immunization rates reported in the immunization-information-systems 
data for children between 19 and 35 months declined from 78% UTD (CDC, 2008a) to 
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71.4% UTD coverage (CDC, 2010b, p. 10). The UTD criteria were four or more doses of 
Td/Tdap; three or more doses of OPV/IPV; one or more doses of meningococcal 
conjugate vaccine; three or more doses of Hib; and three or more doses Hep B vaccine 
(for 4:3:1:3:3). The vaccination 4:3:1:3:3:1:4 dose series has additional four or more 
doses of pneumococcal conjugate vaccine (CDC, 2010b, p. 17). 
Adolescent Vaccine Coverage: Reducing Disease Recurrence and Outbreak 
Key public health contributions to social change with the implementation of 
viable vaccine strategies included reduction in morbidity, disability, and death from 
vaccine-preventable infectious diseases. The effect of middle school-entry requirements 
positively impacted adolescent vaccine coverage. Coverage rates for Hep B vaccines 
increased among adolescents (91%) in states with school-entry requirements (CDC, 
2011m; Wilson, Fishbein, Ellis, & Edlavitch, 2005) compared to (58%), p > .001 in states 
without school-entry vaccine requirements (CDC, 2011n, 2012b; Jacobs & Meyerhoff, 
2004). 
Disparities in Immunization Coverage between NHAs and FCAs 
I identified three reasons adolescents are placed in foster-care services: abuse, 
abandonment, and neglect from their birth parents (American Academy of Pediatrics 
[AAP], 2005). When adolescents were removed from their natural birth home to foster 
care, such actions caused difficult and stressful situations for the adolescent and the 
medical home. Adolescents displaced from their birth family and foster parent(s) must be 
assured they will receive the best possible emotional and physical care (AAP, 2005; 
CDC, 2014c; Leathers, 2005). Because many FCAs were affected by emotional or 
developmental problems, foster parents often face the unfortunate choice of either 
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tackling any psychological issues or obtaining routine preventive health services, such as 
immunization, often to the demise of the latter (AAP, 2005; Leathers, 2005). 
Another barrier to preventive health services FCAs often face is that birth parents 
retain authority to provide consent for all health and medical procedures (American 
Academy of Child and Adolescent Psychiatry [AACAP], 2005; Freundlich, 2003; 
Humiston et al., 2013). These health and medical procedures include immunizations, 
reproductive health, sexually transmitted diseases, HIV testing, and substance abuse 
(AACAP, 2005). The birth parent’s consent often wanes, given the contentious situation 
that result in the removal of the adolescent from the home. Unlike FCAs, those in the 
natural-home setting are unlikely to face these barriers. Barring particular circumstances 
such as lack of health insurance preventing access to preventive health services, most 
adolescents in the natural-home setting adhered to prescribed preventive health services 
(AACAP, 2005; Freundlich, 2003). 
Arkansas Immunization Laws 
Arkansas Immunization Laws for School Enrollment Grades K–12 
Arkansas legislators enacted more than 12 immunization-important laws and 
amendments since 1987 (ALB, 1987). Five of these laws were significant immunization 
laws that grounded the relevance of this study. These five significant AILs were enacted 
in 1987, 1989, 1993, 1995, and 1997, and appear in Table A3 of Appendix A. These five 
immunization laws relate to five critical immunization areas in the scope of this study: 
child care and school-entry vaccine requirements; immunization access, financing, and 
schedules; a statewide immunization registry in Arkansas; adequate minimum percent 
levels of immunization coverage, specific required number of vaccine doses for each 
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series, and vaccine types; disease prevention (ALB, 1995b); and outbreak control. The 
2003 immunization laws had one major societal development: authorizing exemptions for 
medical, personal, religious, and philosophical beliefs (ALB, 2003). Arkansas legislative 
Act 141 of 1987 authorized the Arkansas State Board of Health to mandate proof of 
measles, rubella, and other disease immunization prior to enrollment in daycare facilities 
and schools (ALB, 1973) and Arkansas colleges and universities. 
The Arkansas 1987 immunization law stated two purposes, required proof of 
immunity, and alleviated the potential for an outbreak of communicable diseases (ALB, 
1987). Arkansas legislative Act 387 of 1989 committed to achieving and maintaining 
adequate immunization levels for all children in Arkansas. The minimum required 
immunization levels established by law were 95% of children in public and private 
schools and above 90% of children in childcare facilities (ALB, 1989). 
Arkansas legislative ACT 591 of 1993 addressed availability, adequacy, 
promotion, and use of immunization programs for infants and preschool children in 
Arkansas. These legal provisions also enhanced achievement of minimum immunization 
levels of 95% of children in public and private schools and above 90% of children in 
childcare facilities (ALB, 1989). Two Arkansas laws, Act 432 and 685 of 1995, promoted 
the efficiency and effectiveness of immunization services and coverage for all children in 
Arkansas. 
ACT 685 of 1995 mandated coverage of children’s preventive health care (ALB, 
1995a) from birth through the age of 18, with periodic preventive-care visits (ALB, 
1995b), and appropriate immunizations. ACT 685 funded immunization services under 
the Medicaid program in the State of Arkansas and eased the financial burden for low-
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income, uninsured children through benefits for recommended immunization services. 
The law also provided exemptions for eligible children from any copayment, 
coinsurance, deductible, or dollar-limit provisions in the health-insurance policy. 
ACT 432 of 1995 established the Arkansas statewide childhood-immunization 
registry. The AIR serves three functions: The AIR provides information on childhood-
immunization status from birth to 22 years to parents, guardians, and providers. Second, 
AIL ACT 432 requires physicians and health providers to register and report all vaccines 
administered to children and adolescents from birth to 22 years (ALB, 1995a). Third, AIL 
ACT 432 imposed a penalty of $25 dollars on all providers who do not report 
administered vaccines to the registry (ALB, 1995a). 
In 1997, two AILs, ACT 870 of 1997 and ACT 871 of 1997, mandated 
immunization prior to school enrollment and required specific vaccines for all children 
(ALB, 1997a, 1997b). These two laws impacted the 1990 birth-cohort school enrollment. 
These students were the first adolescent-age cohort to comply with FVSE requirements. 
The law required immunizations for students in kindergarten through 12th grade who 
attended Arkansas schools (ALB, 1997a). AILs also authorized the ADH and Arkansas 
Department of Education to impose penalties for violation. 
Arkansas Act 871 of 1997 also placed compliance enforcement responsibilities on 
school boards, superintendents, and principals of all schools. In PCA, school nurses have 
direct responsibility to verify immunization records and require each student to receive 
all age-appropriate vaccines (ALB, 1987). AIL ACT 870 of 1997 authorized the 
Arkansas State Board of Health to require school-children receive immunization prior to 
enrollment in public or private school from kindergarten through 12th grade, or childcare 
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facilities, and for other purposes. Similarly, ACT 871 required age-appropriate 
immunization of children with OPV/IPV, Td/Tdap, red (rubeola) measles, rubella, and 
other diseases designated by the State Board of Health. 
Arkansas Immunization Exemptions 
ACT 999 of the 2003 Arkansas legislative regular session authorized 
immunization exemptions based on philosophical, religious, and personal beliefs. The 
ADH is the only legal authority to approve and grant exemptions each year (ALB, 2003). 
Several researchers suggested associations among immunization exemptions, 
immunization coverage, and immunization rates. In Arkansas, requests for immunization 
exemptions increased following 2003 (Safi et al., 2012; Thompson et al., 2007). 
However, no published studies exist on specific associations between immunization rates 
and exemptions. In addition, no published studies exist on 1990 PCABC adolescent 
immunization rates, based on analysis of AIR data in the literature. 
Changes in Arkansas Rules and Regulations 1990–2012 
AIRR changes were consistent with ACIP adolescent-vaccine routine 
recommendations. Arkansas school-entry vaccine requirements were limited to five 
vaccines, tetanus and diphtheria toxoids, and Tdap (CDC, 2013). The human 
papillomavirus and meningococcal conjugate vaccine were also recommended for 
adolescents (CDC, 2013). The ADH increased VAR-dose requirements to two dose series 
in AIRR in 2006 due to the resurgence of VAR in Arkansas (Lopez et al., 2006). 
Childhood and adolescent vaccines recommended against 11 childhood diseases 
in the United States since 1900 are Hep B, Td/Tdap; measles, mumps ( CDC, 2012d), 
congenital rubella syndrome CRS, Hib, OPV/IPV (Salk, 1955b), smallpox, and VAR 
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(CDC, 1999d). These 11 vaccines, except for smallpox, were required for school entry in 
Arkansas and established in Table II immunization regulations for children attending 
kindergarten through 12th grades (ADH, 2008). Adolescent immunization changes 
applicable to this study are changes in the number of vaccine doses and schedules 
implemented between 2003 and 2008. Extensive cohort vaccine changes appear in 
Appendix A., Table A2. 
Arkansas adolescent immunization rates were persistently low, compared to 
national immunization indicators established in Healthy People 2020 (2012). Arkansas 
immunization rates ranked lower compared to other states in the region with similar 
demographics and rural populations. The Arkansas 1995 immunization law required 
vaccine compliance and immunization reporting for enrollment in daycare facilities, 
Grades K–12, colleges, universities, military, and for state employees (ADH, 2008; ALB, 
1995a). The 1995 immunization law directly improved adolescent immunization rates 
and indirectly reduced immunization disparities among adolescents. 
Evaluating Changes in Arkansas Rules and Regulations 2000–2008 
Evaluation changes in Arkansas rules enhanced school-entry immunization 
requirements. Arkansas rules and regulations pertaining to changes in vaccine types, 
number of doses, and vaccine administration from 2000 to 2008 were important in 
compliance with school-entry immunization requirements. Immunization relationships or 
correlations existed between changes in adolescent immunization rates and changes in 
Arkansas and national requirements (Kroger, Sumaya, Pickering, & Atkinson, 2011). 
Arkansas State mandated immunization rules and regulations, influenced changes in 
quantitative variables such as number of doses required for completion of vaccine series, 
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age-appropriate doses, and vaccine UTD coverage. This evaluation of changes in 
adolescent immunization regulations facilitated assessment and determination of any 
relationships or correlations to changes in immunization rates and changes in state-
mandated immunizations. 
Change emphases were on vaccine doses because no changes had occurred in 
AIRR since 1995 (see Appendix A, Table A2; ADH, 2008). The 2000 Table II of AIRR 
requirements were limited to adolescents spanning seventh through 12th grades. A 
second criterion was age-appropriate completion of required immunization for children 
aged 13 to 18. Adolescent students in the seventh grade UTD required three doses of 
Tdap, three doses of Hep B vaccine, two doses of a measles-containing vaccine (usually 
MMR), three doses of OPV/IPV vaccine, and one dose of VAR vaccine (ADH, 2000). 
Adolescent transfer students from seventh grade through 12th grade received similar 
UTD requirements (ADH, 2000). The chronological list of the immunization rules and 
regulations between 2001 and 2008 follows from Table II of the 2001 AIRR. 
In 2001 and 2002, no new changes or additions accrued for adolescents who 
began seventh through 12th grades. In 2003, AIL authorized exemptions for medical, 
religious, and philosophical beliefs (ADH, 2003). AIL made no changes in 2004 and 
2005 for adolescents. In 2006, Table II included recommendations for the addition of a 
second dose of VAR for adolescents (CDC, 2006a) in seventh grade through 12th grades 
(ADH, 2006). No changes accrued in 2007 or 2008. 
Solution to Low Adolescent Immunization 
Adolescent immunization solutions to low-immunization rates were implemented 
at policy and individual levels. The Healthy People 2000 national health promotion 
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identified immunization as a national health priority (USDHHS, 1999). Federal solutions 
to low-immunization rates (Kalies, Redel, Varga, Tauscher, & von Kries, 2008) since 
1994 included funding eligibility insurance programs, Medicaid, and the VFC program 
(CDC, 2012l; Zhou, Santoli, et al., 2005). Federal law required VIS sheets for each 
vaccine. A VIS was an immunization strategy and a national policy (USDHHS, 1987) 
that targeted education of adolescents, parents, and physicians on vaccine safety and 
adverse events. Healthcare providers educated parents, adolescents, and children before 
administering vaccines. These health-promotion strategies and mechanisms targeted 
multiple levels that influenced individual health behaviors at the interpersonal, 
community, organization, and policy levels. 
The individual immunization health-behavior-change approaches contributed to 
increases in adolescent immunization rates (Stokley et al., 2011). The parental-influence 
approach targeted interpersonal increases in knowledge, awareness, and attitudes, and 
provided potential solutions that addressed parental reasons for not immunizing 
adolescents (Darden et al., 2011). Individual health-behavior change for parents involved 
multiple mechanisms of influence that incorporated social networks, organization, and 
policy influences. Parents who refused to vaccinate their adolescents had to sign and 
document the informed refusal of consent to vaccinate (Burns & Zimmerman, 2005). 
WIC and VFC programs improved parental awareness (Kennedy, Stokley, Curtis, & 
Gust, 2011) and knowledge of the benefits of vaccines, contributing to increases in 
childhood and adolescent access to vaccines and immunization rates. 
Community solutions included clinical decision support and maximized 
opportunities to immunize adolescents during each wellness visit (Schaffer et al., 2008; 
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Szilagyi et al., 2008). Solutions included immunization standing orders and EHR 
immunization audits to minimize missed opportunities and increase immunization rates 
(Burns & Zimmerman, 2005). The implemented reminder/recall systems were time and 
cost intensive (Burns & Zimmerman, 2005); however, direct immunization 
communication between providers and vaccine recipients or parents of recipients were 
effective and increased immunization rates (T. C. Davis et al., 2001). Healthcare 
providers who used EHR recall/reminder systems improved adolescent immunization 
rates (Clark, Butchart, Kennedy, & Dombkowski, 2011; Fiks et al., 2013; Hambidge, 
Phibbs, Chandramouli, Fairclough, & Steiner, 2009; Szilagyi et al., 2002). Pharmacists’ 
additional roles as vaccinators also increased immunizations in inner-city, rural, and 
nontraditional sites beyond local county health units (Hogue, Grabenstein, Foster, & 
Rothholz, 2006; Ndiaye et al., 2003; Neuhauser, Wiley, Simpson, & Garey, 2004). 
Policy solutions included school-entry laws (ALB, 1967; Omer, Salmon, 
Orenstein, deHart, & Halsey, 2009; Orenstein & Hinman, 1999), access to immunization 
in Arkansas (ALB, 1967) through federal and state eligibility programs such as VFC, 
Medicaid, and supplemental children’s insurance (ARKIDS) programs in Arkansas 
(ADHS, 2011c). Legislative actions of immunization laws and school-entry requirements 
influenced societal and environmental levels. School-based immunization clinic practices 
aligned with increased adolescent immunization coverage (Allison et al., 2007; Daley et 
al., 2009; Federico, Abrams, Everhart, Melinkovich, & Hambidge, 2010; McNall, Lichty, 
& Mavis, 2010). 
The central concept of adolescent immunization health was individual behavior 
change related to specific health, contributing large social-change impacts and beneficial 
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economic gains (Lee, Feaver, Miller, Hedberg, & Ehresmann, 2004). Commensurate 
health gains decreased childhood disease and deaths and increased life expectancy. 
Adolescent immunization contributed to several other great achievements of vaccinations 
in the 20th century and the first 2 decades of the 21st century (CDC, 1999c).  
The specific health problems of unvaccinated adolescents related to individual 
behavior change were VPD resurgence, outbreaks, disease transmissions, and 
importations of measles, mumps, pertussis, and VAR (CDC, 2006b, 2006e, 2012d). Other 
effective solutions that increased immunization rates included reduced adolescent-crowd 
opportunities, minimized proximal interaction between disease carriers and exposed 
unvaccinated or underimmunized individuals, increased social distancing, and school 
closings during outbreaks (Glass & Barnes, 2007; C. Jackson, Vynnycky, Hawker, 
Olowokure, & Mangtani, 2013; Miller et al., 2010). During the prevaccine era of the 19th 
and 20th centuries, childhood diseases and mortality were prevalent (CDC, 1999a). Since 
vaccines were licensed and introduced as part of a health-promotion strategy, childhood 
diseases have significantly decreased and mortality has declined (CDC, 2000a). For 
example, approximately 4 million people were infected annually with measles during the 
1963 measles prevaccine era (Zhou et al., 2004). 
Vaccines contributed to personal high economic costs (Lee et al., 2004; Zhou, 
Harpaz, Jumaan, Winston, & Shefer, 2005) and societal costs (Shapiro et al., 2011), and 
provided communitywide and societal protection from disease morbidity and mortality 
(Zhou et al., 2004). Parental delayed vaccination of their children as a consequence of 
vaccine hesitation, resistance, and refusal at the individual level increased the risk of 
resurgence of diseases (Opel et al., 2011). Disease risks were greater during the 
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predominant host-agent-environment models of disease experienced during the 
prevaccine era of societal and environmental outbreaks, epidemics, and pandemics (Opel 
et al., 2011). 
The relevance of adolescent immunization is more important today than in the 
20th century as a result of narrow social distancing (Reluga, 2010). In addition, 
adolescent immunizations are relevant because of the frequency of disease transmission 
facilitated by global travel, the availability of cost-effective vaccines (Whitney, Zhou, 
Singleton, & Schuchat, 2014), and increased parental objection and refusal of vaccines 
(Diekema, 2012; WHO, 2011a). Experiences ranging from immunization resistance to 
global poliomyelitis eradication initiatives aligned with parental health-behavior 
influences in Afghanistan, India, Nigeria, and Pakistan (CDC, 2009g; WHO, 2011b). 
Increased use of vaccines provided effective defenses in environments where global 
disease transmissions were facilitated by factors related to individual, community, and 
societal behaviors. 
Theoretical Foundation 
The Theory of Games 
The theoretical foundation used in this study was the TOG (von Neumann & 
Morgenstern, 1944). I applied TOG constructs as a mathematical model to measure 
individual vaccine behavior (Bauch & Earn, 2004; Bauch et al., 2003), called individual 
equilibrium, because the FVSE affects the group’s interest, known as the group optimum. 
Individual equilibrium examines the probability and cost of delayed vaccination among a 
population, whereas the group optimum examines the probability of preemptive 
vaccination coverage and minimum payoff death or disability from VPD, for which there 
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is routine vaccination among a population. If the proportion of preemptively vaccinated 
individuals in the group is significantly large and the disease is sparsely distributed across 
the population, then community or herd immunity exists in the group. Thus, community 
or herd immunity mitigates the payoff for preemptive vaccination in the group, to avoid 
or minimize death or disability. Individuals with self-interest behavior therefore choose 
not to become vaccinated. 
Framework for Modeling 
TOG was an important framework used to model an individuals’ probability of 
vaccination, calculated for the 1990 PCABC. I also calculated the group payoff deaths for 
preemptive vaccination coverage. Vaccination payoff deaths references the cost 
associated with VPDs if individuals with self-interest in the group were not vaccinated. 
The TOG construct predicted individual and group vaccine behavior. This predictive 
function was essential and significant in preemptive vaccination calculations (Bauch et 
al., 2003) for public health interventions of disease resurgence, outbreaks, epidemics, and 
pandemics. Participants’ strategies, individual self-interest adolescent actions, and group 
altruistic action are key constructs of the TOG (Bauch et al., 2003). 
The TOG was also useful in evaluating vaccine policy and assessing advantages 
of vaccination self-interest and group utilitarian optimization (Galvani et al., 2007). The 
probability, proportion, frequency, and immunization outcome of UTD variables aligned 
with the key predictive payoff death functions in this quantitative study. These 
immunization outcome UTD variables were vaccine-coverage rates for FVSEs for school 




The social-change impact of adolescent immunization-uptake prediction is 
valuable to public health functions. The TOG application in immunization quantitative 
analysis incorporated in several research studies included vaccine uptake among 
adolescents (Reluga, Bauch, & Galvani, 2006), immunization rates (Niccolai & Hansen, 
2015; Skoff & Martin, 2016), UTD predictors, and uptake coverage (Ibuka, Chapman, 
Meyers, Li, & Galvani, 2010). The TOG was an effective model used in this study to 
investigate and describe risk factors associated with health outcomes (Bauch et al., 2003). 
The low-immunization rates among populations explained the individual and group-
equilibrium framework (Bauch et al., 2003). For example, VGT explained how self-
interest, altruistic decisions, and maximization and minimization of payoff concepts or 
frameworks (Bauch & Earn, 2004) influenced immunization policy (Bauch et al., 2003). I 
applied TOG constructs and determined how individuals’ decisions or actions related to 
immunization uptakes and coverage rates probabilities (Bauch & Earn, 2004). Similarly, 
Arkansas immunization policy influenced school-entry vaccine requirements (ADH, 
2008) and contributed to increased immunization rates for specific vaccines (Morita, 
Ramirez, & Trick, 2008). 
The TOG was important in understanding, investigating, and developing solutions 
for health problems with multilevel risk factors such as immunization (Bauch & 
Bhattacharyya, 2012; Bauch et al., 2003). The TOG framework was also applicable to 
significant determinants and predictors of vaccine uptake (Bauch, 2005) during acute 




Summary and Conclusion 
Summary 
This study determined how HOR aligned with vaccination coverage UTD. This 
associative concept was significant in vaccine-coverage improvements and interventions. 
Increased adolescent immunization rates contribute to community health and prevention 
of VPD outbreaks. Individual decisions to vaccinate often relate to self-interest (Ibuka et 
al., 2014). VPD outbreaks among school children and index cases are more likely to 
occur among unvaccinated children compared to vaccinated children with waned 
immunity (Skoff, Cohn, Clark, Messonnier, & Martin, 2012; Sugerman et al., 2010). 
VPD outbreaks are also common among highly vaccinated populations that were 
underimmunized and only received one dose in a vaccine series (Lopez et al., 2006; 
Sugerman et al., 2010). 
Outbreaks of VPDs reported in Arkansas included pertussis in 2001 (Wheeler et 
al., 2004) and VAR in 2005 (Lopez et al., 2006). Disease outbreaks such as pertussis 
associated with pneumonia, encephalitis complications, hospitalization, and deaths 
reported during the California pertussis outbreak (California Department of Public 
Health, 2010). School outbreaks of VPDs frequently disrupt educational activities, 
increase absenteeism due to illness (King et al., 2006), and lead to hospitalization and 
school closure (M. M. Davis et al., 2008). VPDs such as VAR are highly contagious and 
easily transmitted (CDC, 1999c) by airborne and contact between persons (Ross, 1962; 
Schmid & Jumaan, 2010). Control of VPD outbreaks is financially costly and a public 
health burden (Wheeler et al., 2004). 
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Societal and individual health costs were consequences of unassured full 
immunization coverage among at-risk populations. At the societal level, these costs 
include disease transition among socially congregating adolescents at public venues and 
events. The outcomes of congregating groups at sports events, church activities, and 
shopping complexes often results in increased illness and hospitalization in the 
community (Reynolds et al., 2008). At the individual level, costs associated with lost 
productivity and wages often occurs when parents or guardians stay home to care for 
affected children (M. M. Davis et al., 2008). 
Conclusion 
For this study, I analyzed data from the AIRD to establish vaccine UTD status for 
the 1990 PCABC. Differences emerged in vaccine-coverage uptake between NHAs and 
FCAs among the PCABC. PCABC FVSE immunization rates were included in the four 
main outcomes. A literature review gap emerged in that peer-reviewed studies on 
disparities of vaccination coverage for the FVSE among NHAs and FCAs in the 1990 
PCABC were not found or did not exist. The AIRD analysis implemented in this study 
quantitatively addressed this gap in the literature. Several peer-reviewed studies 
previously addressed components of immunization in Arkansas, including infant and 
childhood coverage rates, VPD outbreaks, vaccine exemptions, school-enrollment 
requirements, immunization policies, and state-mandated immunization laws. However, 
these studies did not apply quantitative analysis of immunization-registry data, nor did 
they focus on NHAs and FCAs in the 1990 PCABC to establish immunization-coverage 
rates for the FVSE. The NIS-Teen coverage rates reported for adolescents in Arkansas 
(CDC, 2008a; Darden et al., 2013; Jain, Singleton, Montgomery, & Skalland, 2009; 
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Stokley et al., 2011) were based on a random-digit dialing survey (RDDS) of sampled 
households. RDDS consents were corroborated with consent from participants to use 
provider-based immunization data. In contrast, this study was an archival cohort analysis, 
and consent from participants was not required to access deidentified registry data. I 
satisfied all institutional review board (IRB) requirements and gained approved for this 
study. 
The next chapter of this dissertation, Chapter 3, includes the research 
methodology. Key sections of Chapter 3 consist of the study design, research questions, 




Chapter 3: Research Method 
Study Purpose 
I achieved four main purposes in this quantitative study. The first was to calculate 
and compare adolescent immunization rates between the 1990 adolescent PCABC 
adolescent and the U.S. national adolescent immunization data from 2003 and 2008. The 
second purpose of the study was to identify whether an association emerged between 
HOR, defined as NHA or FCA, and the UTD status of FVSE. The third purpose was to 
determine whether disparities in immunization rates existed based on sociodemographic 
risk factors that included age, gender, race, and ethnicity in PCAs. The fourth purpose, 
based on the TOG, was to develop mathematical models to illustrate how an individual’s 
decision to receive vaccination for the FVSE affected the group interest. 
Research Design and Rationale 
Research Design 
I used the cross-sectional study design to conduct this quantitative inquiry. 
Because information on vaccine coverage and HOR were captured at a single point in 
time, the cross-sectional design was the ideal study design; however, no feasible methods 
could account for temporality. Although other quantitative study designs were useful, the 
inability to account for temporal order made their utility in this instance inappropriate. 
Design Rationale 
The cross-sectional study design was an appropriate design to explain the problem 
statement and answer the four research questions in this study. I analyzed the individual 
immunization registry data to establish immunization rates, vaccines with low uptake, 
and UTD status for NHAs and FCAs, all collected at a single point in time. The cohort 
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independent variable was the HOR, defined as NHA and FCAs. The dependent variables 
were five vaccines required by AIL for school entry: diphtheria, Hep B, MMR, 
OPV/IPV, and VAR. The individual immunization records were coded with unique 
identification criteria and formulae for specific recommended vaccines for school entry 
(ADH, 2008). 
Operationalization of the Theoretical Construct 
Operationalizing Game Theory 
The TOG (von Neumann & Morgenstern, 1944) theoretical construct was 
operationalized using several steps. First, the variables that corresponded to TOG 
constructs included individual equilibrium and group optimum, identified for each FVSE. 
Next, I developed mathematical models to examine individual equilibrium and group 
optimum for each of the FVSE in the 1990 PCABC. Because county data reported to the 
CDC does not distinguish NHA and FCA, I calculated overall probabilities. Additionally, 
if county data for PCA were incomplete in the national database, I used a representative 
sample of the 1990 U.S. birth cohort to calculate attack rates. 
I measured individual health behavior using the frequency function of all vaccine 
doses recorded for that type of vaccine. Appropriate individual immunization was the 
maximum number of doses required, according to recommendations of the CDC for that 
specific vaccine to complete the dose series (CDC, 1999c). For example, Tdap vaccine 
had a maximum of four doses to complete the vaccine series compared to MMR or VAR, 
which required a maximum of two doses to complete the vaccine series. The frequency of 
completed vaccine series used to determine probabilities needed in the calculation of the 
individual equilibrium and group optimum was equal to the total number of individuals 
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with completed vaccine series in the study population. The frequency function was a 
statistical tool that predicted vaccination proportions and probabilities (Bauch, 2005) for 
a given TOG individual equilibrium and group optimum construct. Bauch and Earn 
(2004) used the TOG to explain how individual behavior contributed to adolescent 
immunization coverage rates. 
The Theory of Games Constructs 
The two constructs used as part of the TOG in this study were individual 
equilibrium and group optimum. The payoff calculations used in both mathematical 
models were based on data obtained from the AIR and from the CDC’s immunization 
database, which compiled national immunization rates. 
The following parameters defined the equations to express the individual 
equilibrium and the group-optimum equation: 
• C = optimum cost; 
• Evac = the efficacy of vaccination for an individual who receives the vaccine; 
• dv = the probability of death of the individual from vaccination; 
• peff = the proportion effectively vaccinated; 
• p = the proportion of individuals preemptively vaccinated; 
• r = the risk of attack from a VPD after an outbreak; 
• ϕs(p) = the probability that a delayer becomes infected with disease after an 
outbreak; 
• ds = the probability of death due to a VPD; 
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• ϕv(p) = the probability that a delayer is vaccinated successfully after an 
outbreak; 
• N = the population size. 
The population size was equal to N adolescents in the 1990 PCABC and was 
based on U.S. population census data. The importance of adolescent vaccination is the 
cost of vaccination in terms of death. The cost equals the total number of deaths where 
Evac = −dv and is the probability outcome (Q; Bauch et al., 2003). The group optimum cost 
(C(p)) is the vaccine coverage level needed to avert deaths due to VPD. 
Assumptions 
I noted several assumptions in the calculation of individual equilibrium and group 
optimum. First, the risk of attack from a VPD after an outbreak, r, was based on a priori 
knowledge found in the literature. Additionally, the ϕs(p), probability that a delayer 
became infected after an outbreak, as well as the ds, probability of death due to a VPD, 
was based on a priori knowledge found in the literature. The ϕv(p), probability that a 
delayer was vaccinated successfully after an outbreak was based on the number of 
available vaccine series available in PCA. I assumed enough vaccine existed for any of 
the FVSE, available for all unvaccinated adolescents. I based all other probabilities on 
information obtained from the AIR. 
Constructs Used in the Theory of Game 
Individual equilibrium. I used the individual-equilibrium equation to examine 
the relationship between those who preemptively received vaccination and those who 
delayed vaccination for each of the FVSE. The payoff for an individual who received 
vaccination can be expressed as Evac = −dv where dv is the probability of death from 
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vaccination. Because the probability of death due to vaccination was usually small, dv 
was usually ignored in the equation; therefore, Evac was usually assumed to be 100%, or 1 
when expressed as a probability. I therefore focused on the effect of an individual 
delayed vaccination and the risk of the disease if an outbreak occurred, Edel(p). The 
equation examined vaccine delay and the payoff associated with delay was 
Edel(p) = −r[ϕs(p)ds + ϕv(p)dv], 
where Edel(p) calculates the payoff to an individual who chose to delay vaccination; r is 
the risk of attack from a VPD after an outbreak, calculated as number of people likely to 
become infected if there were no vaccine protection divided by total population at risk of 
becoming infected; ϕs(p) is the probability that a delayer becomes infected with disease 
after an outbreak, calculated as the total number of eligible unvaccinated people divided 
by the total population at risk of becoming infected; ds is the probability of death due to a 
VPD, calculated as the total number of deaths among those who were unvaccinated from 
VPD divided by the total population at risk of becoming infected; ϕv(p) is the probability 
that a delayer is vaccinated successfully after an outbreak, calculated as the total number 
of disabilities among delayers receiving the vaccination divided by total number of 
delayers who received vaccination; and dv is the probability of death of an individual 
from vaccination, calculated as the total number of deaths due to the vaccination divided 
by the total number of those who received the vaccine. 
Because the goal of individual equilibrium, Pind, is to examine the relationship 
between Evac and Edel, one would expect to see a maximized payoff from receiving 
vaccines, where Evac = 1 or 100% vaccine efficacy, no deaths from vaccination, and a 
minimized payoff of delaying vaccination where Edel = 0 or no payoff for delaying 
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vaccination. Therefore the association expected was Evac > Edel. If Evac ≤ Edel; then the 
individual equilibrium, Pind, may approach zero where, although the vaccine is effective, 
the payoff for delaying vaccination may not pose any additional risk of harm (Bauch et 
al., 2003). Under such circumstances, individuals may choose not to be vaccinated, 
thereby eliminating individual equilibrium, Pind. An important assumption to make when 
calculating the individual equilibrium is that individuals will act to increase survival from 
a VPD when vaccines are readily available. See Table 1 on how I identified each 
construct. 
Table 1 
Theory of Game Parameters, Definition, and Sources 
Parameter Definition Source 
r Risk of attack from a vaccine preventable 
disease for an individual  
CDC’s U.S. morbidity national data published in 
the Morbidity and Mortality Weekly Report 
ds Probability of death from a vaccine-
preventable disease for an individual  
CDC’s U.S. mortality national data published in 
the Morbidity and Mortality Weekly Report 
ϕs(p) Probability an individual delayer becomes 
infected after an outbreak 
CDC’s U.S. morbidity national data published in 
the Morbidity and Mortality Weekly Report 
ϕv(p) Probability an individual delayer is 
successfully vaccinated after an outbreak 
Arkansas vaccine stockpile information. CDC 
national vaccine stockpile information. 
N Population size 2000 U.S. census data, for PCA 
Note. Adapted from “Group Interest Versus Self-Interest in Smallpox Vaccination Policy,” by C. T. Bauch, 
A. P. Galvani, and D. J. D. Earn, 2003, Proceedings of the National Academy of Sciences, 100 for Pulaski 
County, Arkansas, Birth Cohort Analysis, 2015. 
The group optimum. For the group interest, it was important to minimize the 
total number of deaths due to vaccination and infection if an outbreak of a VPD occurred. 
Thus, to examine group optimum, I applied the equation 
C(p) = pdv + r(1 − p)[(ds − dv)ϕs(p) + dv], 
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where C(p) was measured as a probability between zero, and 1 was the coverage level 
that would have to be imposed to minimize the total expected number of deaths due to a 
VPD. All other variables are the same as those described for individual equilibrium and 
reported in Table 1. 
Research Methodology 
Immunization Registry Archival Data 
The initial process began with a cover letter and an attached summary of the 
project proposal sent to the deputy director of health programs and state epidemiologist at 
ADH. I sent a request letter to the ADH director for permission to examine official 
archived State Board of Health minutes from 1980 to 2012. These minutes provided 
gainful understanding of background knowledge on the history, policy, and practices of 
immunizations in Arkansas. 
From April 2011 to August 2012 the ADH Immunization and Communicable 
Disease Branch offered me an unpaid graduate internship to work on special projects. I 
initiated the process to request immunization data access during this period. Another 
access-to-data requirement was a memorandum of understanding between ADH and 
ADHS to acquire a foster-care identification roster of Datalink immunization records. I 
sent numerous e-mails and letters of request to ADHS leadership for permission to 
acquire the foster-care identification roster. The ADH Scientific Advisory Committee 




Roadmap to Data Merge 
To obtain the initial list of the 1990 PCABC, I used the Arkansas Department of 
Public Health Vital Statistics database to extract the name, date of birth, gender, race, and 
ethnicity of all children born in 1990 in PCA. The individual birth-record information is 
publicly available when requested. To extract information on children who enrolled in the 
public school system, the list of children born in 1990 was sent to the Arkansas Board of 
Education. Once I obtained the list of identified children who enrolled in public school 
from the Board of Education, this list was sent to the AIR to obtain the immunization 
history of children born in 1990 in PCA who attended public school. 
FCA and NHA data were combined in the immunization-registry data, as required 
by Arkansas law (ALB, 1995a). FCA and NHA data were coded by registry staff—0 = 
FCA and 1 = NHA—then reviewed by a senior epidemiologist before being released to 
me. However, the data were deidentified to protect minors, in accordance with Arkansas 
law (ALB, 1995a). 
The final list obtained from the immunization registry included the patient unique 
identifier, date of birth, age, gender, race, and ethnicity of only cohort children. Figure 1 
illustrates the topography of Arkansas immunization linkage databases. 
Deterministic Data Linkage 
The Arkansas vital-statistics database and the AIRD were large databases that 
contained similar important PCABC unique identifiers and demographic variables (Lin, 
2003). I used these identifiers and variables to develop an optimal file-linkage algorithm 
that yielded quality matched immunization records (Lin, 2011). I performed all linkages 
under close advisement and guidance of the senior statistician at the ADH. I used the 
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algorithm shown in Figures 1 and 2 in the linkage process. The constructed optimal file-
linkage algorithm required three types of data files: birth-certificate data, immunization 
data, and a gold-standard file (Lin, 2011). The birth-certificate-file variables included 
social security number and demographic data (Lin, 2003). The immunization data 
included social security number, date of birth, vaccine type, number of doses, date of 
vaccine administration, and specific demographic data. 
 





Figure 2. Optical file linkage algorithm. 
Note. Adapted from “Designing the optimal file linkage algorithm,” by T. M. Lin, 2003, retrieved 
from Retrieved from http://webcast.hrsa.gov/conferences/mchb/cdc/mchepi2003/index 
.htm, and “Designing the optimal file linkage algorithm OFLA,” by T. M. Lin, 2004, retrieved 
from http://www.lexjansen.com/scsug/2004/Lin%20-%20Designing%20the%20Optimal 
%20File%20Linkage%20Algorithm.pdf. 
The deterministic linkage algorithm achieved accuracy and true positive matches 
of linked records from the independent databases (Lin, 2011). I achieved true positive 
matches of linked records when I combined unique identifiers such as social security 
numbers with gender, name, and birth date variable fields (Grannis, Overhage, & 
McDonald, 2002; Lin, 2011). The deterministic linkage algorithm was accurate for 
matched records, achieved high sensitivity of 90–92%, and maintained 100% specificity 
of linked records (Grannis et al., 2002). Therefore, the deterministic-linkage-algorithm 
method was appropriate to link birth records with immunization records in this study. 
The deterministic method of data linkage was important and matched records 
from the vital records and immunization database (Lin, 2003). The data-linkage process 
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has potential problems associated with errors such false negatives, false positives, and 
duplicate records when matching data sets or records (Bohensky et al., 2010; Lin, 2003). 
Therefore, I matched a proportion of records and a proportion remained unmatched 
(Bohensky et al., 2010). New parameters included the addition of race, gender, and 
ethnicity, assimilated in the linkage to match all unmatched records (Grannis et al., 2002; 
Lin, 2003). 
IRB Approvals 
I completed all ADH IRB requirements, which included Health Insurance 
Portability and Accountability Act (HIPAA) compliance, confidentiality, and privacy 
trainings. This was the required regulatory process to obtain archival data from the ADH. 
I obtained IRB approvals from ADH and Walden University (03-17-15-0137370) and 
eventually obtained the data from ADH, after the dissertation committee approved the 
draft proposal and after Walden University IRB approved the IRB application to conduct 
this study. The Walden approval number for this study is 03-17-15-0137370. 
Instrumentation 
I did not require a study instrument to establish a calculated adolescent 
immunization rate. I used archival data from the AIRD to obtain information on 
immunization rates for the 1990 birth cohort, PCA (ADH, 2008). I obtained archival data 
for the 1990 PCABC upon approval of the ADH SAC. This archival data contained 
immunization histories and records of all children born in PCA between January 1, 1990 
and December 31, 1990. Each individual immunization record contained a history of 
vaccine type, date of administration, demographic, and a deidentified number instead of a 
name. The registry data combined FCA and NHA data, as required by law. The registry 
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staff coded FCA and NHA data; then senior epidemiologists reviewed the coding before 
releasing the data to me. This process ensured protection of minors in accordance with 
Arkansas law. All 1990 cohort names were in the registry. The deidentified data were 
coded as 0 for FCA and 1 for NHA. 
Target Population 
The target population was adolescents in the 1990 PCABC, and had three 
inclusion criteria: (a) adolescents aged 13–18, born between January 1 and December 31, 
1990 in PCA; (b) attended public schools in PCA from 1996 to 2008; and (c) had 
immunization records in the AIRD. The 1990 cohort PCA was stratified in two groups: 
NHA and FCA. FCA represented the high-risk group because of their social status as 
wards of the state. The cohort demographic distribution was by gender; race including 
Caucasian, African American, and other; and age, assumed to be constant because of 
their identical birth year 1990. 
Target-Population Approximate Size 
The ADH reported 9,102 births in PCA in 1990 (ADH, 2015). The targeted 
analyzed population of adolescents born in 1990 in PCA was limited to the universe of 
individuals who were 13 years old in 2003, attended public school, and had vaccine 
records in the AIRD. 
Foster-Care Sample Size 
The average annual enrollment of FCAs in the ADHS system from 2000 to 2008 
was 83.11 per year. The largest foster-care enrollment was 164 adolescents in 2006. The 
estimated annual sample-size range was 83 to 164 adolescents (ADHS, 2010). The 
sample size was less than the cohort population due to a proportion who attended private 
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school, immigration and emigration, relocation, mortality, and loss to follow up. Several 
other factors influenced the FCA sample size such as social family structure, domestic 
violence, family social disruption, and judicial actions due to child abuse and 
maltreatment (ADHS, 2010). 
The AIR data were coded for FCA and NHA as zero and 1, respectively. The 
foster-care sample size was based on the total number of adolescents coded as foster care 
in the 1990 PCABC. The AIR received all reported immunization histories, provided 
confirmation, and verified compliance with immunizations for school enrollment (ALB, 
1995a). The AIRD incorporated functions to match the name and unique identification 
roster of adolescents with their immunization histories, for analysis that determined 1990 
PCABC immunization rates. 
Sampling and Sampling Procedure 
Sampling Strategy 
The study sample was drawn from census data of 5,257 births, registered in ADH 
vital statistics, for PCA (ADH, 2015) and from AIRD. All records with date of birth, 
location, date of vaccination, dose, lot number, and type of vaccine administered were in 
the sample and analyzed. Physicians, healthcare providers, and all facilities that 
administered vaccines were required to report the name, date of birth, location, date of 
vaccination, dose, vaccine lot number, and type of vaccine administered to all children 
and adolescents within 30 days to the AIRD (ALB, 1995a). 
Sampling frame 
The sampling frame was based on population and I used the HL7 form for the 
entire cohort population data collection. Healthcare providers are required to use the HL7 
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form to report individually administered immunizations to the registry (ALB, 1993). The 
sampling frame in this study was not a predetermined sample of selected households. 
Inclusion criteria. This study had four inclusion eligibility criteria: vaccine types, 
date of birth and geographic location, specific year interval, and education. The four 
eligibility criteria were (a) children with health-provider-reported immunization records 
for five routinely recommended vaccines required for school entry; (b) children with birth 
dates between January 1, 1990 and December 31, 1990 who were born in PCA, (c) 
eligible cohort children who attended public schools in PCA between 1996 and 2008, and 
(d) vaccine records in the AIR. 
Exclusion criteria. Children who did not attain the four inclusion eligibility 
criteria defined in the cohort period were excluded from the study analysis. The first 
criterion was date of birth. The second criterion was geographic criterion and was limited 
to the contiguous residential zip codes in PCA. The third exclusion criterion in this study 
was school attendance. I excluded adolescents born in 1990 who were not enrolled in 
public schools in PCA. The fourth exclusion criterion was children who did not have 
vaccine records in the AIR. For example homeschooled or adolescents who attended 
private schools were excluded from this study because homeschooled children and 
students who did not attend public school are not required to comply with FVSE 
requirement. 
Procedures for Recruitment, Participation, and Data Collection 
This quantitative study design did not require recruitment, participants, or data 
collection. I analyzed archival immunization data from AIRD. I focused and obtained 
access to deidentified Arkansas adolescent immunization data from ADH and did not 
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require participant recruitment procedures. The data were limited to a 1990 birth cohort 
of all births between January 1, 1990 and December 31, 1990, recorded in PCA. 
I sent two request letters to obtain access to data. I sent the AIRD request letter to 
the Chief of Immunization Branch, ADH to request permission to obtain and use 
deidentified AIRD data. I obtained coded immunization data on FCAs and NHAs. The 
AIR removed all names and social security numbers, and maintained confidentiality and 
privacy protection. The ADH is responsible for all immunization records in Arkansas 
(ALB, 1995a). The process to obtain access to deidentified 1990 birth cohort AIRD was a 
significant challenge, due to regulatory requirements. 
Variable Measurements and Definitions 
Measures of Immunization Status 
Measures of immunization status analyzed in this study was FVSE UTD of 
specific rates for each of the FVSE defined in AIL (ADH, 2008). 
Five vaccines for school entry and adolescent up-to-date status. For 
examination of the UTD of the FVSE, I examined each required vaccine. Table 2 outlines 
each vaccine, the number of doses needed, the interval between each administered dose, 
and the age at which the full vaccine is required. In this study, I examined the 1990 birth 
cohort; most adolescents in this cohort were 13 years of age at the time, and I expected 
that all childhood immunizations were completed. However, in some instances, this was 
not the case. Thus, an adolescent was considered not UTD if any of the following 
occurred: 
1. Any one dose was missing among any of the FVSE; 
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2. The interval between the booster dose (the first dose) and any subsequent dose 
was more than 5 days of when the follow-up dose was expected; 
3. An exception was noted to immunization due to religious or political reasons. 
Thus, the analysis of UTD coverage was based on an all-and-on-time or nothing 
concept. For example, UTD was coded as 1 if the adolescent had all required vaccines in 
a series and these vaccines were given within the stated time. An adolescent was coded as 
0 when doses of a given vaccine were missing or when the interval between the booster 
dose and the follow-up exceeded the maximum allowable time between vaccine series. 















at 2nd dose 
schedule 
Minimum 













4 3–4 months 5–6 months or 
within 8 
weeks of 1st 
dose 
7–18 months 




or within 8 
weeks after 
3rd dose 
11–13 years or 
7th grade 
Poliomyelitis 3 3–4 months 5–18 months 
or 8 weeks 
after 1st dose 
19–48 
months or 8 
weeks after 
2nd dose 







49–72 months N/A N/A 11–13 years or 
7th grade 
Hepatitis B 3 3–4 months 5–12 months 
or 8 weeks 
after 1st dose 
13–18 




or 8 weeks 
after 2nd dose 
11–13 years or 
7th grade 






or history of 
diagnosed 
varicella 
N/A N/A 11–13 years or 
7th grade 
Note. Adapted from “Arkansas State Board of Health: Rules and Regulations Pertaining to Immunization 
Requirements,” by Arkansas Department of Health, 2008, Retrieved from http://www.healthy.arkansas 
.gov/Aboutadh/Rulesregs/Immunizationreporting.pdf. 
Education grade and vaccine completion. Table II in AIL identified specific 
numbers of doses and vaccine types required and completed on or before attaining certain 
grade levels (ADH, 2008). The adolescent was unvaccinated if the dose series was not 
completed and documented or if an exemption was noted in the immunization-registry 
records. 
Certain clinical criteria were based on the immunization schedule, such as age and 
interval since the last dose was received and before the next dose was administered. This 
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interval in time was the time between date of birth and the date when the specific vaccine 
was administered, reported in AIR. If the interval of days between vaccine doses was 
within ± 5 days of the maximum length of time required for the next recommended dose, 
those children was considered vaccinated (ADH, 2008; CDC, 2014a, 2014b). However, 
intervals greater than 5 days of the maximum length of time for any vaccine series 
requiring more than one dose meant I classified the adolescent as unvaccinated, if they 
did have a documented new series of completed vaccinations among those previously 
missed. 
In addition to the age vaccine milestone, I also had a grade-appropriate 
vaccination requirement. The state mandated certain vaccine milestones for kindergarten, 
third grade, and seventh grade, to achieve school-entry requirements. Table 2 simplifies 
the recommended schedule and reflects the expected coverage for all children enrolled in 
public school (ADH, 2008). However, the observed immunization coverage varied and 
because of missed vaccine doses, inappropriate intervals sometimes accrued for 
immunization doses or immunization exemptions (LoMurray & Sander, 2011a). 
Age-appropriate status. Age-appropriate status means the specific duration or 
optimal age to receive all vaccine doses in a series (Kim & Lee, 2011). For example, age-
appropriate status for the first dose of Tdap vaccine was 12–15 months (CDC, 2011i). 
Age-appropriate status was expressed as an age-specific trend through measured 
parameters such as rates of vaccine coverage for age-specific groups: younger than 1 
year, 1 to 10 years, and 11 to 18 years (Skoff et al., 2012). In these measurements, the 
numerator was the number of persons in the age-specific group who received the vaccine 
such as Tdap and the denominator was the total number of persons in the cohort who 
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were eligible to receive the vaccine (Lindley, Smith, & Rodewald, 2011). The cohort 
vital statistics data provided eligibility status. Eligibility-inclusion criteria were based on 
the cohort birth date, January 1, 1990 to December 31, 1990, county birth place of 
Pulaski, and valid vaccine doses administered between January 1, 1990 and December 
31, 2008. 
Measure of Home Status 
The ADHS foster-care criteria were legal court and state-award assignment of 
children for social custody-protection services. Children assigned to ADHS social-
protective services were registered in the CHRIS system as foster-care children eligible 
for adoption (ADHS, 2010). The CHRIS system was the source for FCA demographic 
information used by the registry to match vaccine records. The ADHS provided an 
identified FCA name roster to ADH. The ADH matched the FCA names with their 
corresponding vaccine records. All FCA and NHA vaccine records in AIRD were coded, 
deidentified with unique numbers, and then released to me. The ADH also processed 
NHA and FCA vaccine records to protect adolescents and maintain confidentiality and 
privacy. NHAs were individuals who were not wards of the state, never enrolled in 
ADHS, and were not identified in the CHRIS system. 
Variable Definitions 
Vaccination coverage uptake (VCU): The number of adolescents with FVSE-
completed dose series divided by the number of adolescents in the 1990 birth cohort, 
PCA, and then multiplied by 100. 
Immunization rate: The number of adolescents in the age group (1990 PCABC) 
who received FVSE in PCA divided by the number of adolescents in the target 
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population who were legally required to receive FVSE (ADH, 2008; ALB, 1993) 
multiplied by 100,000. 
Age-specific immunization rate: The proportion of vaccines in a dose series 
received by children, as prescribed in ACIP immunization schedules (CDC, 2007d). For 
example, this category includes the number of adolescents of a specific age such as 13–
15 years old in the 1990 PCABC who received a number of vaccine doses of FVSE 
divided by the total number of adolescent vaccine doses of FVSE in that target 13–15-
year age group who are legally required to receive FVSE (ADH, 2008; ALB, 1993) 
multiplied by 100,000. 
Five vaccines for school entry (FVSE): Four doses of Td/Tdap, three doses of Hep 
B, two doses of MMR, three doses of OPV/IPV, and two doses VAR (ADH, 2008). 
Pulaski County, Arkansas birth cohort (PCABC): Adolescents born in PCA in the 
birth cohort between January 1, 1990 and December 31, 1990. 
Natural-home adolescent (NHA): An adolescent who lives with their natural or 
adoptive parents, has never been in child-protective services, and attended public schools 
from 1996 to 2008 in PCA (ADHS, 2010). 
Foster-care adolescent (FCA): An adolescent up to age 18 years who does not 
live in their natural or adoptive parents’ residence and are under court-ordered judicial 
protective care supported through ADHS control (ADHS, 2010). 
Potential Covariate Variables 
Age, race, ethnicity, and gender were important covariates in which immunization 
coverage for the FVSE differed between groups, thereby confounding true associations. 




Covariate Codes, Pulaski County, Arkansas, 1990 Birth Cohort 
Covariates Codes 
Caucasian W 
African American AA 
Other O 
Hispanic H 






Immunization-completion calculation. I calculated the total number of doses 
per vaccine recommended for FVSE based on adolescent-age distribution in Appendix A, 
Table A1, adopted from tables in AIRR (ADH, 2008). Each vaccine dose series had a 
maximum number of doses required to complete the vaccine series. I based the vaccine-
completion calculation on addition of all valid doses at appropriately administered 
intervals established in the ACIP vaccine schedules (CDC, 2008b). 
Independent and dependent variables. The independent variable was HOR, 
defined as NHA or FCA in the 1990 PCABC. The dependent variables were UTD and 
age-appropriate UTD FVSE. Potential covariates included gender, race, and ethnicity. 
Descriptive Statistics 
Descriptive statistics were a descriptive quantitative analysis plan for normal-
distribution archival-immunization data. The quantitative parametric test included 
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multivariate analysis and statistical central tendencies: frequencies. The specific 
cumulative vaccines required for school entry were Td/Tdap, Hep B, MMR, OPV/IPV, 
and VAR. I analyzed the 1990 PCABC archival-immunization data from AIRD with SAS 
9.3 software (Cary, North Carolina, USA). 
I counted duplicate vaccine doses for the same vaccine series administered at 
spaced interval as valid doses in the numerator. I corrected multiple different 
immunization dates for the same vaccine series based on the ACIP vaccine schedule 
(CDC, 2008b). I considered a vaccine series to have been completed if the total number 
of valid doses was equal to the number of doses for that vaccine type. I repeated this 
process for all FVSE and calculated the percent of immunization rates. 
AIR built immunization-registry records from health-provider documented and 
reported immunization histories of individually administered vaccines (Khare et al., 
2000). However, it was important to maintain the accuracy and completeness of the 
immunization histories and eliminate significant errors in children’s names, dates of 
birth, vaccine types, no data reported, and overall duplicate records to calculate coverage 
accurately (Khare et al., 2000). Each unique identifier number accompanied vaccine type 
with doses administered. If the same vaccine dose was administered beyond the required 
maximum dose number, then I considered the rest to be duplicates and did not include 
them in the analysis. Thus, I defined excess doses as over-immunization. 
The names of individual adolescents were not important in this analysis. ADH 
coded individual immunization records with a unique number and identified all FVSE 
vaccine doses received and documented in that record. I did not count or include the 
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vaccine doses that fell outside the defined ACIP vaccine schedule (CDC, 2008b) in the 
analysis as valid doses for that vaccine series. 
Research Questions and Hypotheses 
Four Research Questions and Data-Analysis Plan 
This data analysis plan addressed four research questions. 
RQ1: Are the calculated 2006–2008 adolescent percent vaccination uptake (VCU) 
for FVSE among the 1990 Birth cohort in PCA (PCABC) significantly different 
from the FVSE reported 2006–2008 U.S. national adolescent estimated 
immunization rates? 
Ho1: There is no difference between the 2006–2008 PCABC calculated 
percent VCU for the FVSE and the reported 2006–2008 U.S. adolescent 
national immunization teen (NIS-Teen) estimated percent VCU for the FVSE. 
Ha1: There is a difference between the 2006–2008 PCABC calculated percent 
VCU for the FVSE and the reported 2006–2008 U.S. adolescent NIS-Teen 
estimated percent VCU for the FVSE. 
Research Question 1 analysis plan. To compare rates in the PCABC and the 
United States, I conducted direct standardization, standardizing the rates by age. The 
standardization accounted for any mixing of a third factor, age, and vaccine coverage 
uptake. The goal of the standardized rates was to account for any mixing of a third factor 
and multiple other factors with the primary association of interest. I then performed the t-




Direct-standardization statistical tool. I standardized the PCA birth cohort 
PCABC vaccine UTD to the 2010 U.S. Census to compare adjusted rates between 
PCABC and U.S. NIS-Teen. I determined the total population census for 2010 for the 
United States, Arkansas, and PCA from the U.S. Census Bureau for 2010. An example of 
direct standardization steps and Table 4 illustrate how I adjusted immunization rates. I 
extracted the age distributions total census for 16, 17, and 18 years from the U.S. Census 
Bureau to determine the weighted factor (w) for each age group. The number of PCA 
adolescents was the numerator. The number of U.S. adolescents in the U.S. Census 2010 
was the denominator. The numerator divided by the denominator equaled the weighted 
factor. The weighted factor is the fraction of PCA adolescents for each age group, 13–18 
years, depending on the years 2003–2008, based on U.S. Census adolescents for that 
year. I determined the weighted factor for each age group (13–16 years for 2006) for 
PCABC and U.S. NIS-Teen. I converted the vaccine percentage from SAS frequency 
analysis to fractions (m) for each vaccine for each year 2003–2008. I multiplied the m 
value by the w for each age stratum for that year. Then m*w yielded the adjusted UTD for 
that age. I repeated this multiplication for ages 13–16 years (if 2006), then summed to 

















Age m w m*w Age m w m*w 
13 x b xb 13 x b Xb 
14 x b xb 14 x b Xb 
15 x b xb 15 x b Xb 




Note. PCABC = Pulaski County Arkansas birth cohort; NIS = national immunization surveys. 
Direct standardization steps. 
1. U.S. 2010 total census came from the U.S. Census Bureau 
2. Arkansas population 2010 
3. Total number of adolescents each year 16, 17, and 18 years 
4. PCA number of age specific 16, 17, and 18 years 
5. Vaccine percentages for each year 2006, 2007, and 2008 
6. Immunization rates from the SAS frequency for each vaccine for each year 
2003–2008: 2003 represents age 13. Next, I determined PCABC and U.S. 
NIS-Teen percentages for UTD all vaccines Td/Tdap, Hep B, MMR, 
OPV/IPV, and VAR. The vaccine UTD is the m value in the equation to 
determine the adjusted vaccine UTD for 2010 
7. The weighted factor w was the percent of PCA based on U.S. Census 
adolescents for that year. 
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8. m*w yielded the adjusted UTD for that age. I repeated these multiplications 
for 13–16 years for 2006 because in 2006 the cohort was 16 years old. I 
summed m*w to obtain the 2006 UTD for each vaccine. 
9. D and P were the confidence-interval-value minimum and maximum ranges. 
RQ2: Are there differences in percentage of FVSE vaccine coverage uptake 
between NHA and FCA among adolescents in the 2003–2008 PCABC? 
Ho2: There is no significant difference in FVSE coverage uptake between the 
HOR defined as NHA and FCA in the 2003–2008 PCABC. 
Ha2: There is a significant difference in FVSE coverage uptake between the 
HOR defined as NHA and FCA in the 2003–2008 PCABC. 
Research Question 2 analysis plan. I dichotomized FVSE as yes, UTD for all 
five vaccines, or no, not UTD, even if one vaccine was missing. I conducted chi square 
analysis to examine whether an association emerged between UTD FVSE and HOR: 
NHA or FCA. A significant association existed; I then conducted multiple logistic 
regressions to determine the odds of being UTD for FVSE for an NHA versus an FCA. I 
conducted multiple logistic regressions to control for the confounding effects of age, race, 
ethnicity, and gender. 
Chi square test statistic and confounding analysis. 
• I calculated the chi-square test (χ2) and reported p-values in Chapter 4. 
• I used the chi-square test (χ2) to test the association between NHA/FCA HOR 
and the vaccine UTD dependent variable. 
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• I found that confounding variables distorted the strength of the relationship 
between the independent variable HOR (NHA or FCA) specific stratum and 
the UTD outcome variable. 
• I calculated and compared five-vaccine UTD rates among NHA/FCA-specific 
stratum related to a covariate variable (race, gender, and ethnicity). 
• I compared NHA and FCA stratum-specific association significance with 
vaccine UTD-specific stratum when controlling or adjusting for race, gender, 
and ethnicity. 
• For example, NHA or FCA had a stratum for race (African American, 
Caucasian, and other); gender (male or female); and ethnicity (Hispanic and 
non-Hispanic). 
• The criteria for significant association was p-value (p < .05) when I included a 
confounder stratum (race, gender, and ethnicity) in the logistic regression 
model, based on test statistics of p-value (p < .05) and the odds ratio (OR) 
likely associated value (if the OR has a positive or negative value). Caucasian 
adolescent was the reference (1) in the race covariate. 
• I performed the chi-square test (χ2) analysis, OR calculations in SAS 
applications. I controlled and eliminated the confounding variable to establish 
a clearer relationship between the NHA/FCA and UTD. 
• I performed manual calculations of the chi-square test vaccine UTD. 
• χ2 = (o − e)2/e; observed (o), expected (e). 
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RQ3: Is the association between HOR, defined as NHA and FCA, and UTD of 
FVSE coverage mediated through sociodemographic characteristics, which 
include age, race, ethnicity, and gender in PCABC? 
Ho3: The associations between HOR, as defined as NHA or FCA, and UTD 
FVSE in PCABC is not mediated through sociodemographic characteristics, 
including age, race, ethnicity and gender. 
Ha3: The associations between HOR, defined as NHA or FCA, and UTD 
FVSE in PCABC is mediated through sociodemographic characteristics, 
including age, race, ethnicity and gender. 
RQ3 analysis plan. I examined the statistically significant effect mediation by 
sociodemographic characteristics on the main-effect association, association between 
HOR, and UTD FVSE (see Figure 3). I conducted multiple logistic regression analyses 
by including interaction terms in the model. I performed bivariate logistic regression to 
examine the association between FVSE and HOR while controlling for covariates race, 
gender, and ethnicity. I report the results in Chapter 4. 
Multiple logistic regression model to account for mediated variables. 
• I tested if the mediating variable has a significant direct or indirect effect on 
the relationship between NHA/FCA (X variable) and vaccine UTD (Y 
variable). 
• I tested the effect significance-based calculated OR and p < .05 in the 
regression model to determine if the mediator variable p-value estimates 




Figure 3. Mediating effect diagram. 
 
Three outcomes. 
• I gained a better understanding of the overall relationship between NHA/FCA 
(X variable), vaccine UTD (Y variable), and covariates. 
• I performed a bivariate logistic regression to examine mediation from 
covariables. 
• The mediator explains the X–Y relationship when a significant association 
emerged with or without the mediator. If the X and Y variables and covariates 
aligned or related because of a mediator (M) variable such as gender, race, and 
ethnicity, then M facilitated the association between X and Y. Changes in OR 




• I measured the association and mediation bases estimates of OR and p < .05; 
p-value significance was based on p < .05. 
I measured three outcomes using estimates of p-value based on p < .05. 
• Mediation present: The calculated p-value diminished to near zero (.0001), a 
direct effect is not significant, and the mediator is present. The effect of X on 
the mediator is significant and the effect of the mediator on Y is significant. 
• Partial mediation: The direct effect of X to Y is borderline significant when the 
mediator is absent. 
• No mediation: The direct effect from X to the mediator is insignificant and the 
Mediator to Y is insignificant. 
Accounting for mediated variables will increase understanding of three potential 
outcomes when the mediating variable is included in the multiple logistics model. 
Determining mediation. A variable must satisfy three criteria before it is deemed 
a mediator. It must align with the main outcome variable; it must align with the exposure 
variable; and it must be in the causal pathway between the exposure variable and the 
outcome variable. I conducted bivariate analyses to determine whether each covariate 
satisfied these criteria. Each variable that was not associated with the outcome variable 
and the exposure variable was not a mediator. Further testing prevented Type II error, 
incorrectly concluding that mediation does not exist. These bivariate regression processes 
detected simple mediation (Preacher & Hayes, 2008) and identified any differences in 
direct and indirect mediation (Preacher & Hayes, 2004). The additional examination 
decomposed any causal association to expose the contribution of each variable 
(MacKinnon, Lockwood, Hoffman, West, & Sheets, 2002). This process ensured 
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exhaustive and complete testing (MacKinnon et al., 2002) of all variables in the bivariate 
logistic regression analysis, examining the association between FVSE and HOR and 
mediating variables (Baron & Kenny, 1986; MacKinnon, Krull, & Lockwood, 2000). The 
extent and strength of the association revealed and explained, for each variable, the effect 
of that variable on the outcome (Preacher & Hayes, 2004). 
RQ4: Will differences in individual vaccine payoff, measured by avoidance of 
disease development as a result of vaccine receipt, affect group interest, measured 
by deaths as a result of nonvaccination for the FVSE among the PCA? 
Ho4: Differences in individual vaccine payoff, measured by avoidance of 
disease development as a result of vaccine receipt, will not affect group 
interest, measured by deaths as a result of nonvaccination, for the FVSE 
among the 1990 PCABC. 
Ha4: Differences in individual vaccine payoff, measured by avoidance of 
disease development as a result of vaccine receipt, will affect group interest, 
measured by deaths as a result of nonvaccination, for the FVSE among the 
1990 PCABC. 
Research Question 4 analysis plan. I operationalized the vaccination TOG 
equation parameters and developed a model for payoffs. I then applied the individual 
equilibrium equation and group optimum equation to calculate payoffs. The r (attack 
rate) parameter was significant in the two equations: 
• The attack rate [r] for a VPD was the number of persons in the age group with 




• The individual strategy was the delayer strategy: The goal was to delay 
vaccine maximized protection-benefit payoff, reduce risk from VPD attack, 
and diminish death from vaccine. 
• I used the attack rate r in the individual equilibrium equation to calculate the 
probability of death due to VPD or vaccine. 
• The group optimum is a preemptive strategy: The payoff outcome minimizes 
the expected cost of vaccination, which is death from VPD. 
• I used the attack rate r in the group optimum equation to calculate the 
expected cost of vaccination: the level of vaccine coverage to minimize death 
due to VPD or vaccine. 
The individual-equilibrium equation. I used the individual-equilibrium 
equation to examine the relationship between those who preemptively received 
vaccination and those who delayed vaccination for each of the FVSE. The payoff for an 
individual receiving vaccination can be expressed as Evac = −dv where dv is the 
probability of death from vaccination. Because the probability of death due to vaccination 
was usually small, I usually ignored dv in the equation; therefore, I usually assumed Evac 
was 100%, or 1 when expressed as a probability. Therefore the focus was on the effect of 
an individual who delayed vaccination and the risk of acquired disease when an outbreak 
occurred. Edel (p) was the equation to examine vaccine delay and the payoff associated 
with delay: 
Edel (p) = −r[ϕs(p)ds + ϕv(p)dv], 
where, Edel(p) calculated payoff when an individual chose to delay vaccination; r is the 
risk of attack from a VPD after an outbreak occurred, calculated as the number likely to 
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become infected when no vaccine protection was divided by total population at the risk of 
becoming infected. ϕs (p) is the probability that a delayer becomes infected with the 
disease after an outbreak; calculated as the total number of eligible unvaccinated divided 
by the total population at risk of becoming infected. ds is the probability of death due to a 
VPD; calculated as the total number of deaths among those who are unvaccinated from 
VPD divided by the total population at risk of becoming infected. ϕv (p) is the probability 
that a delayer was vaccinated successfully after an outbreak; calculated as the total 
number of disabilities among delayers receiving the vaccination divided by the total 
number of delayers who received vaccination. dv is the probability of death of the 
individual from vaccination; calculated as the total number of deaths due to the 
vaccination divided by total number of those receiving the vaccine. 
Because the goal of the individual equilibrium, Pind was the examined relationship 
between Evac and Edel, the mathematical model for a maximized payoff of receiving a 
vaccine was significant. In the model where Evac = 1 or 100% vaccine efficacy, no deaths 
from vaccination occurred, and a minimized payoff of delayed vaccination where Edel = 0 
had no payoff for delayed vaccine. Therefore, the expected association was Evac > Edel. 
When Evac ≤ Edel then the individual equilibrium, Pind, may approach zero, where, 
although an effective vaccine existed, the payoff for delayed vaccine did not pose any 
additional harm (Bauch et al., 2003). Under such circumstances, individuals chose not to 
be vaccinated, thereby zeroing out the individual equilibrium, Pind. An important 
assumption when calculating individual equilibrium was that individual behaviors would 
increase survival from VPDs when vaccines were readily available. 
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The group optimum. The group interest and importance was to minimize the 
total number of deaths due to vaccination and infection when an outbreak of a VPD 
occurred. Thus, I examined the group optimum and applied the equation 
C(p) = pdv + r(1 − p)[(ds − dv)ϕs(p) + dv], 
where C(p) was measured as a probability between zero and one. This was the coverage 
level required and imposed to minimize the total expected number of deaths due to a 
VPD. All other parameters in the group-optimum equation and variables were the same 
as those described in the individual equilibrium. 
Threats to Validity 
External Validity 
The results of this study were drawn from a sample of children born in a 1990 
PCABC. External validity was the ability to generalize results of this study from a sample 
to the general population (Trochim, 2006). The results are generalizable to the population 
of all children born in 1990 in PCA who attended public schools between the ages of 6 
and 18 years from 1996 to 2008. 
Extrapolating results of the study to other adolescent populations threatens the 
validity of the study. External factors during the data periods influenced certain causal 
relations between variables. Such influencing factors had the same effect when the results 
were generalized to another population. For example, in 2003 Arkansas state law allowed 
immunization exemptions based on medical, philosophical, religious, and personal beliefs 
(ADH, 2003). The effect of the law influenced immunization rates for vaccines such as 
exemptions from Hep B, VAR, and Tdap at the time and age when the vaccine was to be 
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administered. During 2003, adolescents in the 1990 birth cohort were 13 years old, 
eligible, and required to receive these seventh-grade vaccines. 
The methods and analysis of registry data were replicable when I defined 
immunization parameters, variables, and outcomes. Dissemination of research results is 
important for future research (Steckler & McLeroy, 2007). These results provide 
evidence-based immunization rates and may support strategies to prevent disease, 
hospitalization, and mortality among adolescents in PCA. 
Internal Validity 
This study had four significant internal validly threats: immunization enrollment 
and reporting (Stevenson et al., 2000), no vaccine history or missing records, 
immunization data-quality assurance (American Immunization Registry Association, 
2008), and duplicate records (American Immunization Registry Association, 2006). 
Errors in vaccine administration included documentation of date of birth and vaccination 
dates (Khare et al., 2000). These threats contributed to incorrect reported results. 
Therefore, individual-history record completeness and correctness of variables in 
immunization data were essential in maintaining the accuracy of the reported outcomes. 
Incomplete vaccine-records data were due to passive reporting to AIR and 
provider delays beyond the allowed 30-day reporting period. Another problem with 
record accuracy was duplicate records (American Immunization Registry Association, 
2006). Immunization-record duplication occurred when transposing name order, date of 
birth, wrongly coded vaccines, incorrect vaccine type, errors in documented dose series 
number, errors in lot numbers, and incorrect reported date of immunization. Vaccine-
history data were lost, not reported, or incomplete due to electronic transmittal, or used 
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incompatible electronic formats or software. The HL7 2.x data-exchange format was the 
compatible standard that used an open architecture and facilitated effective immunization 
data transfer between healthcare providers and AIR (ADH, 2011a). 
The research focus was to examine each record for duplicate vaccine doses and 
invalid doses. The unique identifier-number feature aggregated all vaccine records 
associated with the unique number. Therefore, documentation of the same vaccine type 
administered with the same date of administration indicated duplication. I included only 
one dose of that specific vaccine, administered on the same day, in UTD calculations and 
completion of that vaccine dose series. I matched an individual’s date of birth with 
interval dates of vaccine administration to enhance outcome accuracy and minimize 
internal-validity threats. I verified complete vaccine-dose series and birth-date matches 
with established ACIP schedules for vaccine series completion for childhood- and 
adolescent immunization schedules. Standardized EHR with compatible HL7 2.x 
exchange software increased accuracy in Datalink between provider offices and the AIR. 
Use of handwritten reports exacerbated errors. Bar-code systems used in scanning patient 
records and vaccine vitals at point of vaccine administration further eliminated any 
clerical documentation errors (Khare et al., 2000). This efficient system linked to the 
registry, thereby eliminating delays in passive reporting. Also, computerized systems 
improved individual vaccine-records documentation and retrieval. Duplicate records were 
minimized and points of delivery enhanced through documentation of correct names, 




Confidentiality, privacy, and personal protected information were ensured through 
deidentification of all immunization data for FCA and NHA. I recruited no participants 
for this study; therefore I had no ethical concerns related to recruitment materials, 
processes, and plans to address them. I completed the ADH ethical-research 
requirements, Walden University IRB application, and the National Institutes of Health 
certification course. ADH ethical-research requirements consisted of understanding the 
Health Insurance Portability Accountability Act, confidentiality, and privacy training. I 
obtained the data-use agreements from ADH and ADHS to enable access to research 
data. 
Institutional Review Board Application 
I submitted an IRB application to the ADH with clear declaration that this study 
did not involve or require any human subjects or participants. The IRB application was 
required because information for this study involved confidentiality of individual health-
protected information. The name and identifiable individual information for each 
immunization record was blinded to me as assurance of the confidentiality of minors 
involved in this adolescent-cohort immunization study. I signed a memorandum of 
understanding that the registry data were deidentified in that all names, social security 
numbers, and any identifiable information were removed prior to receiving the data sets 
from the ADH. 
The ADH SAC and Walden University received IRB-request applications. I 
obtained IRB approvals from each board before receiving any AIRD data. I submitted a 
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certificate of completion of the National Institute of Health course on Protecting Human 
Research Participants as part of the IRB-application process. 
Ethical Concerns in Archival Data 
Risk/benefit assessment. No risk or probability and magnitude of harm or 
discomfort was imposed on any participant in this study. This research was limited to 
immunization archival data. All personal information was deidentified and the ADH did 
not release participants’ names to me. Although primary data collection was not part of 
this study, data collected by the AIR met scientific standards for research data, as 
prescribed by federal law under section 45 CFR 46.102(h)(i)). 
Benefit assessment. This immunization research has potential health-related 
impacts and benefit for future policy, campaigns, or interventions. Any identified 
vaccines with low coverage offered benefits to future adolescents through the 
implementation of intervention or policies that target increased immunization coverage. 
High-immunization rates lower the risk of disease among individuals (Glanz et al., 2010). 
Any vaccine that achieved an immunization rate of 90% or greater, as established by the 
Healthy People 2020 indicator, contributed community protection through herd immunity 
(National Network for Immunization Information, 2006; Schlenker, Bain, Baughman, & 
Hadler, 1992). Immunization rates of 90% and greater for populations were protective 
over time and reduced the risk of VPD outbreaks such as varicella (Lee et al., 2008; 
Vázquez et al., 2004). The risk of disease greatly diminished when populations achieved 
critical immunization coverage thresholds. For example, coverage thresholds occurred at 
levels as low as 85% for diphtheria, measles, rubella, and smallpox, and at 94% for 




I used a cross-sectional study design to conduct this quantitative inquiry. The 
cross-sectional design was appropriate because I analyzed and compared archival data on 
PCABC NHA and FCA immunization rates for FVSE. The methodology was a 
quantitative analysis of four research questions and commensurate hypotheses. The 
outcomes measured in this inquiry included UTD for FVSE and percent vaccine coverage 
uptake among PCABC. Study results were generalized to PCABC. The theoretical 
foundation in this study was the TOG construct (von Neumann & Morgenstern, 1944). 
This cross-sectional-design study employed a retrospective secondary analysis of 
data collected through the AIR between 1990 and 2008 for the PCABC. The statistical 
analyses were frequency, chi square, direct standardization, bivariate, and multiple 
logistic regressions, determining that immunization-rate differences and disparities 
existed among groups. The four findings from this quantitative analysis of the AIR data 
contributed justification for immunization campaigns and public health interventions. 
First, I calculated direct standardization adolescent-vaccination-coverage uptakes for 
FVSE. I compared the adjusted vaccines uptake rates for the 1990 PCABC to U.S. 
adolescent coverage uptakes from 2006 to 2008. Second, chi-square analysis identified 
and compared differences in vaccine coverage between NHAs and FCAs among the 1990 
PCABC. Third, I evaluated strength of association between HOR with vaccine UTD with 
multiple and bivariate logistic regression analysis. For the 1990 PCABC, fourth, I used 
VGT with applied individual equilibrium and group optimum constructs, and 
mathematical-model equations that contributed to quantify payoff deaths associated with 
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vaccination decisions. The TOG posited that the decisions of a group influence individual 
behavior. 
Analysis data were archival data from AIR for the 1990 PCABC. The analysis 
plan was operationalized based on the four research questions and hypotheses. I defined 
the independent variables, covariates, and dependent variables in the text along with 
descriptive quantitative statistical tools used in this study. The important outcomes were 
primary associations of HOR with immunization, vaccine UTD, and percent coverage 
uptake. 
The analysis in this study answered four main research questions and hypotheses 
and compared FCA and NHA. This was important because the actions of a group 
influence individual immunization behavior (Bauch et al., 2003). The adolescent-
vaccination coverage uptake was a significant component in this study because of the 
FVSE. I used the individual equilibrium construct of TOG to examine the probability of 
preemptive vaccination among individuals in the PCABC. If the proportion of population 
preemptively vaccinated was greater than the proportion of population who refused the 
vaccine, then the population achieved a herd immunity threshold. 
The theoretical foundation for this study was the TOG. I used TOG constructs 
(von Neumann & Morgenstern, 1944) to explain individual and group decisions related to 
vaccination coverage uptake. Using the TOG framework, I calculated the threshold level 
of VCU (Bauch & Earn, 2004) in a population herd immunity required to prevent disease 




The adolescent-vaccination coverage uptake was a significant component in this 
study. I used the TOG construct (von Neumann & Morgenstern, 1944) to explain 
vaccination decisions related to coverage uptake. The factors that affected individual 
decisions to vaccinate related to self-interest (Ibuka et al., 2014), actions of others 
(Meszaros et al., 1996), risk of infections, and perceived costs and benefits (Basu et al., 
2008; Whitney et al., 2014) associated with primary immunization-access factors. 
The TOG (von Neumann & Morgenstern, 1944) offered an important modeling 
framework for adolescent immunization actions, choices, or behaviors to maximize or 
minimize payoffs. The “game” was a social situation that required behavior, choice, 
actions, and payoff. The payoffs were quantifiable consequences associated with a 
particular event, action, or behavior of each participant (M. C. Jackson et al., 2015). The 
modeling included probabilities, proportions, and frequencies of immunization actions, 
choices, or behaviors. 
The importance of game theory and vaccination was the cost or payoffs associated 
with adolescent immunization actions, choices, or behaviors. For example, group 
equilibrium was the decision to immunize and the consequences of that immunization 
(protection, disease, or death). The probability, frequencies, and proportion were 
quantifiable actions performed by participants. I calculated the uncertainty actions of 
participants to predict or forecast adolescent immunization behavior. The social-change 
impact of predicting adolescent immunization uptake was valuable for public health 
functions. 
Three positive social-change implications accrued from this study. First, results 
impact parents, community stakeholders, and legislative policymakers, providing 
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awareness, knowledge, and understanding of the FVSE VCU-coverage quantifiable 
evidence. The second positive social change was the ability to make informed decisions 
to vaccinate (Shim, Kochin et al., 2010) associated with VCU coverage, vaccine UTD, 
and disease outbreaks (Anderson & May, 1985). Another positive social change from this 
study is the ability to calculate the minimum number of total deaths from not vaccinating 
adolescents (Bauch & Earn, 2004) against infections from each of the five required 
adolescent vaccines among the 1990 PCABC. The research focus of Chapter 4 was the 
data analysis, interpretation, and presentation of results. 
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Chapter 4: Results 
Study Purpose 
This cross-sectional study had four main purposes. The first purpose was to 
calculate and compare adolescent immunization rates between the 1990 PCABC and the 
U.S. national adolescent immunization survey from 2003 and 2008. The second purpose 
was to assess whether an association would emerge between HOR, defined as NHA or 
FCA, and UTD status of FVSE. The study’s third purpose was to determine if the 
associations between HOR and UTD FVSE in PCABC were mediated by such 
sociodemographic risk factors as age, gender, race, and ethnicity. The fourth purpose was 
to test a mathematical model based on vaccination-coverage uptake and the TOG. 
Data Collection 
From January 1, 1990 to December 31, 1990, the PCA had 9,102 recorded live 
births. However, only 3,371 met the data-collection criteria. The four eligibility data 
collection criteria were (a) date of birth, (b) geographic criterion, (c) school attendance, 
and (d) vaccine records in the AIR registry. From the 3,371 children, 74,292 
immunization observations were recorded between 1990 and 2008 that covered the 
FVSE. An observation was defined as each data point in the vaccine record. For example, 
date of birth in a record is an observation. Similarly, gender, race, date of vaccine 
administration, vaccine type, dose number in the vaccine series, and location are all 
observations in a record for a vaccine-dose administration for each visit. I evaluated the 
immunization records for all PCABC 1990 members based on established vaccine-dose 
criteria (ADH, 2008) to determine vaccination UTD status for FVSE. 
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From the extracted data, I was able to identify the demographic characteristics of 
the 3,371 adolescents born in PCA in 1990, based on demographic ethnicity, gender, and 
race. I defined ethnicity as Hispanic or not Hispanic, gender as male and female, race as 
African American, Caucasian, and Other (which included Asian, Native American, and 
Native Alaskan Islander). The HOR of the adolescent was the independent variable 
defined as NHA and FCA. The UTD status was the dependent variable and was 
calculated based on the ADH and CDC vaccination schedule for the FVSE, which 
included Td/Tdap, Hep B, MMR, OPV/IPV, and VAR. I used Microsoft Excel and SAS 
9.3 software (SAS Institute, 2012) for data analysis. 
Results 
Demographic Characteristics 
Of the 3,371 adolescents, 53.2% were African American, 30.7% were Caucasian, 
and 16.1% identified as Other. Adolescent females accounted for 54.9% of the birth 
cohort. The majority of the birth cohort was non-Hispanic (97.3%). Overall, only 527 of 
the adolescents (15.6%) were UTD for all FVSE. The UTD analysis for FVSE was 
reported for HOR, gender, ethnicity, and race. The total UTD status for FCA was 29.4% 
compared to 15.1% UTD for NHA. The PCABC overall UTD immunization rate for 
FVSE was 15.6%. PCABC females were 15.4% UTD, compared to 16.4% UTD for 
PCABC males. The UTD status for Hispanics was 16.5%, compared to 15.5% UTD for 
non-Hispanics. 
Table 5 shows the overall cohort vaccine-coverage uptake for the FVSE. The 
VAR vaccine-coverage uptake among PCABC was 1.6 times lower than the FVSE 
coverage. Among the PCABC, none of the vaccines reached the 90% coverage 
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recommended by Healthy People 2020 for any race or ethnic group. However, an overall 
association between race and ethnicity and UTD status for FVSE did emerge in that 
African-American adolescents were more likely to be UTD than Caucasian and other-
race adolescents (see Table 6). 
Table 5 
Pulaski County 1990 Birth Cohort Vaccine-Coverage Uptake, 2008 
Vaccine No  Yes 
N % N (%) % 
Td/Tdap  570 16.9 2797 83.1 
Hep B  1,099 32.6 2268 67.4 
MMR  751 22.3 2616 77.7 
OPV/IPV  522 15.5 2845 84.5 
VAR  2,705 80.3 662 9.7 
FVSE coverage 2843 84.4 524  15.6 
Note. Td/Tdap = tetanus-diphtheria/tetanus-diphtheria-acellular pertussis; Hep B = hepatitis B; MMR = 
measles-mumps-rubella; OPV/IPV = poliomyelitis; VAR = varicella. 
Table 6 
Pulaski County, Arkansas 1990 Birth Cohort Population and Five Vaccines for School 
Entry FVSE Coverage Uptake By Race 
FVSE vaccine UTD status by race 
Total  No  Yes 
Race N % N % N % χ2 p-value 
Total 3,371 100.0 2,840 84.3 531 15.7 25.93 < .0001 
African American 1,792 53.2 1,456 81.3 336 18.7   
Caucasian  1,036 30.7 907 87.5 129 12.5   
Other  543 16.1 477 87.8 66 12.2   
Note. Statistically significant, p < .05. 
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Research Question 1 and Hypothesis 1 
RQ1: Are the calculated 2006–2008 adolescent percent vaccination uptake (VCU) 
rates for FVSE among the 1990 Birth cohort in PCA (PCABC) significantly 
different from the reported FVSE 2006–2008 U.S. national adolescent estimated 
immunization rates? 
Ho1: There is no difference between the 2006–2008 PCABC calculated 
percent VCU for the FVSE and the reported 2006–2008 U.S. adolescent 
national immunization teen (NIS-Teen) estimated percent VCU for the FVSE. 
Ha1: There is a difference between the 2006–2008 PCABC calculated percent 
VCU for the FVSE and the reported 2006–2008 U.S. adolescent NIS-Teen 
estimated percent VCU for the FVSE. 
Direct-Standardization Analysis 
As shown in Table 7, I compared the PCABC adjusted UTD coverage rates to 
U.S. adjusted UTD coverage rates for 2006–2008 U.S. NIS-Teen. These results for 
adjusted vaccine percent UTD coverage rates were based on U.S. 2010 Census data. The 
U.S. NIS-Teen had a greater vaccine percentage of coverage uptakes for Hep B (12.0%), 
MMR (11.6%), and VAR (70.2%) compared to PCABC from 2006 to 2008. Except for 
Td/Tdap, PCABC had 16.4% vaccines coverage uptake greater than that of the United 
States for 2006–2008. I included no comparison for OPV/IPV because U.S. NIS-Teen 
has not collected polio data since 2000, when polio was eradicated in the United States. 
The greatest vaccine differences between the two groups emerged among the UTD 




Adjusted Adolescent Vaccine Coverage Uptake Differences (as Percentages) Between 
Pulaski County, Arkansas Birth Cohort and United States, 2006–2008 
Pulaski County, AR. 1990 birth cohort  U.S. National Immunization Survey 
Vaccine 2006 2007 2008 Average 2006 2007 2008 Average t-test p-value 
Td/Tdap 84.0 84.0 83.8 83.9 58.2 72.3 72.1 67.5 3.51 .025 
Hep B  77.9 75.6 74.2 75.9 82.1 87.6 87.9 85.9 4.59 .01 
MMR 77.7 77.7 77.7 77.7 87.1 88.9 89.3 88.4 15.86 .000009 
OPV/IPV 86.2 86.0 82.8 85.0 N/A N/A N/A NA N/A N/A 
VAR 17.0 17.4 28.8 21.1 89.4 91.8 92.7 91.3 17.59 .000006 
Note. Td/Tdap = tetanus-diphtheria/tetanus-diphtheria-acellular pertussis; Hep B = hepatitis B; MMR = 
measles-mumps-rubella; OPV/IPV = poliomyelitis; VAR = varicella; Pulaski County, AR birth cohort 
1990 Data Analysis, p < .05 statistically significant; *Standardized to 2010 U.S. population. 
Also shown in Table 7, I conducted a student’s t test for each vaccine—Td/Tdap, 
Hep B (12.0%), MMR (11.6%), and VAR—to determine whether statistically significant 
differences arose in adjusted average VCU reported for PCABC and the United States. A 
statistically significant difference emerged for each vaccine—Td/Tdap, Hep B (12.0%), 
MMR (11.6%), and VAR at p < .05—between PCABC and the United States. 
Figure 4 illustrates the vaccine trends from 2006 to 2008 for PCABC and the 
United States. The PCABC coverage declined 0.2% for Td/Tdap between 2006 and 2008 
compared to U.S. adolescents’ 14.1% Td/Tdap coverage increase from 2006 to 2007 and 
0.2% decline from 2007 to 2008. Hep B coverage showed a 3.7% coverage decline in 
PCABC between 2006 and 2008. In contrast, U.S. adolescents had 5.8% increased 
coverage for Hep B between 2006 and 2008. MMR coverage showed a 2.2% coverage 
increase among U.S. adolescents between 2006 and 2008 compared to no coverage 
change in the PCABC. OPV/IPV coverage showed a 3.4% decline among the PCABC 
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between 2006 and 2008. In contrast, no U.S. data was available because the CDC 
discontinued its household polio survey after 2006 because polio was declared eradicated 
in the United States in 2000(CDC, 2011). The PCABC VAR vaccine coverage uptake 
increased by 11.4% between 2006 and 2008 compared to a 3.3% increase among U.S. 
adolescents. 
 
Figure 4. Adjusted adolescent vaccine-coverage rate trends, United States and Pulaski 
County, AR, 2006–2008. 
 
Research Question 2 and Hypothesis 2 
RQ2: Are there differences in percentage of FVSE vaccine coverage uptake 
between NHA and FCA among adolescents in the 2003–2008 PCABC? 
Ho2: There is no significant difference in FVSE coverage uptake between the 
HOR defined as NHA and FCA in the 2003–2008 PCABC. 
Ha2: There is a significant difference in FVSE coverage uptake between the 
HOR defined as NHA and FCA in the 2003–2008 PCABC. 
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The chi-square analysis (χ2) results for RQ2 are in Table 8. An association arose between 
HOR and vaccine uptake for four of the FVSE. Only Td/Tdap was not associated with 
HOR and vaccine coverage. For all other individual vaccines, vaccine coverage was 
higher among FCA than NHA. These three vaccines—Hep B, MMR, and VAR—had 
strong positive associations with HOR. In contrast, OPV/IPV had weaker positive 
association with HOR compared to the Hep B, MMR, and VAR vaccines. Children in 
foster care, contrary to prior hypotheses, are no less likely to complete immunization 
requirements than children in natural-home settings. 
Table 8 
Home of Residence Vaccine Coverage Uptake Comparison, 1990 Pulaski County, 
Arkansas Birth Cohort 
 Foster care  Natural home   
 N  %  N  %   
Vaccine Yes No Yes No Yes No Yes No χ2 p-value 
Td/Tdap  103 15 87.3 12.7 2,694 555 82.9 17.1 1.55 .21 
Hep B  96 22 81.4 18.6 2,172 1,077 66.9 33.1 10.89 .001 
MMR 107 11 90.7 9.3 2,509 740 77.2 22.8 11.89 .0006 
OPV/IPV 108 10 91.5 8.5 2,737 512 84.2 15.8 4.61 .0318 
VAR 43 75 36.4 63.6 619 2,330 19.1 80.9 21.79 < .0001  
FVSE 35 83 29.7 70.3 619 2,630 19.1 80.9 18.5 < .0001  
Note. Td/Tdap = tetanus-diphtheria/tetanus-diphtheria-acellular pertussis; Hep B = hepatitis B; MMR = 
measles-mumps-rubella; OPV/IPV = poliomyelitis; VAR = varicella; p < .05 statistically significant. 
To determine whether vaccine coverage remained associated with HOR after 
controlling for race, ethnicity, and gender, I conducted multivariable logistic regression 
analyses. After controlling for sociodemographic risk factors, HOR no longer associated 
with UTD status for FVSE. As shown in Table 9, the race variable is the confounder 
because it influenced the outcome of UTD status for FVSE. Race influences the 
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relationship between FVSE and HOR, specifically through the OR, by increasing the 
likelihood of association between FVSE and HOR. In fact, compared to Caucasian 
adolescents, African American adolescents were statistically 77% more likely to be UTD 
for FVSE (OR = 1.77, 95% CI 1.49–2.09) whereas adolescents listed as Other were 46% 
less likely to be UTD (OR = 0.54, 95% CI 0.43–0.67). 
Table 9 
Logistic Regression Examining the Association Between Five Vaccines for School Entry 
and Home of Residence Controlling for Univariates 
Variable and covariate Odds ratio (OR) 95% confidence limits p-value 
Home-Residence  
Foster-care adolescent 1.02 0.67–1.56 .91 
Natural-home adolescent 1  
Gender    
Male 1 0.86–1.17 .99 
Female 1   
Race     
African American 1.77 1.49–2.09 < .0001 
Other 0.54 0.43–0.67 < .0001 
Caucasian 1   
Ethnicity     
Hispanic 1.21 0.78–1.87 .4005 
Non-Hispanic 1 
  
Note. p < .05 statistically significant. 
Therefore, I conducted multivariable logistic regression (see Table 9) to 
determine whether mediation existed between HOR, sociodemographic characteristics, 
and vaccine UTD coverage. In answering RQ2, I found that HOR was associated with 
FVSE. However, after controlling for sociodemographic risk factors, HOR was no longer 
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statistically significantly associated with UTD for FVSE. Therefore, this finding satisfied 
one of the criteria for mediation, that the association between the main outcome variable 
and the exposure variable may be mediated by a third variable. 
For this research question, I further examined whether the overall association 
found in Research Question 2 could have been due to mediation. Results suggested that 
one variable, race, mediated the association between HOR and UTD for FVSE. 
Specifically, African American adolescents, regardless of their HOR, were statistically 
significantly more likely to be UTD for FVSE compared to Caucasian adolescents. In 
contrast, adolescents categorized as Other, regardless of HOR, were significantly less 
likely to be UTD for FVSE compared to Caucasian adolescents (see Table 9). 
Research Question 3 and Hypothesis 3 
RQ3: Is the association between HOR, defined as NHA and FCA, and UTD 
FVSE coverage mediated through sociodemographic characteristics, which 
include age, race, ethnicity, and gender in PCABC? 
Ho3: The associations between HOR, defined as NHA or FCA, and UTD 
FVSE in PCABC is not mediated through sociodemographic characteristics, 
including age, race, ethnicity and gender. 
Ha3: The associations between HOR, defined as NHA or FCA, and UTD 
FVSE in PCABC is mediated through sociodemographic characteristics, 
including age, race, ethnicity and gender. 
I conducted bivariate analyses to determine whether each covariate listed in Table 
10 satisfied these criteria. If I failed to find an association between either the outcome 
variable and the mediator or the exposure variable and the mediator, then that variable 
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was not considered a mediator. The result for the bivariate mediation effect between 
HOR and race for African American was not statistically significant (OR = 1.23; 95% CI 
0.85–1.88). African Americans were 23% more likely than Caucasians to be associated 
with HOR. The bivariate mediation effect between HOR and race for Other race groups 
was statistically significant (OR = 0.19; 95% CI 0.07–0.53). Other race groups were 81% 
less likely than Caucasians to with HOR. These results showed a weak positive 
association between HOR and race when including all race categories in the analysis, 
regardless of their home status as NHA or FCA. 
When I tested HOR mediated by gender, the results for males were not 
statistically significant (OR = 1.29; 95% CI 0.90–1.85, p = .1716). Similarly, results for 
HOR mediated by ethnicity for Hispanic was not statistically significant (OR = 1.29; 
95% CI 0.90–1.85, p = .1716). Then I conducted univariate analysis for the association 
between race and UTD for FVSE. Results were statistically significant for African 
Americans (OR = 1.79; 95% CI 1.51–2.12; p = < .0001) and Other race (OR = 0.48; 95% 
CI 0.39–0.59; p=< .0001). African Americans were 79% more likely than Caucasians to 
be associated with UTD for FVSE. Other race groups were 52% less likely than 




Bivariate Logistic Regression Results for Examining Possible Variables in the 
Association Between FVSE and HOR 
Variable and covariate Odds ratio 95% confidence limits p-value 
Home Residence (NHA and FCA) Mediated by Race  
   
Association between HOR and Race 
   
African American 1.23 0.85–1.88 .2422 
Other 0.19 0.07–0.53 .0016 
Caucasian 1.00 
Association between Race and UTD for All FVSE 
African American 1.79 1.51–2.12 < .0001 
Other 0.48 0.39–0.59 < .0001 
Caucasian 1.00 
Home Residence Mediated by Gender  
 
    
Association between Gender and HOR 
   
Male 1.29 0.90–1.85 .1716 
Female 1.00 
Association between Gender and UTD for FVSE 
 
Male 0.98 0.85–1.14 .8072 
Female 1.00 
Home Residence Mediated by Ethnicity        
Association between HOR and ethnicity 
   
Hispanic 1.07 0.61–1.88 .806 
Not Hispanic 1.00 
Association between Ethnicity and UTD for FVSE 
 
 Hispanic 1.12 0.64–1.96 .6984 
 Not Hispanic 1.00 
Note. p < .05 statistically significant. 
I stratified HOR in Table 10 for the three covariates—race, ethnicity, and 
gender—to examine mediation. Race (OR = 1.79; 95% Cl, 1.51–2.12; p < .0001) 
significantly aligned with FVSE, but gender and ethnicity did not. The race OR and 
p-value did not decrease or change during multivariate and bivariate logistic regression 
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analyses. However, change did emerge in the ORs and p-values for gender and ethnicity. 
Race mediated the association between HOR and FVSE based on established statistical 
mediation criteria (Baron & Kenny, 1986; Fairchild & MacKinnon, 2009; MacKinnon et 
al., 2000; Preacher, Zyphur, & Zhang, 2010; Sobel, 1986). 
The results shown in Table 11 of the logistic regression hypothesis test for HOR 
and FVSE revealed significant association when controlling for specific univariates: 
home-residence FCA versus NHA (OR = 1.61; 95% Cl 1.47–3.34–1.56; p = 0.0001), 
African American race versus Caucasian race (OR = 2.22; 95% Cl 1.29–2.004; 
p=<.0001) when controlling for Other race groups. An association emerged between 
HOR and FVSE, stratified for FCA versus NHA in logistic regression analysis (see Table 
11). Controlling for covariates showed that FCAs have 122% greater odds of FVSE than 
NHAs after adjusting for race. This outcome also shows that race is significant in the 
model. 
Table 11 
Logistic Regression Examining the Association Between Five Vaccines for School Entry 
and Home of Residence FCA vs. NHA Controlling For Covariates 
Variable and covariate Odds ratio 95% confidence interval p-value 
Home-Residence FCA vs. NHA 2.22 1.47–3.34 .0001 
Race African American vs. Caucasian 1.61 1.29–2.004 < .0001 
Race Other vs. Caucasian  0.94 1.29 .405 
Note. p < .05 statistically significant. 
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Results Research Question 4 and Hypothesis 4 
RQ4: Will differences in individual vaccine payoff, measured by avoidance of 
disease development as a result of vaccine receipt, affect group interest, measured 
by deaths as a result of nonvaccination for the FVSE among the PCA? 
Ho4: Differences in individual vaccine payoff, measured by avoidance of 
disease development as a result of vaccine receipt, will not affect group 
interest, measured by deaths as a result of nonvaccination, for the FVSE 
among the 1990 PCABC. 
Ha4: Differences in individual vaccine payoff, measured by avoidance of 
disease development as a result of vaccine receipt, will affect group interest, 
measured by deaths as a result of nonvaccination, for the FVSE among the 
1990 PCABC. 
Table 12 reports the VGT results of the estimated payoff death for each of the 
nine vaccine-preventable diseases (diphtheria, hepatitis, measles, mumps, pertussis, 
poliomyelitis, rubella, tetanus, and varicella) and compares the results for individual 
equilibrium to the group optimum summarized payoff death for these same diseases. The 
estimated payoff deaths for the individual equilibrium for diphtheria was 2.61; pertussis 
1.30; tetanus 3.39; Hep B 5.44; measles 0.001; mumps 0.000095; rubella 0.222; 
OPV/IPV 0.001; and VAR 12.03. The estimated payoff deaths for the group optimum 
were diphtheria 0.441; pertussis 0.22; tetanus 0.57; Hep B 1.78; measles 0.0002; mumps 
0.000021; rubella 0.050; OPV/IPV 0.0002; and VAR 9.66. 
The four highest estimated numbers of deaths were for varicella (12.0 deaths), 
Hep B (5.4), tetanus (3.4), and diphtheria (2.6). These four highest estimated deaths with 
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individual equilibrium, defined as a vaccine delayer or individual self-interest group. The 
four lowest estimated numbers of deaths reported in Table 12 are mumps (0.000021 
death), measles (0.0002), poliomyelitis (0.0002), and rubella (0.05). These four lowest 
estimated numbers of deaths are associated with the group optimum, also defined as the 
preemptive vaccinator or altruistic group. 
Table 12 
Pulaski County Arkansas 1990 Birth Cohort Estimated Payoff Comparison Deaths 
Vaccination Game Theory 
 Individual equilibrium deaths Group optimum deaths 
 
Diphtheria 2.610000 0.441000 
Pertussis 1.300000 0.220000 
Tetanus 3.390000 0.570000 
Hepatitis B 5.440000 1.780000 
Measles 0.001000 0.000200 
Mumps 0.000095 0.000021 
Rubella 0.222000 0.050000 
Poliomyelitis 0.001000 0.000200 
Varicella 12.030000 9.660000 
Note. Pulaski County Arkansas Birth Cohort 1990 Data Analysis. 
VGT payoff deaths represent vaccine-behavior scenarios and estimated numbers 
of deaths that would occur among this cohort of 3,371 adolescents if vaccines were 
unavailable due to refusal, shortage, or disruption in supply during an outbreak. 
Consequently, among the four highest estimated deaths, cohort adolescents in the 
individual-delayer–self-interest equilibrium who refused VAR vaccine would experience 
a high number of deaths compared to adolescents in the group-optimum preemptive-
vaccinator or altruistic group. 
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Because fewer deaths are predicted for group-optimum behavior, this is the better 
vaccine behavior. These results suggests that preemptive vaccination was the most 
protective behavior strategy during an outbreak where group optimum had an estimated 
9.6 varicella deaths compared to 12.0 among individual delayers or the self-interested. 
The group optimum Hepatitis B outcome was an estimated 1.78 death compared to 5.44 
Hepatitis B deaths among individual equilibrium or the self-interested delayer 
equilibrium. Similarly, in the preemptive-vaccinator group optimum an estimated 0.57 
tetanus deaths emerged, compared to 3.39 tetanus deaths among individual equilibrium or 
self-interest delayers. The group optimum estimated 0.441 death from diphtheria 
compared to 2.61 diphtheria deaths among individual equilibrium or self-interest 
delayers, suggesting the vaccine-delayer behavior offers a riskier outcome during an 
outbreak or disease resurgence. 
The estimated deaths reported in Table 12 differed from and were higher than the 
actual number of deaths reported in Table B1 (ADH, 2015). The reported number of 
deaths in Table B1 is attributable to improvements in public health (CDC, 1999b) and 
improvements in disease surveillance, hospitalizations, and laboratory and medical 
services. Therefore, the choice of either the individual equilibrium vaccine behavior, self-
interest or vaccine refusal, or the group optimum and preemptive vaccinator before an 
outbreak was important based on the estimated burden of the number of deaths associated 
with that specific vaccine. 
Individual equilibrium was the self-interest and vaccine-delayer strategy whereas 
group optimum was the altruistic or group strategy. I calculated the vaccine estimated-
payoff deaths based on a model generated from the analysis and the VGT mathematical 
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formula (Bauch et al., 2003). I reported the estimated payoff deaths for each of the nine 
VPDs: diphtheria, pertussis, tetanus, hepatitis B, measles, mumps rubella, poliomyelitis, 
and varicella. The best protection against these nine diseases were the five vaccines 
diphtheria, Hep B, MMR, OPV/IPV, and VAR that are required for school entry in PCA. 
The vaccine-efficacy values of the five vaccines diphtheria, MMR, OPV/IPV, and 
VAR are important in the payoff-death calculation for each of the nine diseases protected 
by these vaccines. Tables B5 and B6 contain variables to calculate payoff deaths or risks 
associated with the individual equilibrium (Pind) and group equilibrium (Pgr) constructs 
defined in the VGT. The VGT predicts the payoffs where the individual choice depended 
on the group choice. The game-theory constructs were behavior choices of self-interest or 
group interest that correlated with small or large vaccine-coverage rates. These 
parameters in each equation included probabilities of disease mortality, disease 
morbidity, disease attack rate, proportion of vaccinated or unvaccinated, efficacy of 
vaccines, probability of death from the vaccine, and protective values related to 
preemptive or delayed vaccination. 
Table B5 focuses on the individual equilibrium whereas Table B6 focuses on 
group optimum. The main difference between Table B5 and Table B6 is the vaccine-
delayer choice and the probability that the delayer became infected after a disease attack 
(ds). Consequently, vaccine delay, risk of disease, and probability of successful vaccine 
during an outbreak influenced the individual-equilibrium payoff deaths. The vaccine 
behavior strategy was to delay or refuse vaccination. Each individual equilibrium 
equation parameter was used in the payoff-death calculation and these parameters are 
clearly defined in Table B7. 
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The main focus in Table B6 was the proportion of preemptive vaccinated 
population and minimized total number of deaths. I used the defined parameters to 
calculate group equilibrium in Table B6. Some disease parameters were constant for both 
groups such as probability of death from vaccine (dv), probability of death from VPD 
(ds), disease attack rate (r), and total number in the cohort. When the parameters in each 
equation were executed to obtain the payoff values for that vaccination choice or 
behavior, the comparison determined the preferred vaccination strategy before disease 
outbreaks occurred. 
Table 12 illustrated the calculated payoff death scenario for the individual 
equilibrium and the group optimum for each disease. The payoff deaths were larger in the 
individual-equilibrium scenario. When the payoff-death scenario for each disease was 
compared to the group optimum, smaller numbers of payoff deaths aligned with the 
group-optimum scenario. 
The conclusion was that more deaths occurred in individual equilibrium, where 
vaccine refusal was the dominant vaccination-behavior choice. The group optimum had 
fewer payoff deaths, as reported in Table 12. Therefore, the desired and preferred 
vaccination choice was the group optimum because of the minimal numbers of deaths 
associated with preemptive vaccination choice. The group optimum offered the greater 
preemptive public health protection during an outbreak for any of the nine VPDs. 
Summary 
The results and findings from analysis of the four research questions and 
hypotheses help explain the relationships between HOR and vaccine coverage. The first 
finding showed that U.S. adolescents have higher immunization coverage for Hep B, 
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MMR, and VAR than PCABC from 2006 to 2008. The exception was PCABC 
immunization rates for Td/Tdap, which was 16.4% greater than U.S. immunization rates. 
The U.S. comparative data for OPV/IPV was unavailable to evaluate against PCABC 
OPV/IPV data. The low finding for PCABC matches the research problem statement. 
Low vaccinations are associated with disease outbreaks (CDC, 2013). The low vaccine 
coverage and the consequences of low-vaccination rates are supported by several 
previous researchers on immunization strategies to increase coverage rates (Humiston et 
al., 2013; USDHHS, 2010b). Examples of strategies to increase vaccinations include the 
Behavior Risk Factor Surveillance System, the WIC program, the VFC program, school 
immunization laws, and Healthy People 2020 (CDC, 2013). 
The second finding revealed that FCAs had a 10.6% higher UTD for FVSE than 
NHAs. The immunization rate for FCAs was greater than NHAs for each specific 
vaccine. In fact, FCA immunization rates for MMR (90.7%) and OPV/IPV (91.5%) 
attained the greater-than-90% threshold recommended by Health People 2010. Compared 
to FCA immunization rates, NHAs failed to achieve the recommended 90% threshold for 
any of the FVSE. This finding differs from other published studies and the expectation 
that FCAs are more predisposed to have fragmented medical homes than NHA. Other 
authors averred that, compared to NHAs with stable medical homes, FCAs have low 
immunization coverage due to social disruption and fragmented medical homes to access 
recommended age-specific vaccines. High vaccine UTDs are associated with stable 
medical homes (Humiston et al., 2013). 
The third finding from the bivariate logistic regression revealed that race 
mediated the association between HOR and UTD for FVSE. Specifically, African 
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Americans have 80% greater odds of FVSE and Other races have 10% lower odds of 
FVSE compared to Caucasians, after adjusting for residence. The race ORs explained that 
race was significant regardless of residence status. This finding is significant because, 
historically, African Americans have had lower vaccination rates compared to 
Caucasians. Also, race was significant and accounted for in the model. The justification 
for not including gender and ethnicity (Hispanic and non-Hispanic) in the model was that 
these groupings did not significantly associate with FVSE. 
The fourth finding from the VGT analysis showed that group optimum had lower 
estimated deaths compared to individual equilibrium for all nine vaccine-preventable 
diseases. This finding of lower estimated deaths associated with group optimum supports 
the VGT framework (Bauch et al., 2003). The VGT analysis also revealed that individual 
equilibrium had higher estimated deaths for each of the nine diseases compared to group 
optimum. High estimated deaths related to low immunization, which is not protective 
during a vaccine-preventable disease outbreak (Bauch et al., 2003). 
In Chapter 5, I discuss the research findings, study limitations, implications, and 
positive social change. 
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Chapter 5: Discussion, Conclusions, and Recommendations 
Introduction 
The purpose of this quantitative study was to examine adolescent immunization 
rates and uptake coverage for the 1990 PCABC. In Arkansas, some anecdotal evidence 
emerged that a disparity existed in vaccination coverage among adolescents in foster care 
compared to those in their natural home (Daniels, Jiles, Klevens, & Herrera, 2001; 
Lindley et al., 2011; Smith, Jain, et al., 2009; Smith, Santoli, et al., 2005). I implemented 
a retrospective cohort design to examine this immunization-coverage problem among 
PCABC. I analyzed immunization records for PCABC from the AIRD to answer four 
research questions. Although Arkansas law requires UTD immunization for FVSE, only 
15.6% of PCABC attained the legal immunization requirement for FVSE. 
This study produced four findings from the data analysis. First, U.S. adolescent 
adjusted vaccine-coverage uptake rates were 12.0% higher for Hep B, 11.6% for MMR, 
and 70.2% for VAR than for PCABC. For Td/Tdap, adjusted PCABC immunization rates 
were 16.4% higher than for U.S. adolescents. The second finding revealed FCAs had 
10.6% higher UTD status for FVSE compared to NHAs. The immunization rate for FCAs 
was greater than NHAs for each specific vaccine. FCA immunization rates for MMR 
(90.7%) and OPV/IPV (91.5%) attained greater than the 90% threshold recommended by 
Healthy People 2010 compared to none among NHA. The third finding was an 
association between HOR and UTD status for FVSE. The results from a bivariate logistic 
regression revealed that race mediated the association between HOR and UTD status for 
FVSE. Specifically, African Americans have 80% greater odds of being UTD with FVSE 
and Other races have 10% lower odds of being UTD with FVSE compared to Caucasians, 
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after adjusting for home residence. Fourth, findings from the VGT analysis revealed 
individual equilibrium had higher estimated deaths for each of the nine diseases 
compared to the group optimum. 
Chapter 5 is organized into seven parts: introduction, research results, 
interpretations of findings, limitations of the study, recommendations, implications, and 
conclusion. 
Research Findings and Theoretical Context 
The study results included significant underimmunization for individual vaccines 
among the PCABC. Only 15.6% of PCABC were UTD for FVSE. Significant differences 
emerged from 2006 to 2008 in UTD vaccine coverage between PCABC and U.S. 
adolescents. During 2006 to 2008 U.S. adolescents showed higher average adjusted UTD 
coverage rates for Hep B (85.9%); MMR (88.9%), OPV/IPV (no data available), and 
VAR (91.3%), compared to average adjusted PCABC Hep B (75.9%), MMR (77.7%), 
OPV/IPV (85.01%), and VAR (21.1%). In general, U.S. adolescents showed average 
lower Td/Tdap adjusted UTD coverage rates (67.5%) compared to PCABC (83.9%); the 
difference between the U.S. and PCABC t tests was 3.51, p = .025. 
I found significant associations between HOR and UTD status for FVSE (χ2 = 
18.5, p≤.0001) from the chi-square analysis. The specific vaccines associated with HOR 
were Hep B (χ2 = 10.89, p 0.001), MMR (χ2 = 11.89, p = .0006), OPV/IPV (χ2 = 4.61, 
p=.318), and VAR (χ2 = 21.79, p < .0001). The vaccine not associated with HOR was 
Td/Tdap (χ2 = 1.55, p = .21). I further compared FCAs to NHAs; and the findings 
revealed that among FCAs only MMR (90.7%) and OPV/IPV (91.5%) achieved the 90% 
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UTD immunization threshold established in Healthy People 2010. In contrast, NHA had 
no vaccines that attained Healthy People 2010 immunization recommendations. 
The mediation analysis revealed race mediated the association between HOR and 
UTD status for FVSE (OR = 1.79; 95% Cl 1.51–2.12; p = < .0001). This finding explains 
that African Americans have 80% greater odds of being UTD with FVSE compared to 
Caucasians, after adjusting for HOR. The race ORs explained that race was significant, 
regardless of HOR. The mediation analysis revealed race was a mediating variable. Race 
mediated the association between HOR and UTD status for FVSE. 
The quantifiable payoffs or deaths associated with vaccine behavior and strategies 
supported the constructs in VGT. The theoretical construct for this study was the VGT 
(Bauch et al., 2003; von Neumann & Morgenstern, 1944). The quantified differences 
between the vaccine self-interest strategy and group-interest strategy in VGT are 
important findings. Disparity emerged for estimated deaths for each reported disease 
between individual equilibrium and group optimum immunization. These findings 
confirmed similar results reported by Bauch et al. (2003). Overall, study findings showed 
greater estimated deaths among individual equilibrium compared to group optimum. 
Specifically, the mortality differences ranged greater than one to three deaths for 
diphtheria, hepatitis B, pertussis, tetanus, and varicella diseases. In addition, a similar 
trend but with smaller differences emerged in estimated deaths between individual 
equilibrium and group optimum for measles, mumps, poliomyelitis, and rubella diseases. 
The estimated payoffs or deaths for individual-equilibrium specific-disease-rank 
order, highest to lowest, was varicella, 12.03 estimated deaths; hepatitis B, 5.44 estimated 
deaths; tetanus, 3.39 estimated deaths; diphtheria, 2.61 estimated deaths; pertussis, 1.30 
114 
 
estimated deaths; rubella, 0.222 estimated deaths; measles, 0.001 estimated deaths; 
poliomyelitis, 0.001 estimated deaths; and mumps, 0.0000895 estimated deaths. 
The group optimum estimated death rate for specific-disease-rank orders was 
similar to that for individual equilibrium. However, group optimum estimated deaths 
were lower compared to those for individual equilibrium. The group-optimum disease-
rank order from highest to lowest was varicella, 9.66 estimated deaths; Hepatitis B, 1.78 
estimated deaths; tetanus, 0.57 estimated deaths; diphtheria, 0.441 estimated deaths; 
pertussis, 0.22 estimated deaths; rubella, 0.05 estimated deaths; measles, 0.002 estimated 
deaths; poliomyelitis, 0.0002 estimated deaths; and mumps, 0.000021 estimated deaths. 
Four findings emerged. First, the 2003 to 2008 U.S. adjusted UTD vaccine rates 
for FVSE were greater than those for PCABC except for Td/Tdap. Second, significant 
differences existed between FCA and NHA individual vaccine UTD coverage-uptake 
rates. The FVSE was (χ2 = 18.5, p < .0001). In comparison, I found the FCA FVSE 
uptake rate (29.7%) was greater than that of the NHA FVSE (19.1%). 
Third, an association emerged between HOR and UTD status for FVSE when 
stratified for FCA versus NHA (OR = 2.22; 95% CI 1.47–3.34, p = .0001). Results 
revealed FCA had 2.2 greater odds of UTD status for FVSE than NHA after adjusting for 
race However, race aligned with UTD status for FVSE, and African Americans were 1.8 
times more likely to be UTD for FVSE compared to Caucasians. Race was a mediating 
variable in the association between being UTD with FVSE and HOR in the bivariate 
logistic regression model analysis. The mediator variables were gender and ethnicity in 
the multivariate analysis. Fourth, I reported individual equilibrium or self-interest 
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strategy in the VGT had greater estimated payoffs or deaths compared to the group-
optimum or group-interest strategy. 
Interpretation of the Findings 
Low UTD coverage is an endemic public health problem (Dempsey & Zimet, 
2015; Dorell et al., 2011) similar to the evident underimmunization problem prevalent in 
PCABC. This study provided two main contributions to the literature. It provided 
evidence that African Americans had higher UTD vaccine coverage for all five vaccines, 
compared to Caucasians. Evidence reported in Table 6 did not support findings from 
other studies that showed African Americans historically had low vaccine-coverage rates. 
First, results from other registry data driven studies were lower for African 
American UTD coverage rates compared to findings from this PCABC study. The 
registry data are population-level-based data that are reproducible and stable (Bundy et 
al., 2013; Gowda, Dong, Potter, Dombkowski, & Dempsey, 2013; LoMurray & Sander, 
2011a; Rees-Clayton, Montgomery, Enger, & Boulton, 2013) compared to sample-based, 
survey-dependent, dynamic, and fluid studies (Lindley et al., 2011a). Immunization 
registries have more reliable data (Curran, Bednarczyk, & Omer, 2013) and may be the 
gold standard for immunization population results compared to survey samples. These 
registries have comprehensive data and accurate descriptions of characteristics of young 
adolescents who have received recommended vaccines (Rees-Clayton et al., 2013). 
Second, this study supported the value of registry data (Gowda et al., 2013; 
LoMurray & Sander, 2011a) required to establish verifiable true vaccine coverage based 
on historical documentation (Bundy et al., 2013) compared to surveyed vaccine-coverage 
studies (Curran et al., 2013). Furthermore, the registry system includes the AIRD, but 
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improved by eliminating duplicate and mismatched records to become useful, accurate, 
and efficient reporting tools for adolescent immunization (Rees-Clayton et al., 2013; 
Sittig, Teich, Osheroff, & Singh, 2009). I used registry data to examine trends in 
adolescent immunization similar to other published studies (LoMurray & Sander, 2011b; 
Rees-Clayton et al., 2013). Immunization-registry data are more reliable than surveys 
because of data cleaning, new technology, and standardized provider-reporting systems to 
the registry (Bundy et al., 2013). 
A trend below the optimal 90% Healthy People threshold for UTD coverage rates 
persisted among PCABC and U.S. adolescents between 2006 and 2008. The low UTD 
rates for FVSE coverage associated with disease outbreaks among PCABC and U.S. 
adolescents are consistent with published literature on vaccines (CDC, 2009b). The low 
VAR coverage among PCABC may be attributed to varicella outbreaks in Arkansas in 
2001, 2004, and 2006 (Gould et al., 2009; Lopez et al., 2006). Exposed siblings or those 
with a history of varicella did not require VAR immunization, and thus did not require 
reporting to the immunization registry, which is consistent with the low immunization 
trend between 2006 and 2008. 
A congruent trend emerged in high UTD coverage rates among FCAs compared 
to NHAs. Similarly, FCAs had higher UTD rates for FVSE than NHAs. Furthermore, 
FCAs attained the Healthy People 2010 objectives for two vaccines—MMR and 
OPV/IPV—compared to none among NHAs. I found no significant or appreciable 
increases in vaccine uptake after the age of 16 among PCABC. This may be due to 
migration of individuals in the cohort. Vaccine coverage rates decreased over time from 
2006 to 2008 among PCABC because the 1990 birth cohort was not fixed, but limited to 
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birth date and other inclusion criteria. Children moved in and out of the study area and 
vaccines administered outside Pulaski, Arkansas, may not have been reported to the 
registry. If the coverage rates of those who moved were better than those who stayed 
behind, one might expect to see a slight decrease in coverage between 2006 and 2008. 
FCAs had greater UTD vaccine-coverage uptake rates for all FVSE compared to 
NHAs. The FVSE coverage uptake for FCAs was 29.7%, whereas for NHAs it was 
19.1%, and χ2 =18.5 (p = .0001). Children in foster care, contrary to prior hypotheses, are 
no less likely to complete immunization requirements than children in natural home 
settings. The significant differences in vaccine-coverage-uptake rates between FCAs and 
NHAs may be attributed to court-ordered immunization enforcement policies for all 
children entering the foster care system (ADHS, 2010). NHAs may exercise their 
medical, philosophical, and religious exemption rights allowed under Arkansas 
immunization laws (ADH, 2004b; ALB, 2003). This evidence of social services 
regulations and laws supports the contributions of other factors not included in the data 
and may account for the observed FCA–NHA differences in immunization rates. 
The bivariate logistic model revealed an association between race and UTD for 
FVSE. Study findings revealed differences in odds of UTD for FVSE among PCABC 
race categories. Future race-specific interventions may improve overall PCABC 
immunization rates through education, recall/reminder messages, and social media 
information. For example, pediatricians, school nurses, health providers, and public 
health stakeholders may target each race category with culturally specific messages. The 
targeted messages may include evidence-based information with particular parental 
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vaccine concerns that address vaccine safety, delay, autism, trust, exemptions, hesitancy, 
and refusal. 
African Americans contributed more than 50% of the PCABC population 
compared to Caucasians (30.7%). This sociodemographic distribution may not account 
for or completely explain the proportionally increased UTD coverage among PCABC. 
The dichotomous outcome variable of “Yes or No” for UTD for FVSE in the registry 
database may not include other measurable contributory factors that are not usually 
collected. However, in the general population, the inverse distribution occurs such that 
Caucasians account for the greater percentage of the population. Caucasians are twice as 
likely to receive vaccines compared to other races in the general population (Darden et 
al., 2011; Stokley et al., 2011). However, for race, a significant association emerged 
between African American and vaccine coverage UTD status when controlling for HOR, 
and Caucasian was the reference variable (OR = 1.77; 95% Cl 1.49–2.09). African 
Americans were 1.8 times more likely to have UTD vaccine-coverage-uptake rates. This 
association could not be explained from the data within the scope of this study. The 
association between race and immunization rates was established in the literature with 
inverse results to those of this study. Similarly, for race, a significant association emerged 
between Other and vaccine coverage UTD status when controlling for HOR, and 
Caucasian was the reference variable (OR = 0.54; 95% Cl 0.43–0.67). Other races had 
10% lower odds of reaching UTD for FVSE. 
This study supported VGT, which posits that the behavior of a group influences 
individual behavior (von Neumann & Morgenstern, 1944). In VGT, I partitioned 
participants into two groups: individual equilibrium/delayers/free-riders/refusers and 
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group optimum/preemptors/early acceptors/vaccinators. The study also confirmed the 
Bauch et al. (2003) construct of vaccine-uptake-behavior payoff differences between 
preemptors and delayers. Diseases with high estimated deaths require preemptive 
vaccinations, which are protective against potential disease risks, exposures, and 
outbreaks, and can help reduce unintended deaths. A correlation emerged between high-
vaccine UTD and low number of estimated deaths associated with VGT. I concluded that 
high-vaccine UTD protects against disease outbreaks. 
The interpretation of the higher estimated payoffs or deaths confirmed that the 
self-interest strategy was a high-risk behavior. Individual equilibrium indicated that this 
delayer vaccination strategy has greater estimated costs and higher estimated risks. The 
benefit of delaying vaccination was not protective. Vaccine delay increases VPD 
morbidity (Bauch & Bhattacharyya, 2012; Schlenker et al., 1992), which may result in 
death after a VPD outbreak (Bauch & Earn, 2004; Bauch et al., 2003; Baxter et al., 2013). 
The group optimum was a better and less costly strategy because lower estimated payoffs 
or deaths aligned with this preemptive vaccinator strategy. The benefits of the group 
optimum were protective and fewer estimated deaths would accrue during a VPD 
outbreak. 
In summary, the findings yielded four important interpretations. First, U.S. 
adolescents had higher adjusted vaccine-UTD for Hep B, MMR, and VAR compared to 
PCABC. Overall, U.S. adolescents are more protected against Hepatitis B, measles, 
mumps, rubella, and varicella outbreaks compared to PCABC. Second, immunization 
rates among NHAs are low compared to FCAs. NHAs have less immunization protection 
and higher disease risk and exposure. The consequences of high disease predisposition 
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are disease risk and high estimated deaths during VPD outbreaks. VGT supports these 
consequences. In addition, low immunizations with increased disease outbreaks, school 
absenteeism, poor school performance, and adolescent hospitalization. 
Third, the interpretation of improved immunization among African Americans in 
this cohort is that future possibilities exist to sustain this vaccination gain among this 
historically low-performing race. In future research, the process can be duplicated once 
these contributory factors are explored and understood. The challenge is to understand 
contributing factors associated with increased UTD for FVSE among African Americans 
in PCABC. Although contributing factors associated with increased immunizations are 
known in the published literature (Atwell et al., 2013; Darden et al., 2013; Diekema, 
2012), they are outside the scope of this study. Immunization contributing-factor data 
were not collected and were unavailable for analysis in this PCABC study.  
Fourth, the interpretation of VGT group-optimum preemptive vaccination 
behavior is protective compared to alternative behaviors. Preemptive vaccinations are 
encouraged because reducing the risks of outbreaks has greater individual and 
community-health benefits.VGT analysis showed numbers of payoff deaths associated 
with individual equilibrium are higher than group optimum. This finding supports VGT, 
showing that preemptive vaccination behavior among group optimum is protective and 
associated with fewer deaths. In contrast, however, individual-equilibrium vaccination 
behavior is riskier and aligns with higher numbers of deaths during a VPD outbreak or 
resurgence. 
This study contributed evidence of increased vaccination among historically low-
performing groups. Future researchers may examine benefits of immunization-registry 
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data and assess their reliability, compared to survey-sample data. Future researchers may 
enhance potential changes in cultural and social beliefs toward immunization among 
African Americans. Future research is needed to determine if mothers whose children are 
enrolled in vaccination social programs, such as VFC or WIC, are more receptive to 
vaccinations. Empirical data from a larger population study are desirable to indicate that 
vaccination is an essential requirement for enrollment in other welfare programs. 
Socioeconomic data analysis with African Americans immunization data may justify 
increase in immunization among such historically low-performing races as African 
Americans. Community and faith-based immunization research should include African 
Americans and address immunization safety, education, beliefs, biases, and cultural 
attitudes (Gamble, 1997); social media and vaccine hesitancy (Dredze et al., 2015); and 
health-provider ethical practices (Dempsey & Zimet, 2015). School nurses may use these 
findings to encourage parents to immunize their children. Community campaigns citing 
this improvement among this social group could cultivate community trust building. 
Awareness of immunization improves among members of a social class with historical 
mistrust for immunization. 
Limitations of the Study: Generalizability 
The study results and findings are generalizable to the 1990 birth cohort of all 
children who met the study criteria, born between January 1, 1990 and December 31, 
1990 in PCA, and had immunization records in the AIR. There were 9,102 live births in 
1990, from which I obtained the representative sample for this study cohort. The study 
was based on 3,371 children from the 1990 birth cohort and met the a priori established 
selection criteria such as foster care, geography, and documented immunization records 
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in the AIR. Records in the AIR database contained internal-validity issues similar to other 
states’ immunization registries; documents contained incomplete records and many types 
of errors in reporting immunization information (Khare et al., 2000). The PCABC 1990 
study did not measure or include known factors associated with low-immunization rates 
frequently analyzed in vaccine-coverage studies: socioeconomic factors(Wooten et al., 
2007), lack of access to care, parental attitudes, and educational levels. Arkansas registry 
data were limited to vaccine type, vaccine-administration date, birth date in 1990, 
ethnicity, gender, and race demographic factors. 
The racial and ethnic profile of the 1990 PCABC population was not comparable 
to the total United States, given the sample size (3,371), and the number of African 
Americans (1,851; 53.2%); Caucasians (1,036; 30.7%); and Others (543; 16.1%). 
Nevertheless, the findings should be generalizable to similar populations in the United 
States, given that all states receive federal funding, such as from the VFC fund, and 
follow the CDC ACIP guidelines (CDC, 2008b; Sneller et al., 2008). NHAs (96.3%) 
comprise a greater proportion of the population of interest compared to FCAs (3.7%). In 
contrast to FCAs (3.7%), NHAs’ (96.3%) profiles in PCA were widely different from 
those of other counties across the United States. Furthermore, important variables 
associated with vaccination-coverage rates—including socioeconomic status, parental 
attitudes toward vaccination, and medical, philosophical, and religious exemptions—
were not captured or available in the AIR. In addition, social values, educational levels, 
and parental attitudes toward children’s immunization may be different and influential in 
parents’ immunization decisions. These factors were not captured in the data. Inclusion of 
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such data in the analysis may help provide analytic evidence and explain differences in 
immunization rates in this study. 
The limitations of this study included missing records, underreporting, and lack of 
reporting, such as in the case of the VAR, where more than 80% of the cohort had less 
than one dose of the VAR. Underimmunization among the other four vaccines was fairly 
consistent and in the range of 5–10% disparity from the desired 90% threshold 
recommended in Healthy People 2010 (USDHHS, 2000). I excluded incomplete or 
mismatched records from the analysis to minimize internal-validity limitations and 
unreliable results. I did not include duplicate doses of the same vaccine for the same 
unique identified immunization record when calculating UTD, which was limited to 
immunization rates based on the criteria in Appendix A, Table A1. Foster care residence 
was defined as any foster care residence regardless of duration in foster care and age 
when the child entered into foster care. This crude definition may have overestimated the 
benefit of foster care residence since the foster care system has strict immunization 
policies and is a potential limitation of the study. Another limitation was not all foster 
care children were included in this study because of place of birth. Excluding them may 
have limited the power to falsify the null hypothesis. The validity and reliability of 
interpretations of the results are applicable and specific to 1990 adolescents in PCABC. 
Recommendations 
The three main recommendations areas are research, public health stakeholders, 
and study improvement. 
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Recommendations for Research 
Race- and culture-based immunization messaging through social media, 
physicians, and health provider recall/reminder messages may enhance vaccination 
acceptance for children and adolescents. African Americans have 1.8 greater odds of 
FVSE compared to Caucasians. These successful contributing factors may be included in 
educational interventions to increase adolescent immunization rates. I recommend future 
researchers examine race- and culture-focused messaging, physicians, and health 
provider influence, and social media contributing factors to this successful improvement 
in a historically low-performing race in PCABC.  
Recommendations for Public Health Stakeholders and Health Practitioners 
U.S. adolescents have higher immunization coverage for Hep B, MMR, and VAR 
compared to PCABC from 2006 to 2008. I recommend targeted vaccine intervention 
campaigns to encourage parents to accept vaccines to attain the 90% threshold 
established in Health People 2010. A targeted campaign in PCABC will address 
underimmunization. Social media immunization messages, school-based clinics, and 
physician recall/reminder are established best practices. Race- and culture-based 
immunization messaging through social media, physicians, and health provider 
recall/reminder messages may enhance vaccination acceptance for children and 
adolescents. Direct physician and health-provider vaccination communication with 
parents and adolescents may build trust and reduce vaccination misinformation that 
predisposes parents to delay, hesitate, refuse, or seek exemptions (Safi et al., 2012). 
Underimmunization for Hep B (15.5%) was higher than for Td/Tdap and MMR, 
although the Hep B booster dose was strongly recommended for this age (Sneller et al., 
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2008; Wei et al., 2010) due to high-risk behavior among this age group. The Hep B 
vaccine was also a seventh-grade school requirement (ADH, 2008). The low uptake of 
VAR is of concern and a history of varicella disease should be reported in the registry to 
reflect natural immunity compared to vaccine-induced immunity. The frequent 
importation of measles, recent outbreaks, and cases of measles in Arkansas (ADH, 
2012b) require further investigation. 
This study contributed evidence of increased vaccination among historically low-
performing groups. The results could provide social-change benefits as public health 
officials, healthcare providers, policymakers, and community members plan intervention 
strategies that encourage parental vaccine decisions and improve UTD coverage among 
PCABC. Healthcare providers may include these results in vaccine communications 
during FCA and NHA wellness visits. Policymakers may include these findings to justify 
interventions and policies that sustain increased immunization coverage among FCA and 
NHA. 
Recommendations for Study Improvement 
I recommend clean and complete immunization information-systems data. The 
immunization-registry data used in this study required data cleaning. Missing, 
mismatched, or incomplete records were excluded from the analysis. 
The Arkansas immunization data-quality and data-registration linkage with the 
Arkansas vital-statistics database requires improvement with advanced technology that 
can identify and control duplicate-records submission from immunization providers. The 
technology implemented in immunization records reduced mismatched-record and 
immunization-reporting errors from health providers (CDC, 2010h; Fath, Andujar, 
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Williams, & Kurilo, 2015; Greene et al., 2009). The implementation of the electronic 
standard HL7 form routinely used to report healthcare-provider immunization to the 
state-registry enhanced data linkage, improved the quality of archival data, and facilitates 
future research. 
The AIR’s real-time quality data provides an advantage for future research. 
Arkansas immunization state laws imposed legal penalties when immunization providers 
or vaccinators do not report to the AIR within 30 days (ADH, 2008). Timely evidence-
based vaccine-coverage data on other birth cohorts provides justification to implement 
new policies that target vaccines and groups with low vaccine-coverage rates. National 
immunization surveys become very expensive and irrelevant. Therefore, I strongly 
recommend future studies on vaccine-coverage uptake base analysis on state-registry 
data. 
Implications for Positive Social Change 
Findings from this study may enhance social-change contributions toward 
immunization campaigns targeting natural-home parents and increase immunization rates 
among PCABC. I partitioned social-change implications in this study into four main 
areas: (a) protect vulnerable unvaccinated NHAs against recent VPD outbreaks; 
(b) reduce vaccine delay, distrust, and hesitancy; (c) build vaccine trust between 
providers and parents of unvaccinated or low UTD NHAs; and (d) health providers 
enhance vaccine communication with hesitant parents of PCABC. 
This dissertation offers information that may lead to protection of vulnerable 
unvaccinated NHAs against recent VPD outbreaks, which would be an important social 
change (NVAC, 2015). Social change through awareness of low UTD for FVSE among 
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NHAs may prevent recent VPD outbreaks and resurgence among vulnerable 
unvaccinated NHAs. Immunization awareness would be an important positive social 
change for adolescents, minimizing school absenteeism and poor school performance 
associated with VPD illness. School immunization requirements contribute positive 
important roles to controlling VPDs (Omer et al., 2008). NHAs had lower UTD coverage 
rates compared to FCAs. Immunization-intervention campaigns targeting low UTD-
performing NHAs with low-immunization rates will contribute to behavioral change to 
mitigate vaccine hesitancy, delay, or refusal. Hesitancy, delay, and refusal contribute to 
low UTD for FVSE among unvaccinated NHAs compared to FCAs with higher coverage 
rates. 
The concerted focus to increase awareness and benefits of vaccines may 
contribute to cultural and behavior change among NHAs to improve their UTD for 
FVSE. Low-vaccination coverage is the most common risk factor associated with 
measles resurgence (Hamborsky et al., 2015; Kennedy & Gust, 2008). Such cultural and 
behavior changes toward vaccine acceptance are positive social changes at the individual 
NHA level. Avoidance of low vaccine coverage among NHAs has immeasurable 
downstream lifetime burden such as adolescent hospitalization. Acute encephalitis, otitis 
media, and coma are reported measles complications (Hamborsky et al., 2015). Mumps 
complications of orchitis in men and oophoritis in women contribute to infertility. 
Permanent unilateral deafness complications from mumps (Hamborsky et al., 2015) may 
impact an adolescent’s school performance and future economic productivity. 
Vaccine delay, distrust, and hesitancy reduction among African Americans would 
contribute to social change. Globally, African American parents who live in households 
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with their children delay vaccine administration for their children (Smith, Humiston, 
Parnell, Vannice, & Salmon, 2010). The African American increased UTD for FVSE 
coverage compared to Caucasians in this study is a positive outcome, influencing 
behavior or attitudes among other African American parents who delay, hesitate, and 
distrust vaccination (Gamble, 1997). Although African Americans had higher UTD 
compared to other races, the preferred target for PCABC was to attain greater than 90% 
UTD for FVSE. Overall, PCABC adolescents did not attain greater than 90% UTD for 
FVSE. Therefore, to attain immunization goals, direct physician–parent communication, 
continuous education, and positive social-media immunization messages are valuable to 
sustain and improve parental acceptance of vaccines for children and adolescents. Parents 
of NHAs may benefit from such information and reduce their vaccination delays, 
hesitations, and distrust (Phadke, Bednarczyk, Salmon, & Omer, 2016). 
Social change as result of the outcomes from this study and others may increase 
immunization rates especially among inner-city African American children (Wood et al., 
1998). Including findings of increased PCABC African American immunization in 
physician–parent communications is valuable. Parents understand and accept empirical, 
verifiable, and convincing evidence. These successful health-provider communications, 
when repeated during wellness visits at inner-city health clinics or community health 
centers, may convince other hesitant parents to accept vaccines. Such individual parental 
vaccine acceptance, when duplicated and incorporated into standard practices in the 




Building vaccine trust between providers and parents of unvaccinated or low 
UTD NHAs may contribute to positive social change. Health providers can cite increased 
coverage rates in UTD for FVSE as validation of vaccine confidence among African 
Americans through effective trustworthy vaccine communication. Vaccine trust built 
between providers and parents of unvaccinated or low UTD NHA may enhance positive 
social change. Health providers can cite increased coverage rates in UTD for FVSE from 
this study as validation and endorsement of vaccine confidence among African 
Americans. Health providers are highly supportive of vaccines and may refer to findings 
from this study to build trust so that parents engage their children in the recommended 
immunizations (NVAC, 2015). 
Healthcare providers enhance vaccine communication with hesitant parents to 
improve UTD rates among PCABC during healthcare visits. Adolescent healthcare visits 
provide excellent opportunities to address concerns about vaccines. Concerns may 
include social norms, attitudes, beliefs, vaccine delays, hesitation, refusal, vaccine safety, 
vaccine effectiveness, vaccination benefits, building trust, confidence, VPD, and 
improving vaccine rates for adolescents. Social change may continue as school nurses 
include information on low-UTD coverage rates among PCABC compared to U.S. 
statistics when communicating and encouraging adolescents to accept vaccines. School 
nurses may use these findings to encourage parents to immunize their children. 
Healthcare-provider communication, endorsement of social norms, and vaccines are 
central components in establishing trust, nurturing, and fostering vaccine confidence 
among hesitant parents (NVAC, 2015). 
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The social change potential benefit could enhance public health officials’ ability 
to plan intervention strategies that encourage parental vaccine decisions and improve 
UTD coverage among PCABC. Healthcare providers may include these results in vaccine 
communications during FCA and NHA wellness visits. Policymakers may include these 
findings to justify interventions and policies that sustain increased immunization 
coverage among FCAs and NHAs. 
This study contributed evidence of increased vaccination among historically low-
performing groups. Future researchers may examine benefits of immunization-registry 
data more reliable than using survey-sample data. Future researchers may enhance 
potential changes in cultural and social beliefs toward immunization among African 
Americans. Community campaigns citing this improvement among this social group 
cultivate community trust building. Awareness of immunization may improve among 
members of a social class with historical mistrust for immunization. 
Parents have direct duties and responsibilities to vaccinate their children to 
provide health protection. Public health laws and policies require parents to comply with 
school-entry vaccine regulations established by Arkansas law (ADH, 2008). The PCABC 
adjusted UTD coverage for FVSE deficiency among Td/Tdap, Hep B, MMR, OPV/IPV, 
and VAR ranged from coverage rates of 5 to 14.1% during 2006–2008. PCABC failed to 
achieve the minimum recommended objectives established in Healthy People 2010. 
These vaccines disparities and deficiencies should be targeted by public health campaigns 
to prevent and reduce the burden of disease outbreaks among school children (Dempsey 
et al., 2015; Gaensbauer, Armon, & Todd, 2014). 
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Preemptive vaccination behavior was protective to the community and provides 
positive social change. High vaccine-coverage rates prevent resurgence of previously 
eradicated diseases, burden of disease imports, and outbreaks of VPDs (Cherry, 2010; 
Toner, 2014; Winter et al., 2012). The public health policies contributing to positive 
vaccine coverage among African Americans should continue to be encouraged. Such 
interventions will enhance improvements in future vaccine coverage and continue to 
break the historic cycle of low coverage among minority groups. 
Low adolescent vaccine coverage was a public health threat and burden because 
adolescents are reservoirs of VPDs (Dempsey et al., 2015) and these diseases are highly 
communicable among school children. Therefore, public health initiatives targeted 
toward these vaccines with low-coverage rates have a preventive and protective impact 
against VPDs in the community. The quantifiable evidence reported in Table 7 for 
specific racial groups was primary justification to influence individual-behavior changes 
and improve the county-level immunization discussion. 
Findings shown in Table 7 and trends shown in Figure 4 also indicated areas of 
significant differences in vaccine-coverage uptake rates among the cohort to initiate 
public health vaccine campaigns and achieve positive social change. Preemptive 
vaccination behavior created positive social change through payoffs, supporting 
justification. Thus, increased vigilance and compliance to reach required vaccination 
coverage would reduce morbidity, hospitalization, health costs, and other public health 
burdens. Preemptive vaccination behavior was preferred because low payoffs aligned 
with fewer deaths that would occur during a VPD outbreak. The correlation of vaccines 
with low-coverage rates and with vaccines that had high-payoff deaths was evident. The 
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vaccine-coverage-uptake results shown in Table 5 for low-coverage vaccines such as 
VAR and Hep B also correlated with high-payoff deaths shown in Table 12. 
The low payoffs associated with preemptive behavior support justification for 
increased vigilance and compliance with vaccination-coverage requirements. The high 
estimated payoffs or deaths for individual self-interest aligned with low vaccine-coverage 
rates. Vaccine refusal (Dredze et al., 2015) or underimmunization increased the risks 
associated with disease outbreaks (Gould et al., 2009; Lopez et al., 2006). The reported 
results and findings also indicated significant correlations between underimmunization, 
race (Smith et al., 2004), and specific vaccines. These results may influence vaccine-
intervention campaigns and public health policy in PCA. Adolescent immunization 
solutions to low immunization rates are implemented through policy at the individual 
level. Healthy People national health promotions from 2000 identified immunization as a 
national health priority (USDHHS, 1999). 
Policy solutions include school-entry laws (ALB, 1967; Omer et al., 2009; 
Orenstein & Hinman, 1999) and access to immunization in Arkansas (ALB, 1967) 
through federal and state eligibility programs including VFC, Medicaid, and the 
supplemental children’s insurance (ARKIDS) program in Arkansas (ADHS, 2011a). 
Legislative actions influence societal and environmental levels through immunization 
laws and school-entry requirements. School-based immunization clinics are associated 
with increased adolescent immunization coverage rates (Allison et al., 2007; Daley et al., 
2009; Federico et al., 2010; McNall et al., 2010). Therefore, increased vaccination-
coverage rates through these innovative modalities for vaccination are achievable and are 
improvements over current traditional vaccination-coverage methods. 
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The use of archival-data analysis with VGT should become the gold standard for 
determining coverage uptake compared to survey methods with potential systematic and 
recall biases. The availability of archival data is an advantage and true evidence of 
immunization providers’ practices, compared to national immunization-survey methods. 
The second advantage is a comparison of different birth cohorts in the same community. 
The third advantage is predicting immunization coverage uptake from analysis of 
archival data with VGT. For example, VGT emphasizes and explains self-interest and 
group behavior, immunization policy decisions, and maximization of payoff concepts 
(Bauch & Earn, 2004; Bauch et al., 2003). I used VGT to establish different payoffs or 
deaths for individual self-interest behavior and group altruistic behavior. Desirable 
vaccination behavior decisions were supported with quantifiable payoff evidence. Future 
archival data analysis with VGT of different birth cohorts in the same community would 
provide comparative justifiable evidence for public health campaigns, vaccination 
intervention, and policy decisions. The empirical implications presented here will 
facilitate vaccination-strategy comparisons for future research. 
Conclusion 
The two novel findings in this study confirmed disparities in state-mandated 
immunizations and reported significant improvement in immunization rates among 
historically low-performing races. The first novel finding in this study confirmed 
disparities in state-mandated immunizations among PCABC. Adolescents in foster care 
were 2.2 times more likely to complete FVSE compared to adolescents in natural homes. 
This novel finding contradicted previous literature that associated NHAs with higher 
immunization rates. The second novel contribution of this PCABC study is that African 
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Americans were 80% more likely than Caucasians to be UTD for FVSE. In other 
population studies, immunization rates among Caucasian adolescents were usually higher 
than those of African Americans. 
This study made two main contributions to the literature. First, the study provided 
evidence that African Americans had higher UTD vaccine coverage for all five vaccines 
compared to Caucasians at the county or community level. This higher vaccine coverage 
of African Americans compared to that of Caucasians is a novel finding, contrasting with 
state and national reports and previous research in which Caucasians were the majority 
race and usually had higher vaccine-coverage rates. Second, this study supported the 
value of registry data required to establish verifiable true vaccine coverage based on 
historical documentation compared to vaccine-coverage survey studies. Several previous 
studies used telephone surveys to establish vaccine-coverage rates (CDC, 2010a). These 
previous survey-designed studies often reported low vaccine-coverage rates for African 
Americans. 
The PCABC study confirmed some information described in previous literature. 
The immunization rates in Arkansas, represented by the PCABC, are lower compared to 
those of the United States. This study supported previous research findings that Arkansas 
vaccine-coverage rates for Hep B, MMR, OPV/IPV, and VAR were lower than U.S. 
national vaccine-coverage rates among adolescents (CDC, 2009b). PCABC vaccine-
coverage rates for Td/Tdap were higher than U.S. national vaccine-coverage rates. 
Estimates of immunization uptake from the national immunization survey should not be 
necessary with the advent of web-enabled immunization registries that facilitate actual 
computation of true vaccine coverage. Children in foster care, contrary to prior 
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hypotheses, are no less likely to complete immunization requirements than children in 
natural-home settings. 
African Americans were twice as likely to complete their vaccine series compared 
to Caucasians. No intuitive explanation arose for African Americans’ vaccine-coverage 
rates from this study. Contributory factors that may explain the African American 
coverage rate are outside the scope of this study. It is possible that, as a race, African 
Americans were more compliant with school vaccine requirements or were enrolled in 
federal vaccine programs compared to members of other races. Therefore, African 
Americans are more receptive to childhood vaccination, as evident in the vaccine-
coverage uptake of school-entry requirements. Furthermore, shifts in vaccine attitudes 
among African Americans and persistent high infant mortality reported in other research 
were outside the scope of this study. 
The analysis of immunization archival data provided empirical evidence in 
establishing vaccine-coverage uptake in this 1990 PCABC. No difference in 
immunization uptake emerged for HOR. Foster children had higher immunization rates 
before adjustment in a multivariate logistic-regression model. The difference, however, 
disappeared after controlling for gender, race, and ethnicity. This study also confirmed an 
immunization disparity between the 1990 PCABC and the NIS-Teen from 2006 to 2008. 
The U.S. NIS-Teen adjusted vaccine-coverage-uptake rates for FVSE were higher 
than the 1990 PCABC adolescent adjusted vaccine-coverage-uptake rates from 2003 to 
2008. This study confirmed the persistent problem of low adolescent immunization 
reported in previous research (Diekema et al., 2005; Imdad et al., 2013; USDHHS, 1999; 
Zhou, Santoli, et al., 2005). Very few studies used archival registry data to establish 
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immunization rates among adolescents (LoMurray & Sander, 2011b). This study 
addressed this gap in the literature and used archival data to establish vaccine-coverage 
rates for PCA. 
Several peer-reviewed studies addressed components of immunization in 
Arkansas. These components included VPDs, exemptions, policy, state-mandated 
immunization laws, regulations, and infant and childhood coverage. However, these 
studies did not apply quantitative analysis of immunization-registry data, nor did they 
focus on NHA and FCA 1990 PCABC to establish immunization-coverage rates for the 
FVSE. The immunization rates reported for adolescents in Arkansas (CDC, 2008a; 
Darden et al., 2013; Jain et al., 2009; Stokley et al., 2011) were based on an RDDS of 
sample households. In contrast, this cross-sectional study focused on archival registry 
deidentified data to establish immunization coverage uptake rates for FVSE among the 
1990 PCABC. 
This study contributed evidence of increased vaccination among historically low-
performing groups. Such improvements enhance potential future changes in cultural and 
social beliefs toward immunization among PCABC and specifically African Americans 
and FCAs. Direct social change encourages school nurses to motivate parents to 
immunize their children. Community immunization campaigns citing these 
improvements among these social groups of people cultivates community trust building 
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Appendix A: Tables 
Table A1 
School Entry Requirements: Arkansas Adolescent Immunization Rules and Regulations 
AIRR Table II, 2008 
Vaccine 
Number of 




4 All Grades Kindergarten to 
12th Grade 
Notarized Annual Application for 
Medical, Religious, and 
Philosophical Exemptions. 
(DTP), Diphtheria/Tetanus (DT 
pediatric), or 




Hepatitis B vaccine 3 Kindergarten, seventh 
grade, and Transfer 
students 
Notarized Annual Application for 




Measles vaccine, Mumps 
vaccine, Rubella vaccine 
(German measles) 
2 All Grades Notarized Annual Application for 




Polio vaccine 3 All Grades Kindergarten to 
12th Grade 
Notarized Annual Application for 
Medical, Religious, and 
Last dose on/ after 4th 
birthday 
Philosophical Exemptions. 
Varicella (chickenpox) 2 Kindergarten, seventh 
grade, and Transfer 
students 
Notarized Annual Application for 
Medical, Religious, and 
Adolescent Philosophical Exemptions. 
13–18 years  
Note. Adapted from Table II of “Arkansas State Board of Health: Rules and regulations pertaining to 





Changes Arkansas Adolescent Immunization Requirements, 1991–2009 
Vaccine 
Required number of doses 




4 Doses 3 Doses 3–4 doses 3–4 doses 3 Doses 
(DTP), Diphtheria/Tetanus 
(DT pediatric), or 
Tetanus/Diphtheria (Td Adult) 
4 Doses 3 Doses 3–4 doses 3–4 doses 3 doses 
Tdap—Adult with Pertussis 
(2008) 
4 Doses 3 Doses 3–4 doses 3–4 doses 3 doses 
7th grade 
1 dose on or after 4th 
birthday). 1 dose of 
Tdap 
Polio  
OPV—Oral  3 doses 3 doses 3 doses 3 doses 3 doses 
IPV—Inactivated   
Rubeola (measles) +MMR 1 dose 2 doses 2 doses 2 doses 2 doses 
(M, M/R, M/M/R) 2002/2004 
Measles 2008 (M, M/R, 
M/M/R, MMRV) 
Dose 2 at least 28 
days after dose 1 
Dose 2 at least 28 
days after dose 1 
MMR (Measles, Mumps, and 
Rubella) 2009 
 Dose 2 at least 28 
days after dose 1 
Rubella (German measles) (R, 
M/R, M/M/R) (R, M/R, 
M/M/R, MMRV) 2008 
1 dose 1 dose 1 dose 1 dose N/A 
Mumps vaccine. (M, M/M/R)  1 dose 1 dose 1 dose 1 dose N/A 
Hepatitis B N/A 3 doses 3 dose 3 doses 3 doses 
2 dose alternative 
schedule for 11–15-
yr. olds 




(Varicella, MMRV) 2008 
1 dose 1 dose 1 or 2 
doses 
1 or 2 doses 1 or 2 doses 
28 days apart 28 days apart 
2 doses for 7th grade; 
13 yrs. and older or 
Disease History 
2 doses for 7th grade; 
13 yrs. and older or 
Disease History 
Note. Adapted from “Arkansas State Board of Health: Rules and regulations pertaining to immunization 










1987 Act 141 Mandated proof of measles, rubella, and other diseases immunization prior to 
enrolling in Arkansas colleges and universities 
1989 Act 387 To achieve and maintain adequate immunization levels for all children in Arkansas. 
Children in childcare facilities 90% and Children in public and private schools 95%. 
1993 ACT 591 Availability, adequacy, promotion and utilization of immunization programs for 
infants and preschool children in Arkansas. 
1995 ACT 432 Established a statewide childhood immunization registry in Arkansas. 
  Immunization registry provides information on childhood immunization status from 
birth to age 22 years to parents, guardians and providers. 
  All providers shall register and report all vaccine administered to children and 
adolescents from birth to age 22 years. 
  Imposed a penalty of $25 dollars enforced to all providers who do not report 
administered vaccines to the registry. 
1995 ACT 685 Mandated coverage of children’s preventive health care from birth through age 18 
years. 
  Funded immunization services under the Medicaid program. 
  Eased financial burden and exempts low income, uninsured children from any 
copayment, coinsurance, deductible or dollar limit provisions. 
1997 ACT 870 Mandated immunization prior to school enrolment and specific required vaccines for 
all children. 
1997 ACT 871 Required immunization for students in kindergarten through 12th grade attending 
Arkansas schools. 
  Authorized immunization compliance enforcement responsibilities on school boards, 
superintendents, and principals, and any school. 
2003 ACT 999 Authorized immunization exemptions for: Personal beliefs, religious, and 
philosophical, and medical exemptions 














Pulaski County wide 
public school enrollment 
Percent 
adolescent cohort 
2001 5th  11 4,168 52,177 8.0 
2002 6th  12 4,134 51,448 8.0 
2003 7th  13 4,216 51,967 8.1 
2004 8th  14 4,140 52,181 7.9 
2005 9th  15 4,797 53,112 9.0 
2006 10th  16 4,360 53,487 8.2 
2007 11th  17 3,703 53,864 6.9 
2008 12th  18 3,123 54,184 5.8 
Note. Adapted from “Statewide Information System Reports: Student Status Counts,” by Arkansas 
Department of Education, 2011, Retrieved from https://adedata.arkansas.gov/statewide/Students 
/StatusCounts.aspx?year=16&search=&pagesize=10. 
Table A5 
Total Number of Foster Care Adolescents School Attendance 2000–2009 
Year Age in years 
Adolescents school 
attendance data 2000–2009 
2000 10 27 
2001 11 42 
2002 12 43 
2003 13 63 
2004 14 90 
2005 15 116 
2006 16 146 
2007 17 135 
2008 18 86 
2009 19 20 
Note. Adapted from Children’s Reporting and Information System, Arkansas Department of Human 




Trends in Pertussis Cases, United States, and Arkansas, 2000–2010 
Year U.S. pertussis cases Arkansas pertussis cases 
2010 27,550 245 
2009 16,858 396 
2008 13,278 197 
2007 10,454 173 
2006 15,632 112 
2005 25,616 208 
2004 25,827 95 
2003 11,647 92 
2002 9,771 486 
2001 7,580 1324 
2000 7,867 44 
Note. Adapted from “Summary of Notifiable Diseases—United States, 2004,” by Centers for Disease 
Control and Prevention, 2006d, Retrieved from http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5353a1 
.htm. 
Table A7 









Pulaski County wide 
public school enrollment 
Percent (%) 
adolescent cohort 
2001 5th  11 4,168 52,177 8.0 
2002 6th  12 4,134 51,448 8.0 
2003 7th  13 4,216 51,967 8.1 
2004 8th  14 4,140 52,181 7.9 
2005 9th  15 4,797 53,112 9.0 
2006 10th  16 4,360 53,487 8.2 
2007 11th  17 3,703 53,864 6.9 
2008 12th  18 3,123 54,184 5.8 
Note. Adapted from “Statewide Information System Reports: Student Status Counts,” Arkansas Department 





Vaccine-Preventable-Disease Reported Cases, All Ages, Pulaski County, Arkansas, 
1995–2012 














Hepatitis B 81 499 78 550 53 365 25 179 
Measles 0 2 1 24 0 0 0 0 
Mumps 1 24 0 1 6 23 0 0 
Pertussis 57 253 413 1613 270 1,179 117 543 
Rubella 0 12 1 4 0 0 0 1 
Tetanus 0 1 1 3 0 1 1 2 
Varicella 0 0 0 0 202 3,466 47 803 
Note. Adapted from Arkansas Department of Health, 2014b. 
Table A9 
Vaccine-Preventable Diseases, By Year of Vaccine Development or Licensure United 
States, 1798–1998 
Disease Year licensed 
Smallpox  1798 
Diphtheria 1923 
Pertussis  1926 
Tetanus  1927 
Poliomyelitis 1955 
Measles  1963 
Mumps  1967 
Rubella  1969 
Hepatitis B  1981 
Haemophilus influenzae type b 1985 
Varicella 1995 
Note. Adapted from “Final 2010 Reports of Nationally Notifiable Infectious Diseases,” Centers for Disease 




Vaccine Codes Arkansas Department of Health, 2005 
Vaccine ID code Type vaccine family Vaccine name 
1; 2; 3; 4; 21; 22; 24; 
31;35; 42;43;44 
A DTP; PED DT; DTAP; Td; DTP-ACTHIB; DTP-HBOC; DTP-
HIB; DTAP/HIB; DTAP/P/HPB; DECAVAC; Tdap; Tetanus 
5;6; and 7 B OPV; EIPV; IPV 
8;9;10;11; and 12 C MMR; M/R; Measles; Rubella; Mumps 
13;14;15;16; 23; 32 D HBOC; PEDVAX-HIB; PROHIBIT; HIB; ACT/OMNI; HEP 
B/HIB 
17;18;19 and 34 E HEP B-3dose; PHEPB-3dos; HBIG; HEP B 2 dose 
27; 89 I Varicella; Chicken PO 
Note. Adapted from “ Unpublished vaccine codes. Internal Immunization Agency communication 
document,” Arkansas Department of Health, 2005. 
Table A11 
Definitions of Variables 
Variable type Variable name 
Type of variable / 
measurement scale 
Independent Adolescent in 1990 cohort Categorical 
FCA Categorical 
NHA Categorical 
Dependent Five Vaccines School Entry (FVSE) Categorical 
Immunization rates Ratio variables 
Up-to-date status UTD Categorical 
Diphtheria Tetanus toxoid acellular Pertussis (DTaP 
DTP, Tap) Nominal; Categorical 
Hepatitis B (Hep B) Nominal; Categorical 
Measles, Mumps and Rubella (MMR) Nominal; Categorical 
Poliomyelitis Nominal; Categorical 
Varicella Nominal; Categorical 
 Covariates Gender Nominal; Categorical 
Race Nominal; Categorical 
Ethnicity Nominal; Categorical 
Age Continuous 
Note. Adapted from Pulaski County, Arkansas Birth Cohort, Analysis 2015. 
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Appendix B: Calculation Tables 
Table B1 
Pulaski County, Arkansas Mortality Data, 1990–2008 
Diphtheria Pertussis Tetanus Hepatitis B Measles Mumps Rubella Poliomyelitis Varicella 
1990 0 0 0 0 0 0 0 0 0 
1991 0 0 0 0 0 0 0 0 0 
1992 0 0 0 0 0 0 0 0 0 
1993 0 0 0 0 0 0 0 0 0 
1994 0 0 0 0 0 0 0 0 0 
1995 0 0 0 0 0 0 0 0 0 
1996 0 0 0 0 0 0 0 0 0 
1997 0 0 0 0 0 0 0 0 0 
1998 0 0 0 0 0 0 0 0 0 
1999 0 0 0 0 0 0 0 0 0 
2000 0 0 0 0 0 0 0 0 0 
2001 0 0 0 0 0 0 0 0 0 
2002 0 0 0 0 0 0 0 0 0 
2003 0 0 0 0 0 0 0 0 0 
2004 0 0 0 0 0 0 0 0 0 
2005 0 0 0 0 0 0 0 0 0 
2006 0 0 0 0 0 0 0 0 0 
2007 0 0 0 0 0 0 0 0 0 
2008 0 0 0 0 0 0 0 0 0 














PCABC 2010 census 2006 NIS 2010 census 
Age m w m*w Age m w m*w 
13 0.846 0.244 0.207 13 0.483 0.244 0.118 
14 0.842 0.247 0.208 14 0.571 0.247 0.141 
15 0.838 0.252 0.211 15 0.642 0.252 0.162 




Hep B Arkansas 
Standard 






PCABC 2010 census 2007 NIS 2010 census 
Age m w m*w Age m w m*w 
13 0.595 0.244 0.145 13 0.886 0.244 0.217 
14 0.842 0.247 0.208 14 0.846 0.247 0.209 
15 0.838 0.252 0.211 15 0.8 0.252 0.202 












PCABC 2010 census 2006 NIS 2010 census 
Age m w m*w Age m w m*w 
13 0.774 0.244 0.189 14 0.87 0.244 0.213 
14 0.778 0.247 0.192 15 0.901 0.247 0.223 
15 0.778 0.252 0.196 16 0.883 0.252 0.222 

















PCABC 2010 census 2006 NIS 2010 census 
Age m w m*w Age m w m*w 
13 0.872 0.244 0.213 13 0.244 0.000 
14 0.865 0.247 0.214 14 0.247 0.000 
15 0.86 0.252 0.217 15 0.252 0.000 












PCABC 2010 census 2006 NIS 2010 census 
Age m w m*w Age m w m*w 
13 0.157 0.244 0.038 13 0.895 0.244 0.219 
14 0.162 0.247 0.04 14 0.893 0.247 0.221 
15 0.172 0.252 0.043 15 0.905 0.252 0.228 




Note. Adapted from PCABC 1990 Data Analysis, 2015; MMR = measles-mumps-rubella; PCABC = 














PCABC 2010 census 
2007 
NIS 2010 census 
Age m w m*w Age m w m*w 
13 0.846 0.194 0.164 13 0.64 0.194 0.124 
14 0.842 0.196 0.165 14 0.704 0.196 0.138 
15 0.838 0.2 0.167 15 0.73 0.2 0.146 
16 0.836 0.203 0.17 16 0.765 0.203 0.155 




Hep B Arkansas 
Standard 






PCABC 2010 census 
2007 
NIS 2010 census 
Age m w m*w Age m w m*w 
13 0.595 0.194 0.115 13 0.906 0.194 0.176 
14 0.842 0.196 0.165 14 0.919 0.196 0.18 
15 0.838 0.2 0.167 15 0.863 0.2 0.172 
16 0.836 0.203 0.17 16 0.854 0.203 0.174 

















PCABC 2010 census 
2007 
NIS 2010 census 
Age m w m*w Age m w m*w 
13 0.774 0.194 0.15 13 0.888 0.194 0.172 
14 0.778 0.196 0.153 14 0.91 0.196 0.179 
15 0.778 0.2 0.155 15 0.872 0.2 0.174 
16 0.778 0.203 0.158 16 0.904 0.203 0.184 












PCABC 2010 census 
2007 
NIS 2010 census 
Age m w m*w Age m w m*w 
13 0.872 0.194 0.169 13 0.194 0 
14 0.865 0.196 0.17 14 0.196 0 
15 0.86 0.2 0.172 15 
 
0.2 0 
16 0.853 0.203 0.173 16 
 
0.203 0 














PCABC 2010 census 
2007 
NIS 2010 census 
Age m w m*w Age m w m*w 
13 0.157 0.194 0.03 13 0.926 0.194 0.18 
14 0.162 0.196 0.032 14 0.929 0.196 0.182 
15 0.172 0.2 0.034 15 0.91 0.2 0.182 
16 0.188 0.203 0.038 16 0.885 0.203 0.18 




Note. Adapted from PCABC 1990 Data Analysis, 2015; MMR = measles-mumps-rubella; PCABC = 














PCABC 2010 Census 2008 NIS 2010 Census 
Age m w m*w Age m w m*w 
13 0.846 0.16 0.135 13 0.641 0.16 0.103 
14 0.842 0.162 0.136 14 0.697 0.162 0.113 
15 0.838 0.165 0.138 15 0.777 0.165 0.128 
16 0.836 0.168 0.14 16 0.748 0.168 0.125 
17 0.836 0.171 0.143 17 0.737 0.171 0.126 




Hep B Arkansas 
Standard 






PCABC 2010 Census 2008 NIS 2010 Census 
Age m w m*w Age m w m*w 
13 0.595 0.16 0.095 13 0.928 0.16 0.148471
14 0.842 0.162 0.136 14 0.931 0.162 0.150686
15 0.838 0.165 0.138 15 0.896 0.165 0.147696
16 0.836 0.168 0.14 16 0.815 0.168 0.136666
17 0.67 0.171 0.114 17 0.829 0.171 0.141563
18 0.674 0.175 0.118 18 0.879 0.175 0.153706
sum(m*w) 74.20% sum(m*w) 87.90% 
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PCABC 2010 Census 2008 NIS 2010 Census 
Age m w m*w Age m w m*w 
13 0.774 0.16 0.124 13 0.903 0.16 0.144 
14 0.778 0.162 0.126 14 0.918 0.162 0.149 
15 0.778 0.165 0.128 15 0.901 0.165 0.149 
16 0.778 0.168 0.13 16 0.862 0.168 0.145 
17 0.778 0.171 0.133 17 0.881 0.171 0.15 












PCABC 2010 Census 2008 NIS 2010 Census 
Age m w m*w Age m w m*w 
13 0.872 0.16 0.14 13 0.16 0 
14 0.865 0.162 0.14 14 0.162 0 
15 0.86 0.165 0.142 15 0.165 0 
16 0.853 0.168 0.143 16 0.168 0 
17 0.853 0.171 0.146 17 0.171 0 












PCABC 2010 Census 2008 NIS 2010 Census 
Age m w m*w Age m w m*w 
13 0.157 0.16 0.025 13 0.94 0.16 0.15 
14 0.162 0.162 0.026 14 0.926 0.162 0.15 
15 0.172 0.165 0.028 15 0.926 0.165 0.153 
16 0.188 0.168 0.032 16 0.925 0.168 0.155 
17 0.188 0.171 0.032 17 0.92 0.171 0.157 




Note. Adapted from PCABC 1990 Data Analysis, 2015; MMR = measles-mumps-rubella; PCABC = 




Individual Payoff Equation Estimated Payoff values Game Theory Comparison 
Individual Equilibrium Equation Edel(p) = −r[ϕs(p)ds + ϕv(p)dv]* 
Vaccine ϕv(p) ds dv p peff ϕs(p) r 
Td/Tdap 0.09 0.01692902 0.000001 0.831 0.83071 0.169290169 0.270034843 
Pertussis 0.09 0.00846451 0.000001 0.831 0.83071 0.169290169 0.270034843 
Tetanus 0.09 0.02200772 0.000001 0.831 0.83071 0.169290169 0.270034843 
Hep B 0.09 0.30355509 0.000001 0.674 0.673597 0.326403326 0.01631913 
Measles 0.09 0.00044609 0.000001 0.777 0.776953 0.223047223 0.002649007 
Mumps 0.09 4.46E−05 0.000001 0.777 0.776953 0.223047223 0.002649007 
Rubella 0.09 0.11152361 0.000001 0.777 0.776953 0.223047223 0.002649007 
OPV/IPV 0.09 0.00775171 0.000001 0.845 0.844966 0.155034155 0.000297 
Varicella 0.09 0.24101574 0.000001 0.197 0.196614 0.803385803 0.018456995 
Individual Equilibrium Equation Estimated Payoff Calculations. * 
Vaccine ϕs(p)ds ϕv(p)dv [ϕs(p)ds + ϕv(p)dv] Edel(p) Cohort Payoff Deaths 
 
Td/Tdap 0.002866 0.00000009 0.002866006 0.0007739 3371 2.605793755   
Pertussis 0.001433 0.00000009 0.001433048 0.000387 3371 1.302937792 
 
Tetanus 0.003726 0.00000009 0.003725781 0.0010061 3371 3.387507333 
 
Hep B 0.099081 0.00000009 0.099081482 0.0016169 3371 5.444181609 
 
Measles 9.95E−05 0.00000009 9.96E−05 2.64E−07 3371 0.000888265 
 
Mumps 9.95E−06 0.00000009 1.00E−05 2.66E−08 3371 8.95E−05 
 
Rubella 0.024875 0.00000009 0.024875122 6.59E−05 3371 0.221866319 
 
OPV/IPV 0.001202 0.00000009 0.001201869 3.57E−07 3371 0.001201868 
 
VAR 0.193629 0.00000009 0.193628715 0.0035738 3371 12.03299894   
Note. Td/Tdap = tetanus-diphtheria/tetanus-diphtheria-acellular pertussis; Hep B = hepatitis B; MMR = 
measles-mumps-rubella; OPV/IPV = poliomyelitis; VAR = varicella; Pulaski County Arkansas 1990 Birth 




Group Optimum Equation Estimated Payoff Values Game Theory Comparison 
Group Optimum Equation C(p) = pdv + r(1 − p)[(ds − dv)ϕs(p) + dv]*     
Vaccine ϕv(p) ds dv P peff ϕs(p) r pdv 1 − p 
Td/Tdap 0.09 0.016929 0.000001 0.831 0.83071 0.16929 0.27 8.31E−07 0.169 
Pertussis 0.09 0.008465 0.000001 0.831 0.83071 0.16929 0.27 8.31E−07 0.169 
Tetanus 0.09 0.022008 0.000001 0.831 0.83071 0.16929 0.27 8.31E−07 0.169 
Hep B 0.09 0.303555 0.000001 0.674 0.6736 0.3264 0.0163 6.74E−07 0.326 
Measles 0.09 0.000446 0.000001 0.777 0.77695 0.22305 0.0027 7.77E−07 0.223 
Mumps 0.09 4.46E−05 0.000001 0.777 0.77695 0.22305 0.0027 7.77E−07 0.223 
Rubella 0.09 0.111524 0.000001 0.777 0.77695 0.22305 0.0027 7.77E−07 0.223 
OPV/IPV 0.09 0.007752 0.000001 0.845 0.84497 0.15503 0.0003 8.45E−07 0.155 
VAR 0.09 0.241016 0.000001 0.197 0.19661 0.80339 0.0185 1.97E−07 0.803 
Group Optimum Equation Estimated Payoff Calculations*         
Vaccine r (1−p) (ds−dv) (ds−dv)ϕs(p) [(ds−dv)ϕs(p)+dv] pdv+r(1−p) C(p) Cohort C(p) Cohort 
Td/Tdap 0.045636 0.016928 0.002866 0.0029 0.04564 0.00013 3371 0.440503 
Pertussis 0.045636 0.008464 0.001433 0.0014 0.04564 6.54E−05 3371 0.220315 
Tetanus 0.045636 0.022007 0.003726 0.0037 0.04564 0.00017 3371 0.572615 
Hep B 0.00532 0.303554 0.099081 0.0991 0.00532 0.00053 3371 1.775147 
Measles 0.000591 0.000445 9.93E−05 0.0001 0.00059 5.93E−08 3371 0.0002 
Mumps 0.000591 4.36E−05 9.73E−06 1E−05 0.00059 6.35E−09 3371 2.14E−05 
Rubella 0.000591 0.111523 0.024875 0.0249 0.00059 1.47E−05 3371 0.049561 
OPV/IPV 4.60E−05 0.007751 0.001202 0.0012 4.7E−05 5.66E−08 3371 0.00019 
VAR 0.014821 0.241015 0.193628 0.1936 0.01482 0.00287 3371 9.663155 
Note. Td/Tdap = tetanus-diphtheria/tetanus-diphtheria-acellular pertussis; Hep B = hepatitis B; MMR = 




Vaccination Theory of Game Parameters Definition and Calculation 
Parameter Definition 
Edel(p) Individual Payoff  
Individual equilibrium Edel(p) = −r[ϕs(p)ds + ϕv(p)dv] 
Group optimum C(p) = pdv + r(1 − p)[(ds − dv)ϕs(p) + dv] 
C(p) Group optimum Payoff  
p  Proportion of individuals preemptively vaccinated 
[Number vaccinated before a disease attack] 
r Attack rate of the disease  
[Number infected from no vaccine divided by population at risk] 
 ϕs(p) Probability an individual delayer becomes infected after an outbreak  
[Number unvaccinated divided by number vaccinated] 
ds Probability of death from vaccine preventable disease 
[Death among unvaccinated divided by total population at risk] 
ϕv(p) Probability an individual delayer is successfully vaccinated after an outbreak  
[Number of vaccinated delayers divided by delayers who received the vaccine] 
pdv Probability of death from vaccine 
dv Probability of death from vaccine defined as vaccine efficacy 
[Number of vaccine deaths divided by number vaccinated ] 








1990 Birth Cohort Children Born In Pulaski County, Arkansas 
ACIP 4:3:1:3:3:1 4+DTP, 3+Polio, 1+MMR, 3+Hib, 3+Hep B, 1+Varicella 
AIRR 4:3:2:3:3:2 4+DTP, 3+Polio, 2+MMR, 3+Hep B, 2+Varicella Vaccine Dose Series 
ACIP Advisory Committee on Immunization Practices 
ADH Arkansas Department of Health 
ADHS Arkansas Department of Human Services 
AIL Arkansas Immunization Laws 
AIR Arkansas Immunization Registry 
AIRD Arkansas Immunization Registry Database 
AIRR Arkansas Immunization Rules and Regulations 
AIRR  4:3:2:3:3:2 Vaccine Dose Series 
ALB Arkansas Legislative Branch 
ARKIDS Medicaid and Supplemental Children’s Insurance 
CDC Centers for Disease Control and Prevention 
CHRIS Children’s Reporting and Information System 
DTP Diphtheria, Tetanus and Pertussis 
DTaP Diphtheria toxoid Tetanus toxoid acellular Pertussis 
EHR Electronic Health Records 
FCA Foster Care Adolescents 
FVSE Five Vaccines For School Entry 
Healthstyles National Healthstyles Survey [CDC focuses on health orientations and practices] 
Hep B Hepatitis B Vaccine 
Hib Haemophilus influenza type b 
HOR home of residence 
IAC Immunization Action Committee 
IOM Institute of Medicine 
IPV  Inactivated Poliomyelitis Vaccine 
IRB Institutional Review Board 
MCV Meningococcal Conjugate Vaccine 
MMR Measles-Mumps-Rubella Vaccine 
NHA  Natural Home Adolescents 
NIS-Teen National Immunization Survey Teen 
NVAC National Vaccine Advisory Committee 
NVDD Number of Vaccine Doses Administered and Documented 
OPV Oral Poliomyelitis Vaccine 
PCA  Pulaski County, Arkansas 
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                                                                                                Table C1 continues 
PCABC Pulaski County, AR birth cohort 
SAC Scientific Advisory Committee 
Td/Tdap Diphtheria/Tetanus-Diphtheria-Acellular Pertussis diphtheria/tetanus-diphtheria-
acellular pertussis 
Tdap Diphtheria/tetanus-diphtheria-acellular pertussis 
TOG Theory of games 
UTD Up To Date Status 
USDHHS U.S. Department of Health and Human Services 
Vaccine Dose Series A1 4:3:1:3:3:1 = 4+DTP, 3+Polio, 1+MMR, 3+Hib, 3+Hep B, 1+Varicella 
Vaccine Dose Series A2 4:3:2:3:3:2 = 4+DTP, 3+Polio, 2+MMR, 3+Hep B, 2+Varicella 
VAR  Varicella Vaccine 
VCU vaccination uptake 
VFC Vaccine For Children 
VGT vaccination game theory 
VIS Vaccine Information Statements 
VPD Vaccine Preventable Diseases 
WHO World Health Organization 
WIC Special Supplemental Nutrition Program for Women, Infants, and Children 
 
